(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act:

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of ~~October 31, 2019,~~April 30, 2020, there were ~~134,095,850~~147,314,497 shares of Class A common stock outstanding and ~~165,004,323~~152,116,890 shares of Class B common stock outstanding, both with a par value of $0.01.

This Quarterly Report on Form 10-Q and Amneal Pharmaceuticals, Inc.'s other publicly available documents contain "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Management and representatives of Amneal Pharmaceuticals, Inc. and its subsidiaries (the "Company") also may from time to time make forward-looking statements. Forward-looking statements do not relate strictly to historical or current facts and reflect management’s assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as “plans,” “expects,” “will,” “anticipates,” “estimates” and other words of similar meaning in conjunction with, among other things: discussions of future operations; expected operating results and financial performance; impact of planned acquisitions and dispositions; the Company’s strategy for growth; product development; regulatory approvals; market position and expenditures.

Because forward-looking statements are based on current beliefs, expectations and assumptions regarding future events, they are subject to uncertainties, risks and changes that are difficult to predict and many of which are outside of the Company's control. Investors should realize that if underlying assumptions prove inaccurate, known or unknown risks or uncertainties materialize, or other factors or circumstances change, the Company’s actual results and financial condition could vary materially from expectations and projections expressed or implied in its forward-looking statements. Investors are therefore cautioned not to rely on these forward-looking statements.

Investors also should carefully read our Annual Report on Form 10-K for the year ended December 31, 2019, including the section captioned “Risk Factors” for a description of certain risks that could, among other things, cause our actual results to differ materially from those expressed in our forward-looking statements. Investors should understand that it is not possible to predict or identify all such factors and should not consider the risks described above and in our Annual Report to be a complete statement of all potential risks and uncertainties. The Company does not undertake to publicly update any forward-looking statement that may be made from time to time, whether as a result of new information or future events or developments.

	Three Months Ended September 30,						Nine Months Ended September 30,						Three Months Ended March 31,
	2019			2018			2019			2018			2020			2019
Net revenue	$	378,283		$	476,487		$	1,229,045		$	1,165,463		$	498,533		$	446,120
Cost of goods sold		267,717			268,567			873,841			634,653			313,578			309,743
Cost of goods sold impairment charges		56,132			7,815			112,441			7,815			1,456			53,297
Gross profit		54,434			200,105			242,763			522,995			183,499			83,080
Selling, general and administrative		63,797			75,486			215,514			156,610			77,976			84,436
Research and development		38,125			42,349			139,999			136,893			36,379			53,858
In-process research and development impairment charges		23,382			650			46,169			650			960			22,787
Charges (gains) related to legal matters, net		14,750			2,589			14,750			(411	)
Intellectual property legal development expenses		2,586			4,401			9,263			13,024			1,270			4,166
Acquisition, transaction-related and integration expenses		3,131			2,231			12,682			216,873			2,575			6,032
Charges related to legal matters														4,500			—
Restructuring and other charges		20,937			(2,156	)		29,933			42,309			2,048			6,161
Operating (loss) income		(112,274	)		74,555			(225,547	)		(42,953	)
Other income (expense):
Operating income (loss)														57,791			(94,360	)
Other (expense) income:
Interest expense, net		(42,209	)		(43,018	)		(129,376	)		(100,691	)		(39,899	)		(43,281	)
Foreign exchange loss, net		(12,531	)		(5,137	)		(9,684	)		(22,518	)		(5,181	)		(5,464	)
Loss on extinguishment of debt		—			—			—			(19,667	)
(Loss) gain on sale of international businesses, net		—			(2,812	)		6,930			(2,812	)
Gain from reduction of tax receivable agreement liability		192,844			—			192,844			—
Other income (expense), net		446			(1,014	)		1,702			725
Total other income (expense), net		138,550			(51,981	)		62,416			(144,963	)
Gain on sale of international business														—			8,818
Other income, net														633			1,107
Total other expense, net														(44,447	)		(38,820	)
Income (loss) before income taxes		26,276			22,574			(163,131	)		(187,916	)		13,344			(133,180	)
Provision for (benefit from) income taxes		389,668			5,109			375,539			(6,943	)
Net (loss) income		(363,392	)		17,465			(538,670	)		(180,973	)
Less: Net loss attributable to Amneal Pharmaceuticals LLC pre- Combination		—			—			—			148,806
Less: Net loss (income) attributable to non-controlling interests		98,386			(10,577	)		208,881			21,191
Net (loss) income attributable to Amneal Pharmaceuticals, Inc. before accretion of redeemable non-controlling interest		(265,006	)		6,888			(329,789	)		(10,976	)
Accretion of redeemable non-controlling interest		—			64			—			(1,176	)
Net (loss) income attributable to Amneal Pharmaceuticals, Inc.	$	(265,006	)	$	6,952		$	(329,789	)	$	(12,152	)
Net (loss) income per share attributable to Amneal Pharmaceuticals, Inc.'s common stockholders:
Benefit from income taxes														(108,173	)		(8,428	)
Net income (loss)														121,517			(124,752	)
Less: Net (income) loss attributable to non-controlling interests														(6,450	)		76,871
Net income (loss) attributable to Amneal Pharmaceuticals, Inc.													$	115,067		$	(47,881	)
Net income (loss) per share attributable to Amneal Pharmaceuticals, Inc.'s common stockholders:
Class A and Class B-1 basic	$	(2.03	)	$	0.05		$	(2.56	)	$	(0.10	)	$	0.78		$	(0.37	)
Class A and Class B-1 diluted	$	(2.03	)	$	0.05		$	(2.56	)	$	(0.10	)	$	0.78		$	(0.37	)
Weighted-average common shares outstanding:
Class A and Class B-1 basic		130,729			127,247			128,822			127,196			147,180			127,687
Class A and Class B-1 diluted		130,729			128,222			128,822			127,196			147,956			127,687

The accompanying notes are an integral part of these consolidated financial statements.

Three Months Ended September 30,

Nine Months Ended September 30,

2019

2018

2019

2018

Net (loss) income

$
(363,392
)

$
17,465

$
(538,670
)

$
(180,973
)
Less: Net loss attributable to Amneal Pharmaceuticals LLC pre-
   Combination

—

—

—

148,806

Less: Net loss (income) attributable to non-controlling interests

98,386

(10,577
)

208,881

21,191

Net (loss) income attributable to Amneal Pharmaceuticals, Inc. before
   accretion of redeemable non-controlling interest

(265,006
)

6,888

(329,789
)

(10,976
)
Accretion of redeemable non-controlling interest

—

64

—

(1,176
)
Net (loss) income attributable to Amneal Pharmaceuticals, Inc.

(265,006
)

6,952

(329,789
)

(12,152
)
Other comprehensive income (loss):

Foreign currency translation adjustments

Foreign currency translation adjustments arising during the period

4,997

(7,939
)

4,014

(8,964
)
Less: Reclassification of foreign currency translation adjustment
   included in net loss

—

—

3,413

—

Foreign currency translation adjustments, net

4,997

(7,939
)

7,427

(8,964
)
Less: Other comprehensive income attributable to Amneal
   Pharmaceuticals LLC pre-Combination

—

—

—

(1,721
)
Less: Other comprehensive (income) loss attributable to non-controlling
   interests

(2,813
)

4,555

(4,207
)

6,131

Other comprehensive income (loss) attributable to Amneal
   Pharmaceuticals, Inc.

2,184

(3,384
)

3,220

(4,554
)
Comprehensive (loss) income attributable to Amneal
   Pharmaceuticals, Inc.

$
(262,822
)

$
3,568

$
(326,569
)

$
(16,706
)

	Three Months Ended March 31,
	2020			2019
Net income (loss)	$	121,517		$	(124,752	)
Less: Net (income) loss attributable to non-controlling interests		(6,450	)		76,871
Net income (loss) attributable to Amneal Pharmaceuticals, Inc.		115,067			(47,881	)
Other comprehensive income (loss):
Foreign currency translation adjustments:
Foreign currency translation adjustments arising during the period		(5,135	)		5,236
Less: Reclassification of foreign currency translation adjustment included in net loss		—			3,373
Foreign currency translation adjustments, net		(5,135	)		8,609
Unrealized loss on cash flow hedge, net of tax		(62,658	)		—
Less: Other comprehensive income (loss) attributable to non-controlling interests		34,456			(4,927	)
Other comprehensive (loss) income attributable to Amneal Pharmaceuticals, Inc.		(33,337	)		3,682
Comprehensive income (loss) attributable to Amneal Pharmaceuticals, Inc.	$	81,730		$	(44,199	)

The accompanying notes are an integral part of these consolidated financial statements.

	March 31, 2020			December 31, 2019
Assets
Current assets:
Cash and cash equivalents	$	405,238		$	151,197
Restricted cash		1,687			1,625
Trade accounts receivable, net		722,682			604,390
Inventories		437,959			381,067
Prepaid expenses and other current assets		204,409			70,164
Related party receivables		1,725			1,767
Total current assets		1,773,700			1,210,210
Property, plant and equipment, net		467,559			477,997
Goodwill		514,733			419,504
Intangible assets, net		1,475,161			1,382,753
Operating lease right-of-use assets		50,943			53,344
Operating lease right-of-use assets - related party		21,616			16,528
Financing lease right-of-use assets - related party		60,632			61,284
Other assets		26,456			44,270
Total assets	$	4,390,800		$	3,665,890
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable and accrued expenses	$	606,925		$	507,483
Current portion of long-term debt, net		29,736			21,479
Revolving credit facility		300,000			—
Current portion of operating lease liabilities		12,125			11,874
Current portion of operating and financing lease liabilities - related party		4,084			3,601
Current portion of note payable- related party		1,000			—
Related party payable		11,195			5,969
Total current liabilities		965,065			550,406
Long-term debt, net		2,772,029			2,609,046
Note payable - related party		35,281			—
Operating lease liabilities		40,615			43,135
Operating lease liabilities - related party		19,874			15,469
Financing lease liabilities - related party		61,069			61,463
Other long-term liabilities		80,846			39,583
Total long-term liabilities		3,009,714			2,768,696
Commitments and contingencies (Notes 5 and 17)
Redeemable non-controlling interests		12,563			—
Stockholders' Equity
Preferred stock, $0.01 par value, 2,000 shares authorized; NaN issued at both March 31, 2020 and December 31, 2019		—			—
Class A common stock, $0.01 par value, 900,000 shares authorized at both March 31, 2020 and December 31, 2019; 147,311 and 147,070 shares issued at March 31, 2020 and December 31, 2019, respectively		1,472			1,470
Class B common stock, $0.01 par value, 300,000 shares authorized at both March 31, 2020 and December 31, 2019; 152,117 issued at both March 31, 2020 and December 31, 2019		1,522			1,522
Additional paid-in capital		611,600			606,966
Stockholders' accumulated deficit		(262,813	)		(377,880	)
Accumulated other comprehensive loss		(33,405	)		(68	)
Total Amneal Pharmaceuticals, Inc. stockholders' equity		318,376			232,010
Non-controlling interests		85,082			114,778
Total stockholders' equity		403,458			346,788
Total liabilities and stockholders' equity	$	4,390,800		$	3,665,890

The accompanying notes are an integral part of these consolidated financial statements.

September 30, 2019

December 31, 2018

Assets

Current assets:

Cash and cash equivalents

$
212,738

$
213,394

Restricted cash

4,320

5,385

Trade accounts receivable, net

518,109

481,495

Inventories

401,827

457,219

Prepaid expenses and other current assets

66,699

128,321

Related party receivables

2,138

830

Total current assets

1,205,831

1,286,644

Property, plant and equipment, net

490,712

544,146

Goodwill

419,671

426,226

Intangible assets, net

1,435,801

1,654,969

Deferred tax asset, net

—

373,159

Operating lease right-of-use assets

56,455

—

Operating lease right-of-use assets - related party

14,930

—

Financing lease right-of-use assets - related party

61,936

—

Other assets

18,607

67,592

Total assets

$
3,703,943

$
4,352,736

Liabilities and Stockholders' Equity

Current liabilities:

Accounts payable and accrued expenses

$
495,857

$
514,440

Current portion of long-term debt, net

21,468

21,449

Current portion of operating lease liabilities

13,467

—

Current portion of operating and financing lease liabilities - related party

3,353

—

Related party payables

765

17,695

Current portion of financing obligation - related party

—

266

Total current liabilities

534,910

553,850

Long-term debt, net

2,614,412

2,630,598

Deferred income taxes

—

1,178

Liabilities under tax receivable agreement

—

192,884

Operating lease liabilities

44,375

—

Operating lease liabilities - related party

14,271

—

Financing lease liabilities - related party

61,719

—

Financing obligation - related party

—

39,083

Other liabilities

38,532

38,780

Total long-term liabilities

2,773,309

2,902,523

Commitments and contingencies (Notes 5, 11 and 13)

Stockholders' Equity

Preferred stock, $0.01 par value, 2,000 shares authorized; none issued at both September 30, 2019 and December 31, 2018

—

—

Class A common stock, $0.01 par value, 900,000 shares authorized at both September 30, 2019 and December 31, 2018; 134,090 and 115,047 shares issued at September 30, 2019 and December 31, 2018, respectively

1,340

1,151

Class B common stock, $0.01 par value, 300,000 shares authorized at both September 30, 2019 and December 31, 2018; 165,005 and 171,261 shares issued at September 30, 2019 and December 31, 2018 respectively

1,651

1,713

Class B-1 common stock, $0.01 par value, 18,000 shares authorized at both September 30, 2019 and December 31, 2018; no and 12,329 shares issued at September 30, 2019 and December 31, 2018, respectively

—

123

Additional paid-in capital

565,641

530,438

Stockholders' accumulated deficit

(345,752
)

(20,920
)
Accumulated other comprehensive loss

(4,879
)

(7,755
)
Total Amneal Pharmaceuticals, Inc. stockholders' equity

218,001

504,750

Non-controlling interests

177,723

391,613

Total stockholders' equity

395,724

896,363

Total liabilities and stockholders' equity

$
3,703,943

$
4,352,736

	Three Months Ended March 31,
	2020			2019
Cash flows from operating activities:
Net income (loss)	$	121,517		$	(124,752	)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization		58,083			48,868
Amortization of Levothyroxine Transition Agreement asset		—			36,393
Unrealized foreign currency loss		5,514			6,490
Amortization of debt issuance costs and discount		2,004			1,601
Gain on sale of international business		—			(8,818	)
Intangible asset impairment charges		2,416			76,084
Deferred tax benefit		—			(9,884	)
Stock-based compensation		4,539			4,347
Inventory provision		15,200			15,650
Other operating charges and credits, net		1,266			1,109
Changes in assets and liabilities:
Trade accounts receivable, net		(60,893	)		(165,012	)
Inventories		(2,778	)		(14,180	)
Income taxes receivable associated with the CARES Act		(110,069	)		—
Prepaid expenses, other current assets and other assets		(26,383	)		22,657
Related party receivables		76			(314	)
Accounts payable, accrued expenses and other liabilities		34,839			695
Related party payables		3,695			656
Net cash provided by (used in) operating activities		49,026			(108,410	)
Cash flows from investing activities:
Purchases of property, plant and equipment		(7,367	)		(17,988	)
Acquisition of intangible assets		(1,050	)		—
Acquisitions, net of cash acquired		(253,625	)		—
Cash sold with international business		—			(3,478	)
Net cash used in investing activities		(262,042	)		(21,466	)
Cash flows from financing activities:
Proceeds from issuance of debt		180,000			—
Payments of principal on debt and financing leases		(7,158	)		(6,750	)
Net borrowings on revolving credit facility		300,000			—
Payments of deferred financing costs		(4,102	)		—
Proceeds from exercise of stock options		5			1,010
Employee payroll tax withholding on restricted stock unit vesting		(503	)		—
Acquisition of non-controlling interest		—			(2,011	)
Tax distribution to non-controlling interest		—			(13,494	)
Payments of principal on financing lease - related party		(263	)		(619	)
Net cash provided by (used in) financing activities		467,979			(21,864	)
Effect of foreign exchange rate on cash		(860	)		(296	)
Net increase (decrease) in cash, cash equivalents, and restricted cash		254,103			(152,036	)
Cash, cash equivalents, and restricted cash - beginning of period		152,822			218,779
Cash, cash equivalents, and restricted cash - end of period	$	406,925		$	66,743
Cash and cash equivalents - end of period	$	405,238		$	63,946
Restricted cash - end of period		1,687			2,797
Cash, cash equivalents, and restricted cash - end of period	$	406,925		$	66,743
Supplemental disclosure of cash flow information:
Cash paid for interest	$	35,386		$	40,032
Cash (paid) received for income taxes, net	$	(3,430	)	$	9,713
Supplemental disclosure of non-cash investing and financing activity:
Notes payable for acquisitions - related party	$	36,033		$	—
Receivable from the sale of international business	$	—		$	35,837
Payable for acquisition of product rights and licenses	$	—		$	50,000

The accompanying notes are an integral part of these consolidated financial statements.

Nine Months Ended September 30,

2019

2018

Cash flows from operating activities:

Net loss

$
(538,670
)

$
(180,973
)
Adjustments to reconcile net loss to net cash used in operating activities:

Gain from reduction of tax receivable agreement liability

(192,884
)

—

Depreciation and amortization

152,932

89,910

Amortization of Levothyroxine Transition Agreement asset

36,393

—

Unrealized foreign currency loss

10,552

21,560

Amortization of debt issuance costs

4,849

4,220

Loss on extinguishment of debt

—

19,667

(Gain) loss on sale of international businesses, net

(6,930
)

2,812

Intangible asset impairment charges

158,610

8,474

Non-cash restructuring and asset-related charges

11,923

—

Deferred tax provision (benefit)

371,683

(9,111
)
Stock-based compensation and PPU expense

16,666

163,991

Inventory provision

67,844

20,755

Other operating charges and credits, net

5,945

(1,955
)
Changes in assets and liabilities:

Trade accounts receivable, net

(46,457
)

(74,711
)
Inventories

(25,906
)

(53,708
)
Prepaid expenses, other current assets and other assets

41,256

9,803

Related party receivables

(1,305
)

10,828

Accounts payable, accrued expenses and other liabilities

(13,932
)

(26,858
)
Related party payables

25

(14,125
)
Net cash provided by (used in) operating activities

52,594

(9,421
)
Cash flows from investing activities:

Purchases of property, plant and equipment

(42,664
)

(63,065
)
Acquisition of product rights and licenses

(50,000
)

(14,000
)
Acquisitions, net of cash acquired

—

(324,634
)
Proceeds from surrender of corporate owned life insurance

43,017

—

Proceeds from sale of international businesses, net of cash sold

34,834

—

Net cash used in investing activities

(14,813
)

(401,699
)
Cash flows from financing activities:

Payments of deferred financing costs and debt extinguishment costs

—

(54,955
)
Proceeds from issuance of debt

—

1,325,383

Payments of principal on debt and capital leases

(20,250
)

(610,482
)
Net borrowings on revolving credit line

—

25,000

Proceeds from exercise of stock options

1,385

3,162

Employee payroll tax withholding on restricted stock unit vesting

(926
)

—

Equity contributions

—

27,742

Capital contribution from non-controlling interest

—

360

Acquisition of non-controlling interest

(3,543
)

(11,775
)
Tax distribution to non-controlling interest

(13,494
)

—

Distributions to members

—

(182,998
)
Payments of principal on financing lease - related party

(1,707
)

—

Repayment of related party note

—

(14,842
)
Net cash (used in) provided by financing activities

(38,535
)

506,595

Effect of foreign exchange rate on cash

(967
)

(1,204
)
Net (decrease) increase in cash, cash equivalents, and restricted cash

(1,721
)

94,271

Cash, cash equivalents, and restricted cash - beginning of period

218,779

77,922

Cash, cash equivalents, and restricted cash - end of period

$
217,058

$
172,193

Cash and cash equivalents - end of period

$
212,738

$
165,192

Restricted cash - end of period

4,320

7,001

Cash, cash equivalents, and restricted cash - end of period

$
217,058

$
172,193

Supplemental disclosure of cash flow information:

Cash paid for interest

$
121,872

$
89,075

Cash received (paid) for income taxes, net

$
11,857

$
(5,379
)
Supplemental disclosure of non-cash investing and financing activity:

Tax distribution to non-controlling interest

$
—

$
35,543

Distribution to members

$
—

$
8,562

	Class A Common Stock				Class B Common Stock				Additional Paid-in		Stockholders' Accumulated			Accumulated Other Comprehensive			Non- Controlling			Total			Redeemable Non-Controlling
	Shares		Amount		Shares		Amount		Capital		Deficit			Loss			Interests			Equity			Interests
Balance at January 1, 2020		147,070	$	1,470		152,117	$	1,522	$	606,966	$	(377,880	)	$	(68	)	$	114,778		$	346,788		$	—
Net income		—		—		—		—		—		115,067			—			5,362			120,429			1,088
Foreign currency translation adjustment		—		—		—		—		—		—			(2,525	)		(2,610	)		(5,135	)		—
Stock-based compensation		—		—		—		—		4,539		—			—			—			4,539			—
Exercise of stock options		1		—		—		—		5		—			—			—			5			—
Restricted stock unit vesting, net of shares withheld to cover payroll taxes		240		2		—		—		90		—			—			(602	)		(510	)		—
Unrealized loss on cash flow hedge, net of tax		—		—		—		—		—		—			(30,812	)		(31,846	)		(62,658	)		—
Redeemable non-controlling interests issued for acquisitions		—		—		—		—		—		—			—			—			—			11,475
Balance at March 31, 2020		147,311	$	1,472		152,117	$	1,522	$	611,600	$	(262,813	)	$	(33,405	)	$	85,082		$	403,458		$	12,563

	Class A Common Stock				Class B Common Stock						Class B-1 Common Stock				Additional Paid-in		Stockholders' Accumulated			Accumulated Other Comprehensive			Non- Controlling			Total
	Shares		Amount		Shares			Amount			Shares		Amount		Capital		Deficit			(Loss) Income			Interests			Equity
Balance at January 1, 2019		115,047	$	1,151		171,261		$	1,713			12,329	$	123	$	530,438	$	(20,920	)	$	(7,755	)	$	391,613		$	896,363
Net loss		—		—		—			—			—		—		—		(47,881	)		—			(76,871	)		(124,752	)
Cumulative-effective adjustment from adoption of Topic 842, net of tax		—		—		—			—			—		—		—		4,957			—			8,604			13,561
Foreign currency translation adjustment		—		—		—			—			—		—		—		—			2,238			2,998			5,236
Stock-based compensation		—		—		—			—			—		—		4,347		—			—			—			4,347
Exercise of stock options		197		2		—			—			—		—		748		—			(7	)		267			1,010
Redemption of Class B Common Stock		320		3		(320	)		(3	)		—		—		1,124		—			(19	)		(882	)		223
Reclassification of foreign currency translation adjustment included in net loss		—		—		—			—			—		—		—		—			1,444			1,929			3,373
Tax distribution		—		—		—			—			—		—		—		—			—			(82	)		(82	)
Other		—		—		—			—			—		—		502		—			—			—			502
Balance at March 31, 2019		115,564	$	1,156		170,941		$	1,710			12,329	$	123	$	537,159	$	(63,844	)	$	(4,099	)	$	327,576		$	799,781

The accompanying notes are an integral part of these consolidated financial statements.

Class A Common
Stock

Class B Common
Stock

Additional
Paid-in

Stockholders'
Accumulated

Accumulated
Other
Comprehensive

Non-
Controlling

Total

Shares

Amount

Shares

Amount

Capital

Deficit

(Loss) Income

Interests

Equity

Balance at July 1, 2019

128,151

$
1,281

170,941

$
1,710

$
544,161

$
(80,746
)

$
(6,750
)

$
289,696

$
749,352

Net loss

—

—

—

—

—

(265,006
)

—

(98,386
)

(363,392
)
Foreign currency translation adjustment

—

—

—

—

—

—

2,184

2,813

4,997

Stock-based compensation

—

—

—

—

6,095

—

—

—

6,095

Restricted stock unit vesting, net of shares withheld to
cover payroll taxes

3

—

—

—

4

—

—

(9
)

(5
)
Redemption of Class B Common Stock

5,936

59

(5,936
)

(59
)

16,481

—

(313
)

(16,391
)

(223
)
Other

—

—

—

—

(1,100
)

—

—

—

(1,100
)
Balance at September 30, 2019

134,090

$
1,340

165,005

$
1,651

$
565,641

$
(345,752
)

$
(4,879
)

$
177,723

$
395,724

~~The accompanying notes are an integral part of these consolidated financial statements.~~

Class A Common
Stock

Class B Common
Stock

Class B-1 Common
Stock

Additional
Paid-in

Stockholders'
Accumulated

Accumulated
Other
Comprehensive

Non-
Controlling

Total

Shares

Amount

Shares

Amount

Shares

Amount

Capital

Deficit

(Loss) Income

Interests

Equity

Balance at January 1, 2019

115,047

$
1,151

171,261

$
1,713

12,329

$
123

$
530,438

$
(20,920
)

$
(7,755
)

$
391,613

$
896,363

Net loss

—

—

—

—

—

—

—

(329,789
)

—

(208,881
)

(538,670
)
Cumulative-effective adjustment from adoption
   of Topic 842

—

—

—

—

—

—

—

4,957

—

8,604

13,561

Foreign currency translation adjustment

—

—

—

—

—

—

—

—

1,759

2,255

4,014

Stock-based compensation

—

—

—

—

—

—

16,666

—

—

—

16,666

Exercise of stock options

205

2

—

—

—

—

922

—

(7
)

468

1,385

Restricted stock unit vesting, net of shares
   withheld to cover payroll taxes

253

2

—

—

—

—

10

—

(5
)

(933
)

(926
)
Redemption of Class B Common Stock

6,256

62

(6,256
)

(62
)

17,605

—

(332
)

(17,273
)

—

Conversion of Class B-1 Common Stock

12,329

123

—

—

(12,329
)

(123
)

—

—

—

—

—

Tax distribution

—

—

—

—

—

—

—

—

—

(82
)

(82
)
Reclassification of foreign currency translation
   adjustment included in net loss

—

—

—

—

—

—

—

—

1,461

1,952

3,413

Balance at September 30, 2019

134,090

$
1,340

165,005

$
1,651

—

$
—

$
565,641

$
(345,752
)

$
(4,879
)

$
177,723

$
395,724

~~The accompanying notes are an integral part of these consolidated financial statements.~~

Class A Common
Stock

Class B Common
Stock

Class B-1
Common Stock

Additional
Paid-in

Stockholders'
Accumulated

Accumulated
Other
Comprehensive

Non-
Controlling

Total

Redeemable
Non-
Controlling

Shares

Amount

Shares

Amount

Shares

Amount

Capital

Deficit

Loss

Interests

Equity

Interest

Balance at July 1, 2018

114,859

$
1,149

171,261

$
1,713

12,329

$
123

$
517,122

$
(19,104
)

$
(6,502
)

$
444,985

$
939,486

$
11,858

Net income

—

—

—

—

—

—

—

6,888

—

10,510

17,398

67

Effect of the Combination

—

—

—

—

—

—

(2,329
)

—

—

—

(2,329
)

—

Foreign currency translation adjustment

—

—

—

—

—

—

—

—

(3,384
)

(4,555
)

(7,939
)

—

Stock-based compensation

—

—

—

—

—

—

3,590

—

—

—

3,590

—

Exercise of stock options

115

1

—

—

—

—

1,369

—

(3
)

(182
)

1,185

—

Reclassification of redeemable non-
   controlling interest

—

—

—

—

—

—

—

64

—

86

150

(150
)
Non-controlling interests from acquisition
   of Gemini

—

—

—

—

—

—

—

—

—

(531
)

(531
)

—

Acquisition of redeemable non-controlling
   interest

—

—

—

—

—

—

—

—

—

—

—

(11,775
)
Tax distribution

—

—

—

—

—

—

—

—

—

(35,543
)

(35,543
)

—

Other

—
��

—

—

—

—

—

408

—

—

(556
)

(148
)

—

Balance at September 30, 2018

114,974

$
1,150

171,261

$
1,713

12,329

$
123

$
520,160

$
(12,152
)

$
(9,889
)

$
414,214

$
915,319

$
—

~~The accompanying notes are an integral part of these consolidated financial statements.~~

Members'

Members'
Accumulated

Class A Common
Stock

Class B Common
Stock

Class B-1
Common Stock

Additional
Paid-in

Stockholders'
Accumulated

Accumulated
Other
Comprehensive

Non-
Controlling

Total

Redeemable
Non-
Controlling

Equity

Deficit

Shares

Amount

Shares

Amount

Shares

Amount

Capital

Deficit

(Loss) Income

Interests

Equity

Interest

Balance at January 1, 2018

$
2,716

$
(382,785
)

—

$
—

—

$
—

—

$
—

$
8,562

$
—

$
(14,232
)

$
10,157

$
(375,582
)

$
—

Period Prior to the Combination

Net (loss) income

—

(148,806
)

—

—

—

—

—

—

—

—

—

97

(148,709
)

—

Cumulative-effective adjustment from
   adoption of ASU 2014-09 (Topic
   606)

—

4,977

—

—

—

—

—

—

—

—

—

—

4,977

—

Capital contribution from non-
   controlling interest

—

—

—

—

—

—

—

—

—

—

—

360

360

—

Distributions to members

—

(182,998
)

—

—

—

—

—

—

(8,562
)

—

—

—

(191,560
)

—

PPU expense

158,757

—

—

—

—

—

—

—

—

—

—

—

158,757

—

Foreign currency translation
   adjustment

—

—

—

—

—

—

—

—

—

—

1,721

—

1,721

—

Capital contribution by Amneal
   Holdings for employee bonuses

27,742

—

—

—

—

—

—

—

—

—

—

—

27,742

—

Period Subsequent to the
   Combination

Effect of the Combination

(189,215
)

709,612

73,289

733

224,996

2,250

—

—

323,589

—

9,437

626,737

1,483,143

—

Redemption of Class B Common
   Stock for PIPE

—

—

34,520

345

(46,849
)

(468
)

12,329

123

165,180

—

(1,965
)

(130,501
)

32,714

—

Redemption of Class B Common
   Stock for distribution to PPU
   Holders

—

—

6,886

69

(6,886
)

(69
)

—

—

24,293

—

(289
)

(19,181
)

4,823

—

Net (loss) income

—

—

—

—

—

—

—

—

—

(10,976
)

—

(21,355
)

(32,331
)

67

Foreign currency translation
   adjustment

—

—

—

—

—

—

—

—

—

—

(4,554
)

(6,131
)

(10,685
)

—

Stock-based compensation

—

—

—

—

—

—

—

—

5,234

—

—

—

5,234

—

Exercise of stock options

—

—

279

3

—

—

—

—

3,610

—

(7
)

(444
)

3,162

—

Reclassification of redeemable non-
   controlling interest

—

—

—

—

—

—

—

—

—

(1,176
)

—

(10,532
)

(11,708
)

11,708

Non-controlling interests from
   acquisition of Gemini

—

—

—

—

—

—

—

—

—

—

—

2,518

2,518

—

Acquisition of redeemable non-
   controlling interest

—

—

—

—

—

—

—

—

—

—

—

—

—

(11,775
)
Tax distribution

—

—

—

—

—

—

—

—

—

—

—

(35,543
)

(35,543
)

—

Other

—

—

—

—

—

—

—

—

(1,746
)

—

—

(1,968
)

(3,714
)

—

Balance at September 30, 2018

$
—

$
—

114,974

$
1,150

171,261

$
1,713

12,329

$
123

$
520,160

$
(12,152
)

$
(9,889
)

$
414,214

$
915,319

$
—

~~The accompanying notes are an integral part of these consolidated financial statements.~~

Amneal Pharmaceuticals, Inc., formerly known as Atlas Holdings, Inc. (the "Company"), was formed along with its wholly owned subsidiary, K2 Merger Sub Corporation, a Delaware corporation ("Merger Sub"), on October 4, 2017, for the purpose of facilitating the combination of Impax Laboratories, Inc. (now Impax Laboratories, LLC), a Delaware corporation then listed on the Nasdaq Stock Market ("Impax") and Amneal Pharmaceuticals LLC, a Delaware limited liability company ("Amneal"). The Company is a holding company, whose principal assets are Amneal Common Units.

Amneal was formed in 2002 and operates through various subsidiaries. Amneal is a vertically integrated developer, manufacturer, and seller of generic pharmaceutical products. Amneal’s pharmaceutical research includes analytical and formulation development and stability. Amneal operates principally in the United States, ~~Switzerland,~~ India, and Ireland. ~~Amneal divested its operations in the United Kingdom on March 30, 2019 and Germany on May 3, 2019. For additional information, refer to~~ ~~Note 3. Acquisitions and Divestitures~~. Amneal sells to wholesalers, distributors, hospitals, chain pharmacies and individual pharmacies, either directly or indirectly.

On October 17, 2017, Amneal, Impax, the Company and Merger Sub entered into the Business Combination Agreement, as amended on November 21, 2017 and December 16, 2017 (the "BCA").

On May 4, 2018, pursuant to the BCA, Impax and Amneal combined the generics and specialty pharmaceutical business of Impax with the generic drug development and manufacturing business of Amneal to create the Company as a new generics and specialty pharmaceutical company, through the following transactions (together, the "Combination", and the closing of the Combination, the "Closing"): (i) Merger Sub merged with and into Impax, with Impax surviving as a wholly owned subsidiary of the Company, (ii) each share of Impax’s common stock, par value $0.01 per share ("Impax Common Stock"), issued and outstanding immediately prior to the Closing, other than Impax Common Stock held by Impax in treasury, by the Company or by any of their respective subsidiaries, was converted into the right to receive ~~one~~1 fully paid and non-assessable share of Class A common stock of the Company, par value $0.01 per share ("Class A Common Stock"), (iii) Impax converted to a Delaware limited liability company, (iv) the Company contributed to Amneal all of the Company’s equity interests in Impax, in exchange for Amneal common units ("Amneal Common Units"), (v) the Company issued an aggregate number of shares of Class B common stock of the Company, par value $0.01 per share ("Class B Common Stock", and collectively, with the Class A Common Stock and Class B-1 common stock of the Company, par value $0.01 , ("Class B-1 Common Stock"), the "Company Common Stock") to APHC Holdings, LLC, (formerly Amneal Holdings, LLC), the parent entity of Amneal as of the Closing ("Holdings"), and (vi) the Company became the managing member of Amneal.

Immediately upon the Closing, holders of Impax Common Stock prior to the Closing collectively held approximately 25% of the Company and Holdings held a majority interest in the Company with an effective voting interest of approximately 75% on a fully diluted and as converted basis through its ownership of Class B Common Stock. Holdings also held a corresponding number of Amneal Common Units, which entitled it to approximately 75% of the economic interests in the combined businesses of Impax and Amneal. The Company held an interest in Amneal of approximately 25%. and became its managing member.

In connection with the Combination, on May 4, 2018, Holdings entered into definitive purchase agreements which provided for a private placement of certain shares of Class A Common Stock and Class B-1 Common Stock (the "PIPE Investment") with select institutional investors (the "PIPE Investors"). Pursuant to the terms of the purchase agreements, upon the Closing, Holdings exercised its right to cause the Company to redeem approximately 15% of its ownership interests in the Company in exchange for 34.5 million shares of Class A Common Stock and 12.3 million unregistered shares of Class B-1 Common Stock (the "Redemption"). The shares of Class A Common Stock and Class B-1 Common Stock received in the Redemption were sold immediately following the Closing by Holdings to the PIPE Investors at a per share purchase price of $18.25 for gross proceeds of $855 million. Following the PIPE Investment, the PIPE Investors owned collectively approximately 15% of the Company Common Stock on a fully diluted and as converted basis.

On May 4, 2018, Holdings also caused Amneal to redeem (the "Closing Date Redemption") 6.9 million of Amneal Common Units held by Holdings for a like number of shares of Class A Common Stock, for future distribution to certain direct and indirect members of Holdings who were or are employees of the Company and to whom were previously issued (prior to the Closing) profit participation units ("PPUs") in Amneal. As a result of the PIPE Investment and Closing Date Redemption, the voting and economic interest of approximately 75% held by Holdings immediately upon Closing was reduced by approximately 18%. The overall interest percentage held by non-controlling interest holders (the "Amneal Group") upon the consummation of the Combination, PIPE Investment and Closing Date Redemption was approximately 57%. As of ~~September 30, 2019~~both March 31, 2020 and December 31, ~~2018,~~2019, the overall interest percentage held by non-controlling interest holders was approximately ~~55% and 57%, respectively.~~51%.

On July 5, 2018, Holdings distributed to its members all Amneal Common Units and shares of Class B Common Stock held by Holdings. As a result, as of ~~September 30, 2019,~~March 31, 2020, Holdings did not hold any equity interest in Amneal or the Company.

During the ~~three months~~year ended ~~June 30,~~December 31, 2019, pursuant to the Company's certificate of incorporation, the Company converted all (12.3 million) of its issued and outstanding shares of Class B-1 Common Stock to Class A Common Stock and such shares of Class B-1 Common Stock have been retired and may not be reissued by the Company. The rights of Class A Common Stock and Class B-1 Common Stock ~~are~~were identical, except that the Class B-1 Common Stock had certain director appointment rights and the Class B-1 Common Stock had no voting rights (other than with respect to its director appointment right and as otherwise required by law).

The accompanying unaudited consolidated financial statements, which are prepared in accordance with generally accepted accounting principles in the United States of America, should be read in conjunction with Amneal’s annual audited financial statements for the year ended December 31, ~~2018~~2019 included in the Company’s ~~2018~~2019 Annual Report on Form 10-K. Certain information and footnote disclosures normally included in annual financial statements have been omitted from the accompanying unaudited consolidated financial statements. In the opinion of management, the accompanying unaudited consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the Company's financial position as of ~~September 30, 2019,~~March 31, 2020, cash flows for the ~~nine~~three months ended ~~September 30,~~March 31, 2020 and 2019 ~~and 2018~~ and the results of its operations, its comprehensive ~~loss~~income (loss) and changes in stockholders' equity for the three ~~and nine~~ months ended ~~September 30, 2019~~March 31, 2020 and ~~2018.~~2019. The consolidated balance sheet data at December 31, ~~2018~~2019 was derived from the Company's audited annual financial statements, but does not include all disclosures required by generally accepted accounting principles ~~generally accepted~~ in the United States of America.

The accounting policies of the Company are set forth in Note 2. Summary of Significant Accounting Policies contained in the Company’s ~~2018~~2019 Annual Report on Form 10-K, except for the impact of the adoption of new accounting standards discussed under Recently Adopted Accounting Pronouncements. The following new significant accounting policy relates to the acquisitions of AvKARE, Inc. and Dixon-Shane, LLC d/b/a R&S Northeast LLC (refer to Note 3. Acquisitions and Divestitures).

When a sale occurs on a contracted item, the difference between the cost the Company pays to the manufacturer of that item and the contract price that the end customer has with the manufacturer is rebated to the Company by the manufacturer. The Company establishes a chargeback (rebate) receivable and a reduction to cost of goods sold in the same period as the related sale. At March 31, 2020, chargebacks receivable was $24 million, net of an immaterial allowance for doubtful accounts.

The preparation of financial statements requires the Company's management to make estimates and assumptions that affect the reported financial position at the date of the financial statements and the reported results of operations during the reporting period. Such estimates and assumptions affect the reported amounts of assets, liabilities, revenues and expenses, and disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. The following are some, but not all, of such estimates: the determination of chargebacks, sales returns, rebates, billbacks, distribution fees, allowances for accounts receivable, accrued liabilities, chargeback receivables, stock-based compensation, valuation of inventory balances, the determination of useful lives for product rights, allowances for deferred tax assets,measurement of assets acquired and liabilities assumed in business combinations at fair value and the assessment of expected cash flows used in evaluating goodwill and other long-lived assets for impairment. Actual results could differ from those estimates.

~~Certain prior period balances have been reclassified to conform to the current period presentation.~~

~~In February 2016, the Financial Accounting Standards Board ("FASB") issued ASU 2016-02,~~ ~~Leases,~~ which was subsequently supplemented by clarifying guidance (collectively, "Topic 842") to improve financial reporting of leasing transactions. Topic 842 requires a lessee to recognize most leases, including those classified as operating, on its balance sheets as right of use ("ROU") assets and lease liabilities and requires disclose of additional key information about leases.

The Company elected to apply the modified retrospective transition provisions of Topic 842 on January 1, 2019, the date of adoption. In addition, the Company elected the package of practical expedients permitted under the transition guidance within the new standard. This allowed the Company to carry forward historical lease classifications. Adoption of this standard resulted in the recording of operating lease ROU assets and operating lease liabilities of $85 million and $86 million, respectively.

The transition guidance of Topic 842 also required the Company to de-recognize the build to suit accounting associated with a related party lease for integrated manufacturing and office space and recognize that transaction as a financing lease as of January 1, 2019. The resulting de-recognition reduced leasehold improvements and a financing obligation by $24 million and $39 million, respectively, and increased non-controlling interests and stockholders' accumulated deficit, net of income taxes, by $9 million and $5 million, respectively. The arrangement was then recognized as a financing lease with an ROU asset and lease liability of $64 million on January 1, 2019. Leases with related parties, the details of which are described in ~~Note 15. Related Party Transactions,~~ ~~are presented separately in the Company's balance sheets.~~

The adoption of Topic 842 did not have a material impact on the Company's consolidated statements of operations. ROU assets and lease liabilities for reporting periods beginning on or after January 1, 2019 are presented under the new guidance, while prior periods amounts were not adjusted and continue to be reported in accordance with previous guidance.

All significant lease arrangements after January 1, 2019 are recognized as ROU assets and lease liabilities at lease commencement. ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the commencement date based on the present value of the future lease payments using the Company's incremental borrowing rate, which is assessed quarterly.

Operating lease expense is recognized on a straight-line basis over the lease term. At each balance sheet date, operating and financing lease liabilities continue to represent the present value of the future payments. Financing lease ROU assets are expensed using the straight-line method, unless another basis is more representative of the pattern of economic benefit, to lease expense. Interest on financing lease liabilities is recognized in interest expense.

Leases with an initial term of 12 months or less (short-term leases) are not recognized in the balance sheet and the related lease payments are recognized as incurred over the lease term. The Company separates lease and non-lease components. A portion of the Company's real estate leases are subject to periodic changes in the Consumer Price Index ("CPI"). The changes to the CPI are treated as variable lease payments and recognized in the period in which the obligation for those payments was incurred.

~~For further details regarding the Company's leases, refer to~~ ~~Note 11. Leases~~.

~~In January 2016, the FASB issued ASU 2016-01,~~ ~~Financial Instruments—Overall (Subtopic 825-10), Recognition and Measurement of Financial Assets and Financial Liabilities~~, which addresses certain aspects of recognition, measurement, presentation, and disclosure of financial instruments. The Company adopted ASU 2016-01 as of January 1, 2019 and it did not have a material impact on the Company's consolidated financial statements.

~~In January 2017, the FASB issued ASU 2017-04,~~ ~~Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment~~ that eliminates the requirement to calculate the implied fair value of goodwill (i.e., Step 2 of today’s goodwill impairment test) to measure a goodwill impairment charge. The Company adopted ASU 2017-04 as of April 1, 2019 on a prospective basis and it did not have a material impact on the Company's consolidated financial statements.

In August 2018, the ~~FASB~~Financial Accounting Standards Board (“FASB”) issued ~~ASU~~Accounting Standards Update (“ASU”) 2018-13, Fair Value Measurement (Topic 82): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement, which modifies the disclosure requirements on fair value measurement. The ~~guidance is~~Company adopted ASU 2018-13 effective ~~for annual periods beginning after December 15, 2019~~January 1, 2020 and ~~interim periods within those annual periods, and early adoption is permitted. The Company is evaluating~~it did not have a material impact on the ~~impact of this new guidance on its~~Company’s consolidated financial statements.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, guidance that changes the impairment model for most financial assets including trade receivables and certain other instruments that are not measured at fair value through net income. The standard will replace today’s "incurred loss" approach with an "expected loss" model for instruments measured at amortized cost and require entities to record allowances for available-for-sale debt securities rather than reduce the carrying amount, as they do today under the other-than-temporary impairment model. It also simplifies the accounting model for purchased credit-impaired debt securities and loans. Entities will apply the standard’s provisions as a cumulative effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The ~~guidance is~~Company adopted ASU 2016-13 effective January 1, 2020 and it did not have a material impact on the Company’s consolidated financial statements.

In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform, which provided elective amendments for ~~the Company for the annual period beginning after~~entities that have contracts, hedging relationships and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. The amendments may be applied to impacted contracts and hedges prospectively through December ~~15, 2019.~~31, 2022. The Company is currently evaluating the impact of this ~~new~~ guidance will have on its consolidated financial statements.

On December 10, 2019, the Company, through its investment in Rondo Partners, LLC (“Rondo”), entered into an equity purchase and operating agreements to acquire approximately a 65.1% controlling financing interest in both AvKARE Inc., a Tennessee corporation, and Dixon-Shane, LLC d/b/a R&S Northeast LLC, a Kentucky limited liability company (“R&S”) (collectively the “Acquisitions”). Prior to closing, AvKARE, Inc. converted to a limited liability company, AvKARE, LLC. AvKARE, LLC is one of the largest private label providers of generic pharmaceuticals in the U.S. federal agency sector, primarily focused on serving the Department of Defense and the Department of Veterans Affairs. R&S is a national pharmaceutical wholesaler focused primarily on offering 340b-qualified entities products to provide consistency in care and pricing.

On January 31, 2020, the Company completed the Acquisitions. The purchase price of $295 million, included cash of $254 million and the issuance of long-term promissory notes to the sellers with an aggregate principal amount of $44 million (estimated fair value of $35 million) (the “Sellers Notes”) and a short-term promissory note (the “Short-Term Seller Note”) with a principal amount of $1 million to the sellers. The cash purchase price was funded by $76 million of cash on hand and $178 million of proceeds from a $180 million term loan. The remaining $2 million consisted of working capital costs (refer to Note 13. Debt). For further detail of the preliminary purchase price, refer to the table below.

For the three months ended March 31, 2020, there were $1 million of transaction costs associated with the Acquisitions recorded in acquisition, transaction-related and integration expenses.

The Acquisitions were accounted for under the acquisition method of accounting, with Amneal as the accounting acquirer of AvKARE, LLC and R&S.

The following is a summary of the preliminary purchase price allocation for the Acquisitions (in thousands):

The acquired intangible assets are being amortized over their estimated useful lives as follows (in thousands):

The estimated fair values of the customer relationships, government contracts and national contracts were determined using the “income approach,” which is a valuation technique that provides an estimate of the fair value of an intangible asset based on market participant expectations of the cash flows that an intangible asset would generate over its remaining useful life. The estimated fair value of the trade name was determined using the “relief from royalty method,” which is a valuation technique that provides an estimate of the fair value of an intangible asset equal to the present value of the after-tax royalty savings attributable to owning the intangible asset. The estimated fair value of the government licenses was determined using the “with-and-without method,” which is a valuation technique that provides an estimate of the fair value of an intangible asset that is equal to the difference between the present value of the prospective revenues and expenses for the business with and without the subject intangible asset in place. The assumptions, including the expected projected cash flows, utilized in the preliminary purchase price allocation and in determining the purchase price were based on management's best estimates as of the closing date of the Acquisitions on January 31, 2020.

Some of the more significant assumptions inherent in the development of those asset valuations include the estimated net cash flows for each year for each asset (including net revenues, cost of sales, selling and marketing costs and working capital / contributory asset charges), the appropriate discount rate to select in order to measure the risk inherent in each future cash flow stream, the assessment of each asset’s life cycle, competitive trends impacting the asset and each cash flow stream, as well as other factors. No assurances can be given that the underlying assumptions used to prepare the discounted cash flow analysis will not change. For these and other reasons, actual results may vary significantly from estimated results.

The Company makes an initial allocation of the purchase price at the date of acquisition based upon its understanding of the fair value of the acquired assets, assumed liabilities and redeemable non-controlling interests. The Company obtains this information during due diligence and through other sources. In the months after closing, as the Company obtains additional information about these assets and liabilities and learns more about the newly acquired businesses, it is able to refine the estimates of fair value and more accurately allocate the purchase price. Only items identified as of the acquisition date are considered for subsequent adjustment. The Company is continuing to evaluate the acquired assets, assumed liabilities and redeemable non-controlling interests associated with the Acquisitions. The Company will make appropriate adjustments to the purchase price allocation prior to completion of the measurement period, as required.

The Sellers Notes and redeemable non-controlling interests were estimated using the Monte-Carlo simulation approach under the option pricing framework. The non-controlling interests are redeemable at the option of either the non-controlling interest holder and Amneal. The fair value of the redeemable non-controlling interests considers these redemption rights.

Of the $96 million of goodwill acquired in connection with the Acquisitions, approximately $65 million was allocated to the Company’s AvKARE segment (refer to Note 18. Segment Information) and approximately $31 million was allocated to the Generics segment. Goodwill was allocated to the Generics segment as net revenue of products manufactured from Amneal and distributed by the Acquisitions is reflected in Generics’ segment results. Goodwill is calculated as the excess of the fair value of the consideration transferred and the fair value of the redeemable non-controlling interests over the fair value of the net assets recognized. Factors that contributed to the recognition of goodwill include Amneal’s intent to diversify its business and open growth opportunities in the large, complex and growing federal healthcare market.

For the three months ended March 31, 2020, the Acquisitions contributed total net revenue of approximately $65 million and operating loss of $1 million, which included approximately $6 million of amortization expense from intangible assets acquired in the Acquisitions, to the Company’s consolidated results of operations.

~~On May 4, 2018, the Company completed the Combination, as described in~~ ~~Note 1. Nature of Operations~~. The unaudited pro forma combined results of operations for the ~~nine~~three months ended ~~September 30, 2018~~March 31, 2020 and 2019 (assuming the closing of the ~~Combination~~Acquisitions occurred on January 1, ~~2017)~~2019) are as follows (in thousands):

The pro forma results have been prepared for comparative purposes only and are not necessarily indicative of the actual results of operations had the closing of the ~~Combination~~Acquisitions taken place on January 1, ~~2017.~~2019. Furthermore, the pro forma results do not purport to project the future results of operations of the Company.

~~The~~Adjustments to arrive at the unaudited pro forma information ~~reflects~~ primarily ~~the following non-recurring adjustments (all of which were adjusted for the applicable tax impact):~~

~~Adjustments to~~increases in selling, general and administrative ~~expense related to transaction costs directly attributable to~~expenses for amortization of acquired intangible assets, net of the ~~transactions.~~ applicable tax impact.

UKU.K. Divestiture

On March 30, 2019, the Company sold 100% of the stock of its Creo Pharma Holding Limited subsidiary, which comprised substantially all of the Company's operations in the United Kingdom, to AI Sirona (Luxembourg) Acquisition S.a.r.l ("AI Sirona") for net cash consideration of approximately $32 million which was received in April 2019. The carrying value of the net assets sold was $22 million, including intangible assets of $7 million and goodwill of $5 million. As a result of the sale, the Company recognized a pre-tax gain of $9 million, inclusive of transaction costs and the recognition of accumulated foreign currency translation adjustment losses of $3 million, within ~~(loss)~~ gain on sale of international business for the ~~nine~~three months ended ~~September 30,~~March 31, 2019. As part of the disposition, the Company entered into a supply and license agreement with AI Sirona to supply certain products for a period of up to two years.

~~Germany Divestiture~~

On May 3, 2019, the Company sold 100% of the stock of its Amneal Deutschland GmbH subsidiary, which comprised substantially all of the Company's operations in Germany, to EVER Pharma Holding Ges.m.b.H. (“EVER”) for net cash consideration of approximately $3 million which was received in May 2019. The carrying value of the net assets sold was $7 million, including goodwill of $0.5 million. As a result of the sale, the Company recognized a pre-tax loss of $2 million, inclusive of transaction costs and the recognition of accumulated foreign currency translation adjustment losses, within (loss) gain on sale of international business for the nine months ended September 30, 2019. As part of the disposition, the Company also entered into a license and supply agreement with EVER to supply certain products for an 18 month period.

4. Revenue Recognition

Performance Obligations

The Company’s performance obligation is the supply of finished pharmaceutical and related products to its customers. The Company’s customers consist primarily of major wholesalers, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The Company’s customer contracts generally consist of both a master agreement, which is signed by the Company and its customer, ~~and~~and/or a customer submitted purchase order, which is governed by the terms and conditions of the master agreement. Customers purchase product by direct channel sales from the Company or by indirect channel sales through various distribution channels.

Revenue is recognized when the Company transfers control of its products to the customer, which typically occurs at a point-in-time, either upon shipment or delivery. Substantially all of the Company’s net revenues relate to products which are transferred to the customer at a point-in-time.

The Company offers standard payment terms to its customers and has elected the practical expedient to not adjust the promised amount of consideration for the effects of a significant financing, since the period between when the Company transfers the product to the customer and when the customer pays for that product is one year or less. Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenues. The consideration amounts due from customers as a result of product sales are subject to variable consideration, as described further below.

The Company offers standard product warranties which provide assurance that the product will function as expected and in accordance with specifications. Customers cannot purchase warranties separately and these warranties do not give rise to a separate performance obligation.

The Company permits the return of product under certain circumstances, mainly upon product expiration, instances of shipping errors or where product is damaged in transit. The Company accrues for the customer’s right to return as part of its variable consideration. See below for further details.

Variable Consideration

The Company includes an estimate of variable consideration in its transaction price at the time of sale, when control of the product transfers to the customer. Variable consideration includes but is not limited to: chargebacks, distribution fees, rebates, group purchasing organization ("GPO") fees, prompt payment (cash) discounts, consideration payable to the customer, billbacks, Medicaid and other government pricing programs, price protection and shelf stock adjustments, sales returns, and profit shares.

The Company assesses whether or not an estimate of its variable consideration is constrained and has determined that the constraint does not apply, since it is probable that a significant reversal in the amount of cumulative revenue will not occur in the future when the uncertainty associated with the variable consideration is subsequently resolved. The Company’s estimates for variable consideration are adjusted as required at each reporting period for specific known developments that may result in a change in the amount of total consideration it expects to receive.

Chargebacks

In the case an indirect customer purchases product from their preferred wholesaler instead of directly from the Company, and the contract price charged to the indirect customer is lower than the wholesaler pricing, the Company pays the direct customer (wholesaler) a chargeback for the price differential. The Company estimates its chargeback accrual based on its estimates of the level of inventory of its products in the distribution

channel that remain subject to chargebacks and historical chargeback rates. The estimate of the level of products in the distribution channel is based primarily on data provided by key customers.

Rebates

The Company pays fixed or volume-based rebates to its customers based on a fixed amount, fixed percentage of product sales or based on the achievement of a specified level of purchases. The Company’s rebate accruals are based on actual net sales, contractual rebate rates negotiated with customers, and expected purchase volumes / corresponding tiers based on actual sales to date and forecasted amounts.

Group Purchasing Organization Fees

The Company pays fees to GPOs for administrative services that the GPOs perform in connection with the purchases of product by the GPO participants who are the Company’s customers. The Company’s GPO fee accruals are based on actual net sales, contractual fee rates negotiated with GPOs and the mix of the products in the distribution channel that remain subject to GPO fees.

Prompt Payment (Cash) Discounts

The Company provides customers with prompt payment discounts which may result in adjustments to the price that is invoiced for the product transferred, in the case that payments are made within a defined period. The Company’s prompt payment discount accruals are based on actual net sales and contractual discount rates.

Consideration Payable to the Customer

The Company pays administrative and service fees to its customers based on a fixed percentage of the product price. These fees are not in exchange for a distinct good or service and therefore are recognized as a reduction of the transaction price. The Company accrues for these fees based on actual net sales, contractual fee rates negotiated with the customer and the mix of the products in the distribution channel that remain subject to fees.

Billbacks

In the case an indirect customer purchases product from their preferred wholesaler instead of directly from the Company, and the contract price charged to the indirect customer is higher than contractual pricing, the Company pays the indirect customer a billback for the price differential. The Company estimates its billback accrual based on its estimates of the level of inventory of its products in the distribution channel that remain subject to billbacks and historical billback rates. The estimate of the level of products in the distribution channel is based primarily on data provided by key customers.

Medicaid and Other Government Pricing Programs

The Company complies with required rebates mandated by law under Medicaid and other government pricing programs. The Company estimates its government pricing accruals based on monthly sales, historical experience of claims submitted by the various states and jurisdictions, historical rates and estimated lag time of the rebate invoices.

Price Protection and Shelf Stock Adjustments

The Company provides customers with price protection and shelf stock adjustments which may result in an adjustment to the price charged for the product transferred, based on differences between old and new prices which may be applied to the customer’s on-hand inventory at the time of the price change. The Company accrues for these adjustments when its expected value of an adjustment is greater than zero, based on contractual pricing, actual net sales, accrual rates based on historical average rates, and estimates of the level of inventory of its products in the distribution channel that remain subject to these adjustments. The estimate of the level of products in the distribution channel is based primarily on data provided by key customers.

Sales Returns

The Company permits the return of product under certain circumstances, mainly upon product expiration, instances of shipping errors or where product is damaged in transit, and occurrences of product recalls. The Company’s product returns accrual is primarily based on estimates of future product returns based generally on actual net sales, estimates of the level of inventory of its products in the distribution channel that remain subject to returns, estimated lag time of returns and historical return rates. The estimate of the level of products in the distribution channel is based primarily on data provided by key customers.

Profit Shares

For certain product sale arrangements, the Company earns a profit share upon the customer’s sell-through of the product purchased from the Company. The Company estimates its profit shares based on actual net sales, estimates of the level of inventory of its products in the distribution channel that remain subject to profit shares, and historical rates of profit shares earned. The estimate of the level of products in the distribution channel is based primarily on data provided by key customers.

Concentration of Revenue

The Company's ~~three~~3 largest customers accounted for approximately 81% and ~~80%~~79% of total gross sales of products for the three ~~and nine~~ months ended ~~September 30,~~March 31, 2020 and 2019, respectively. ~~The Company's three largest customers accounted for approximately 83% and 82% of total gross sales of products for the three and nine months ended September 30, 2018, respectively.~~

~~Significant Products~~Disaggregated Revenue

The Company generally consolidates net revenue by "product family," meaning that it consolidates net revenue from products containing the same active ingredient(s) irrespective of dosage strength, delivery method or packaging size. The Company's significant ~~product families,~~therapeutic classes for its Generics and Specialty segments and sales channels for its AvKARE segment, as determined based on ~~net revenue, and their percentage of the Company's consolidated~~ net revenue for each of the three ~~and nine~~ months ended ~~September 30,~~March 31, 2020 and 2019 ~~and 2018~~ are set forth below (in ~~thousands, except for percentages)~~thousands):

Segment	Product Family	Three Months Ended September 30, 2019
						Three Months Ended March 31,
		$		%		2020		2019
Generics	Levothyroxine Sodium	$	39,767	11%
					Anti-Infective	$	13,253	$	5,942
					Hormonal/Allergy		87,481		102,725
					Antiviral		15,824		14,456
					Central Nervous System ⁽¹⁾		101,575		124,775
					Cardiovascular System		29,679		36,217
					Gastroenterology		23,536		9,556
					Oncology		15,966		14,959
					Metabolic Disease/Endocrine		17,229		17,847
					Respiratory		10,067		9,218
					Dermatology		15,245		12,973
					Other therapeutic classes		21,746		18,177
					International and other		985		15,632
					Total Generics net revenue		352,586		382,477
Specialty	Rytary®		33,710	9%
Generics	Epinephrine Auto-Injector (generic Adrenaclick®)		22,687	6%
Generics	Diclofenac Sodium Gel		19,264	5%
Specialty ⁽¹⁾	Oxymorphone	$	17,142	5%
					Hormonal/Allergy		13,954		10,899
					Central Nervous System ⁽¹⁾		68,311		42,899
					Gastroenterology		48		481
					Metabolic Disease/Endocrine		273		541
					Other therapeutic classes		5,391		8,823
					Total Specialty net revenue		87,977		63,643
AvKARE
					Distribution		31,586		—
					Government Label		21,378		—
					Institutional		3,413		—
					Other		1,593		—
					Total AvKARE net revenue		57,970		—
					Total net revenue	$	498,533	$	446,120

A rollforward of the major categories of sales-related deductions for the ~~nine~~three months ended ~~September 30, 2019~~March 31, 2020 is as follows (in thousands):

The Company has entered into several alliance, collaboration, license, distribution and similar agreements with respect to certain of its products and services with third-party pharmaceutical companies. The consolidated statements of operations include revenue recognized under agreements the Company has entered into to develop marketing and/or distribution relationships with its partners to fully leverage the technology platform and revenue recognized under development agreements which generally obligate the Company to provide research and development services over multiple periods. The Company's significant arrangements are discussed below.

On August 16, 2018, the Company entered into a license and supply agreement with Jerome Stevens Pharmaceuticals, Inc. ("JSP") for levothyroxine sodium tablets ("Levothyroxine"). This agreement designated the Company as JSP's exclusive commercial partner for Levothyroxine in the U.S. market for a ~~10 -year~~10-year term commencing on March 22, 2019. ~~Under~~Additionally, under this license and supply agreement, ~~with JSP,~~ the Company accrued the up-front license payment of $50 million on March 22, 2019, which was paid in April 2019. The agreement also provides for the Company to pay a profit share to JSP based on net profits of the Company's sales of Levothyroxine, after considering product costs.

On November 9, 2018, the Company entered into a transition agreement ("Transition Agreement") with Lannett Company (“Lannett”) and JSP. Under the terms of the Transition Agreement, the Company assumed the distribution and marketing of Levothyroxine from Lannett beginning December 1, 2018 through March 22, 2019, ahead of the commencement date of the license and supply agreement with JSP described above.

In accordance with the terms of the Transition Agreement, the Company made $47 million of non-refundable payments to Lannett. For the ~~nine~~three months ended ~~September 30,~~March 31, 2019, ~~and the year ended December 31, 2018,~~ $37 million, ~~and $10 million, respectively, were~~was expensed to cost of goods sold, as the Company sold Levothyroxine ~~(none~~(NaN in the three months ended ~~September 30, 2019)~~March 31, 2020). As of December 31, 2018, , the Company had a $4 million transition contract liability, which was fully settled in February 2019.

Additionally, during the year ended December 31, 2019, the Company recorded $1 million in cost of sales related to reimbursement due to Lannett for certain of its unsold inventory at the end of the transition period, which was fully settled in March 2020.

On May 7, 2018, the Company entered into a licensing and supply agreement, with Mabxience S.L., for its biosimilar candidate for Avastin® (bevacizumab). The Company will be the exclusive partner in the U.S. market. The Company will pay development and regulatory milestone payments as well as commercial milestone payments on reaching pre-agreed sales targets in the market to Mabxience, up to $72 million. For the ~~nine~~three months ended ~~September 30,~~March 31, 2019 the Company expensed a milestone payment of $1 million, ~~(none for~~to research and development (NaN in the three months ended September 30, 2019), to research and development. For the nine months ended September 30, 2018, the Company expensed a milestone payment of $0.5 million to research and development (none for the three months ended September 30, 2018)March 31, 2020).

Distribution, License, Development and Supply Agreement with AstraZeneca UK Limited

In January 2012, Impax entered into an agreement with AstraZeneca UK Limited ("AstraZeneca") to distribute branded products under the terms of a distribution, license, development and supply Agreement (the "AZ Agreement"). The parties subsequently entered into a First Amendment to the AZ Agreement dated May 31, 2016 (as amended, the "AZ Amendment"). Under the terms of the AZ Agreement, AstraZeneca granted to Impax an exclusive license to commercialize the tablet, orally disintegrating tablet and nasal spray formulations of Zomig® (zolmitriptan)

products for the treatment of migraine headaches in the United States and in certain U.S. territories, except during an initial transition period when AstraZeneca fulfilled all orders of Zomig® products on Impax’s behalf and AstraZeneca paid to Impax the gross profit on such Zomig® products. Pursuant to the AZ Amendment, under certain conditions, and depending on the nature and terms of the study agreed to with the FDA, Impax agreed to conduct, at its own expense, the juvenile toxicity study and pediatric study required by the FDA under the Pediatric Research Equity Act ("PREA") for approval of the nasal formulation of Zomig ® for the acute treatment of migraine in pediatric patients ages six through eleven years old, as further described in the study protocol mutually agreed to by the parties (the "PREA Study"). In consideration for Impax conducting the PREA Study at its own expense, the AZ Amendment provides for the total royalty payments payable by Impax to AstraZeneca on net sales of Zomig ® products under the AZ Agreement to be reduced by an aggregate amount of $30 million to be received in quarterly amounts specified in the AZ Amendment beginning from the quarter ended June 30, 2016 and through the quarter ended December 31, 2020 . In the event the royalty reduction amounts exceed the royalty payments payable by Impax to AstraZeneca pursuant to the AZ Agreement in any given quarter, AstraZeneca will be required to pay Impax an amount equal to the difference between the royalty reduction amount and the royalty payment payable by Impax to AstraZeneca. Impax’s commitment to perform the PREA Study may be terminated, without penalty, under certain circumstances as set forth in the AZ Amendment. The Company recognizes the amounts received from AstraZeneca for the PREA Study as a reduction to research and development expense.

In May 2013, Impax’s exclusivity period for branded Zomig® tablets and orally disintegrating tablets expired and Impax launched authorized generic versions of those products in the United States. As discussed above, pursuant to the AZ Amendment, the total royalty payments payable by Impax to AstraZeneca on net sales of Zomig ® products under the AZ Agreement is reduced by certain specified amounts beginning from the quarter ended June 30, 2016 and through the quarter ended December 31, 2020, with such reduced royalty amounts totaling an aggregate amount of $30 million. The Company recorded cost of sales for royalties under this agreement of ~~$5 million and $14~~$4 million for both the three ~~and nine~~ months ended ~~September 30, 2019 , respectively,~~March 31, 2020 and ~~$5 million and $8 million for~~2019.

During the three ~~and nine~~ months ended ~~September 30, 2018, respectively.~~March 31, 2020, AstraZeneca and the Company agreed to terminate the AZ Agreement and subsequent AZ Amendment effective January 2021.

~~On October 1, 2017, Amneal and Adello Biologics, LLC ("Adello"), a~~For detail on the Company’s related party ~~entered into a license and commercialization agreement. Adello granted Amneal an exclusive license, under its New Drug Application,~~agreements with Kashiv Biosciences, LLC, refer to distribute and sell two bio-similar products in the U.S. Adello is responsible for development, regulatory filings, obtaining FDA approval, and manufacturing, and Amneal is responsible for marketing, selling and pricing activities. The term of the agreement is 10 -years from the respective product’s launch date. In connection with the agreement, Amneal paid an upfront amount of $2 million in October 2017 for execution of the agreement which was expensed in research and development. The agreement also provides for potential future milestone payments to Adello of (i) up to $21 million relating to regulatory approval, (ii) up to $43 million for successful delivery of commercial launch inventory, (iii) between $20 million and $50 million relating to number of competitors at launch for one product, and (iv) between $15 million and $68 million for the achievement of cumulative net sales for both products. The milestones are subject to certain performance conditions which may or may not be achieved, including FDA filing, FDA approval, launch activities and commercial sales volume objectives. In addition, the agreement provides for Amneal to pay a profit share equal to 50% of net profits, after considering manufacturing and marketing costs. The research and development expenses for payments made to Adello for the three and nine months ended September 30, 2019 and 2018 were immaterial.Note 19. Related Party Transactions.

During the three months ended June 30, 2018, in connection with the Combination, the Company committed to a restructuring plan to achieve cost savings. The Company expected to integrate its operations and reduce its combined cost structure through workforce reductions that ~~eliminate~~eliminated duplicative positions and ~~the consolidation of~~consolidated certain administrative, manufacturing and research and development facilities. In connection with this plan, the Company announced on May 10, 2018 that it intended to close its Hayward, ~~California based~~California-based operations.

~~In addition to the actions noted above, on~~On July 10, 2019, the Company announced a plan to restructure its operations that iswas intended to reduce costs and optimize its organizational and manufacturing infrastructure. Pursuant to the restructuring plan as revised, the Company expects to reduce its headcount by approximately 300 to 350 employees, primarily by ~~closing~~ceasing manufacturing at its ~~manufacturing facility located in~~ Hauppauge, NY. As a result of the restructuring plan, the Company estimates that it will incur a pre-tax restructuring charge of approximately $6 to $8 million of cash expenditures related to severance benefits.

~~Other cash expenditures associated with this restructuring plan, including decommissioning and dismantling the sites and other third party costs cannot be estimated at this time (collectively~~NY facility. Collectively these actions comprise the "Plans").

The following table sets forth the components of the Company's restructuring and other charges (in thousands):

The charges related to restructuring impacted segment earnings as follows (in thousands):

The following table shows the change in the employee separation-related liability associated with the Plans, which is included in accounts payable and accrued expenses (in thousands):

Basic earnings (loss) ~~earnings~~ per share of Class A Common Stock and Class B-1 Common Stock is computed by dividing net loss attributable to Amneal Pharmaceuticals, Inc. by the weighted-average number of shares of Class A Common Stock and Class B-1 Common Stock outstanding during the period. Diluted earnings (loss) ~~earnings~~ per share of Class A Common Stock and Class B-1 Common Stock is computed by dividing net income (loss) ~~earnings~~ attributable to Amneal Pharmaceuticals, Inc. by the weighted-average number of shares of Class A Common Stock and Class B-1 Common Stock outstanding, adjusted to give effect to potentially dilutive securities.

The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted earnings (loss) ~~earnings~~ per share of Class A Common Stock and Class B-1 Common Stock (in thousands, except per share amounts):

~~The allocation of net (loss) earnings to the holders of shares of Class A Common Stock and Class B-1 Common Stock began following the closing of the Combination on May 4, 2018.~~ Shares of the Company's Class B Common Stock do not share in the earnings or losses of the Company and, therefore, are not participating securities. As such, separate presentation of basic and diluted earnings per share of Class B Common Stock under the two-class method has not been presented.

The following table presents potentially dilutive securities excluded from the computations of diluted earnings per share of Class A Common Stock and Class B-1 Common Stock (in thousands):

For the three months ended March 31, 2020 and 2019, the Company's benefit from income taxes and effective tax rates were $108 million and (810.6%) and $8 million and 6.3%, respectively. The year over year change in benefit from income taxes was primarily related to the Company’s full valuation allowance and the effects of the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act.”)

As ~~a result~~ of ~~the Combination (refer to~~ ~~Note 1. Nature of Operations~~), the Company became the sole managing member of Amneal, with Amneal being the accounting predecessor for accounting purposes. Amneal is a limited liability company that is treated as a partnership for U.S. federal and most applicable state and local income tax purposes. As a partnership, Amneal is not subject to U.S. federal and certain state and local income taxes. Any taxable income or loss generated by Amneal is passed through to and included in the taxable income or loss of its members, including the Company, on a pro rata basis subject to applicable tax regulations. The Company is subject to U.S. federal income taxes, in addition to state and local income taxes with respect to its allocable share of any taxable income or loss of Amneal, as well as any stand-alone income or loss generated by the Company. Amneal provides for income taxes in the various foreign jurisdictions in which it operates.

The Company records its valuation allowances against its deferred tax assets (“DTAs”) when it is more likely than not that all or a portion of a DTA will not be realized. The Company routinely evaluates the realizability of its DTAs by assessing the likelihood that its DTAs will be recovered based on all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, estimates of future taxable income, tax planning strategies and results of operations. Estimating future taxable income is inherently uncertain and requires judgment. In projecting future taxable income, the Company considers its historical results and incorporates certain assumptions, including projected new product launches, revenue growth, and operating margins, among others.

A valuation allowance, if needed, reduces DTAs to the amount expected to be realized. When determining the amount of net DTAs that are more likely than not to be realized, the Company assesses all available positive and negative evidence. This evidence includes, but is not limited to, prior earnings history, projected future earnings, carryback and carry-forward periods and the feasibility of ongoing tax strategies that could potentially enhance the likelihood of the realization of a DTA. The weight given to the positive and negative evidence is commensurate with the extent the evidence may be objectively verified. As such, it is generally difficult for positive evidence regarding projected future taxable income to outweigh objective negative evidence of recent financial reporting losses.

~~In assessing the need for a valuation allowance in the third quarter of fiscal~~September 30, 2019, the Company ~~considered~~established a valuation allowanced based upon all available objective and verifiable evidence both positive and negative, including historical levels of pre-tax income (loss) both on a consolidated basis and tax reporting entity basis, legislative developments, expectations and risks associated with estimates of future pre-tax income, and prudent and feasible tax planning strategies. The Company ~~currently estimates~~estimated that as of September 30, 2019 it ~~will have~~had generated a cumulative consolidated ~~three year~~three-year pre-tax ~~loss.~~loss, which continued as of December 31, 2019. As a result of ~~this analysis,~~the initial September 30, 2019 and December 31, 2019 analyses, the Company determined that it isremained more likely than not that it will not realize the benefits of its gross DTAs and therefore ~~has~~ recorded aan additional valuation allowance of ~~$372~~$428 million for the ~~three months~~year ended ~~September 30,~~December 31, 2019 to reduce the carrying value of these gross DTAs, net of the impact of the reversal of taxable temporary differences, to zero. As of March 31, 2020, based on its evaluation of available positive and negative evidence, the Company has maintained its position with respect to the valuation allowance.

On March 27, 2020, President Trump signed into law the CARES Act. The CARES Act is an emergency economic stimulus package in response to the coronavirus outbreak which, among other things, includes provisions relating to income and non-income-based tax laws. Some of the key income tax-related provisions include net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. Some of these tax provisions are effective retroactively for years ending before the date of enactment. Other non-income-based tax provisions include deferral of the employer share of Social Security payroll taxes due from the CARES Act date of enactment through December 31, 2020, and a potential 50% credit on qualified wages against employment taxes each quarter with any excess credits eligible for refunds. The Company continues to carefully analyze eligibility and application of both the income tax and non-income-based tax provisions.

The CARES Act permits net operating loss (“NOL”) carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. In addition, the CARES Act allows NOLs originating in 2018, 2019, and 2020 to be carried back to each of the five preceding taxable years to generate refunds of previously paid income taxes. As a result of the CARES Act, the Company expects to carry back approximately $345 million in NOLs generated in 2018 to prior taxable income years.

ASC 740 requires the effect from adjusting deferred tax assets or changes to valuation allowances due to the CARES Act to be recognized as a component of income taxes expense or benefit in the interim period that includes the period in which the new legislation is enacted (quarter ended March 31, 2020), and it cannot be allocated to subsequent interim periods by an adjustment of the estimated annual effective tax rate. In the three months ended March 31, 2020, the Company reclassified the 2018 NOL carryback amount for previously paid income tax to income tax receivable and reversed the corresponding valuation allowance. In carrying back the 2018 loss to an earlier year, the Company is able to benefit the losses at a 35% tax rate rather than the current U.S. corporate tax rate of 21%. Accordingly, the Company recorded a discrete income tax benefit of $110 million for the three months ended March 31, 2020.

In connection with the Combination, the Company entered into a tax receivable agreement (“TRA”) for which it is generally required to pay the other holders of Amneal Common Units 85% of the applicable tax savings, if any, in U.S. federal and state income tax that it is deemed to realize as a result of certain tax attributes of their Amneal Common Units sold to the Company (or exchanged in a taxable sale) and that are created as a result of (i) the sales of their Amneal Common Units for shares of Class A Common Stock and (ii) tax benefits attributable to payments made under the TRA (including imputed interest). In conjunction with the valuation allowance recorded on the DTAs at September 30, 2019, the Company reversed the ~~accrued~~ TRA liability, which had been recorded at the time of ~~$193 million, which resulted in a gain recorded as a component of Other income (expense), net.~~the Combination.

The projection of future taxable income involves significant judgment. Actual taxable income may differ from ~~our~~the Company’s estimates, which could significantly impact the liability under the TRA. As noted above, ~~we have~~the Company has determined it is more-likely-than-not weit will be unable to utilize all of ~~our~~its DTAs subject to TRA; therefore, ~~we have reversed~~the Company has not accrued the liability under the TRA related to the tax savings weit may realize from common units sold or exchanged through ~~September 30, 2019.~~March 31, 2020. If utilization of these DTAs becomes more-likely- than-not in the future, at such time, weAmneal will record liabilities under the TRA, which amounts to approximately $202 million as of ~~up to an additional $193 million~~March 31, 2020 as a result of basis adjustments under Internal Revenue Code Section ~~754, which~~754. Any future recognition of these TRA liabilities will be recorded through charges ~~to our~~in the Company’s consolidated ~~statement~~statements of operations. However, if the tax attributes are not utilized in future years, it is reasonably possible no amounts would be paid under the TRA. Should wethe Company determine that a DTA with a valuation allowance is realizable in a subsequent

period, the related valuation allowance will be released and if a resulting TRA payment is determined to be probable, a corresponding TRA liability will be recorded.

For the three months ended September 30, 2019 and 2018, the Company's provision for income taxes and effective tax rates were $390 million and 1483.0% and $5 million and 22.6%, respectively. The change in provision for income taxes is primarily associated with the charge to record the valuation allowance against the Company’s DTAs.

For the nine months ended September 30, 2019, the Company’s provision for income taxes and effective tax rate were $376 million and (230.2%) For the nine months ended September 30, 2018, the Company’s benefit from income taxes and effective tax rate were $7 million and 3.7% The change in income taxes was primarily due to the provision to record the valuation allowance against the Company’s DTAs. The change is also due to the change in the Company's legal structure subsequent to the Combination. Prior to the Combination, as a limited liability company, income taxes were only provided for the international subsidiaries as all domestic taxes flowed to the members. Subsequent to May 4, 2018, domestic income taxes were also provided for the Company's allocable share of income or losses from Amneal at the prevailing U.S. federal, state, and local corporate income tax rates.

The Company and its subsidiaries file income tax returns in the U.S. federal, and various state, local and foreign jurisdictions. The Company is not currently under income tax audit in any jurisdiction, and it will file its first income tax returns for the period ended December 31, 2018. Impax's federal tax filings for the 2015, 2016 and 2017 tax years are currently under audit and these are the only tax years open under the IRS statute of limitations for Impax. If there were adjustments to the attributes of Impax, they could impact the carryforward losses at the Company, which is the successor in interest to Impax. The Amneal partnership was audited for the tax year ended December 31, 2015 without any adjustments to taxable income. Income tax returns are generally subject to examination for a period of 3 years in the U.S. The statute of limitations for the 2016 and 2017 tax years will, therefore, expire no earlier than 2020. However, any adjustments to the 2016 or 2017 tax years would be pre-transaction when the Company had no ownership interest in Amneal. Under the partnership income tax regulations and audit guidelines, the Company is not responsible for any hypothetical pre-transaction income tax liabilities which pass through to the owners as of the year of any potential income tax adjustment. Neither the Company nor any of its other affiliates is currently under audit for state income tax.

Receivables from customers representing 10% or more of the Company’s gross trade accounts receivable reflected ~~three~~3 customers at ~~September 30, 2019,~~March 31, 2020, equal to ~~35%~~38%, ~~25%~~24%, and ~~25%~~21%, respectively. Receivables from customers representing 10% or more of the Company’s gross trade accounts receivable reflected ~~three~~3 customers at December 31, ~~2018,~~2019, equal to ~~30%~~39%, ~~28%~~25%, and ~~24%~~25%, respectively.

Prepaid expenses and other current assets are comprised of the Company's operating and financing lease portfolio consists of corporate offices, manufacturing sites, warehouse space, research and development facilities and manufacturing equipment. The Company's leases have remaining lease terms of 1 year to 25 years. Rent expense for the three and nine months ended September 30, 2019 was $7 million and $19 million, respectively. Rent expense for the three and nine months ended September 30, 2018 was $6 million and $13 million, respectively. The Company recorded a $2 million impairment charge for the right of use asset associated with its Hauppauge, NY facility during the three and nine months ended September 30, 2019 because the Company’s latest forecast does not support recoverability of that asset. For further details, see ~~Note 6. Restructuring and Other Charges.~~

~~The components of total lease costs were as follows~~following (in thousands):

~~Supplemental balance sheet information related to the Company's leases was as follows (in thousands):~~

At September 30, 2019 financing right of use assets of $3 million, financing short-term liabilities of $1 million and financing long-term liabilities of $2 million associated with our auto fleet are recorded in Other assets, Accounts payable and accrued expenses and Other liabilities, respectively.

~~Supplemental cash flow information related to leases was as follows (in thousands):~~

~~The table below reflects the weighted average remaining lease term and weighted average discount rate for the Company's operating and finance leases as of September 30, 2019.~~

Other assets are comprised of ~~lease liabilities as~~the following (in thousands):

The following is a summary of ~~September 30, 2019 were as follows~~the Company's long-term debt (in thousands):

On May 4, 2018 the Company entered into a senior credit agreement that provided a term loan ("Term Loan") with a principal amount of $2.7 billion and an asset backed revolving credit facility ("Revolving Credit Facility") under which loans and letters of credit up to a principal amount of $500 million, of which $194 million were available at March 31, 2020 (principal amount of up to $25 million is available for letters of credit) (collectively, the "Senior Secured Credit Facilities"). The Term Loan is repayable in equal quarterly installments at a rate of 1.00% of the original principal amount annually, with the balance payable at maturity on May 4, 2025. The Term Loan bears a variable annual interest rate, which is one-month LIBOR plus 3.5% at March 31, 2020. The Revolving Credit Facility bears an annual interest rate of one-month LIBOR plus 1.25% at March 31, 2020 and matures on May 4, 2023. The annual interest rate for the Revolving Credit Facility may be reduced or increased by 0.25% based on step-downs and step-ups determined by the average historical excess availability.

The proceeds of any loans made under the Senior Secured Credit Facilities can be used for capital expenditures, acquisitions, working capital needs and other general purposes, subject to covenants as described below. The Company pays a commitment fee based on the average daily unused amount of the Revolving Credit Facility at a rate based on average historical excess availability, between 0.25% and 0.375% per annum. At March 31, 2020, the Revolving Credit Facility commitment fee rate is 0.375% per annum.

During March 2020, as a precautionary measure to mitigate the uncertainty surrounding overall market liquidity due to COVID-19, the Company borrowed $300 million on the Revolving Credit Facility, all of which is outstanding at March 31, 2020. As the financial markets stabilized following a period of high volatility due to the COVID-19 pandemic, the Company repaid $200 million of borrowings under the Revolving Credit Facility in May 2020.

The Company incurred costs associated with the Term Loan due May 2025 of $38 million and the Revolving Credit Facility of $5 million, which have been capitalized and are being amortized over the life of the applicable debt agreement to interest expense using the effective interest method. The Term Loan has been recorded in the balance sheet net of issuance costs. Costs associated with the Revolving Credit Facility have been recorded in other assets because there were no borrowings outstanding on the effective date of the Revolving Credit Facility. For both the three months ended March 31, 2020 and 2019, amortization of deferred financing costs related to the Term Loan and the Revolving Credit Facility was $2 million.

The Senior Secured Credit Facilities contain a number of covenants that, among other things, create liens on Amneal's and its subsidiaries' assets. The Senior Secured Credit Facilities contain certain negative covenants that, among other things and subject to certain exceptions, restrict Amneal’s and its subsidiaries' ability to incur additional debt or guarantees, grant liens, make loans, acquisitions or other investments, dispose of assets, merge, dissolve, liquidate or consolidate, pay dividends or other payments on capital stock, make optional payments or modify certain debt instruments, modify certain organizational documents, enter into arrangements that restrict the ability to pay dividends or grant liens, or enter into or consummate transactions with affiliates. The Revolving Credit Facility also includes a financial covenant whereby Amneal must maintain a minimum fixed charge coverage ratio if certain borrowing conditions are met. The Senior Secured Credit Facilities contain customary events of

default, subject to certain exceptions. Upon the occurrence of certain events of default, the obligations under the Senior Secured Credit Facilities may be accelerated and the commitments may be terminated. At March 31, 2020, Amneal was in compliance with all covenants.

On January 31, 2020, in connection with the Acquisitions, Rondo Intermediate Holdings, LLC (“Rondo Holdings”), a wholly-owned subsidiary of Rondo, entered into a revolving credit and term loan agreement (“Rondo Credit Facility”) that provided a term loan ("Rondo Term Loan") with a principal amount of $180 million and a revolving credit facility (“Rondo Revolving Credit Facility”) which loans up to a principal amount of $30 million. The Rondo Term Loan is repayable in equal quarterly installments at a rate of 5.0% of the original principal amount annually, with the balance payable at maturity on January 31, 2025. The Rondo Credit Facility bears a variable annual interest rate, which is one-month LIBOR plus 3.0% at March 31, 2020 and matures on January 31, 2025. The annual interest rate for borrowings under the Rondo Credit Facility may be reduced or increased by 0.25% based on step-downs and step-ups determined by the total net leverage ratio, as defined in that agreement. At March 31, 2020, the Company had 0 outstanding borrowings under the Rondo Revolving Credit Facility.

A commitment fee based on the average daily unused amount of the Rondo Credit Facility is assessed at a rate based on total net leverage ratio, between 0.25% and 0.50% per annum. At March 31, 2020, the Rondo Credit Facility commitment fee rate is 0.4% per annum.

Costs associated with the Rondo Term Loan of $3 million and the Rondo Credit Facility of $1 million, which have been capitalized and are being amortized over the life of the applicable debt instrument to interest expense using the effective interest method. The Rondo Term Loan has been recorded in the balance sheet net of issuance costs. Costs associated with the Rondo Revolving Credit Facility have been recorded in other assets. For the three months ended March 31, 2020, amortization of deferred financing costs associated with the Rondo Credit Facility were less than $1 million.

The Rondo Credit Facility contains a number of covenants that, among other things, create liens on the equity securities and assets of Rondo Holdings, Rondo, AvKARE, LLC and R&S. The Rondo Credit Facility contains certain negative, affirmative and financial covenants that, among other things, restrict the ability to incur additional debt, grant liens, transact in mergers and acquisitions, make certain investments and payments or engage in certain transactions with affiliates. The Rondo Credit Facility also contains customary events of default. Upon the occurrence of certain events of default, the obligations under the Rondo Credit Facility may be accelerated and/ or the interest rate may be increased. At March 31, 2020, Rondo was in compliance with all covenants. The Company is not party to the Rondo Credit Facility and is not a guarantor of any debt incurred thereunder.

The Term Loan and Rondo Term Loan require payments of $27 million and $9 million, respectively, per year for the next five years and the balance thereafter.

The Sellers Notes with a stated aggregate principal amount of $44 million and the Short-Term Sellers Note with a stated principal amount of $1 million were issued by Rondo or its subsidiary, Rondo Top Holdings, LLC, on January 31, 2020, the closing date of the Acquisitions. The Sellers Notes are unsecured and accrue interest at a rate of 5% per annum, not compounded, until June 30, 2025. The Sellers Notes are subject to prepayment at the option of Rondo, as the obligor, without premium or penalty. Mandatory payment of the outstanding principal and interest is due on June 30, 2025 if certain financial targets are achieved, the borrowers’ cash flows are sufficient (as defined in the Sellers Notes) and repayment is not prohibited by senior debt. If repayment of all outstanding principal and accrued interest on the Sellers Notes is not made on June 30, 2025, the requirements for repayment are revisited on June 30 of each subsequent year until all principal and accrued interest are satisfied no later than January 31, 2030 or earlier, upon a change in control. The Short-Term Sellers Note is also unsecured and accrues interest at a rate of 1.6% and is due on January 31, 2020.

In accordance with ASC 805, Business Combinations, all consideration transferred was measured at its acquisition-date fair value. The Sellers Notes were stated at the preliminary fair value estimate of $35 million, which was estimated using the Monte-Carlo simulation approach under the option pricing framework. The Short-Term Sellers Note of $1 million was recorded at the stated principal amount of $1 million, which approximates fair value. The $9 million discount on the Sellers Notes will be amortized to interest expense using the effective interest method from January 31, 2020 to June 30, 2025 and the carrying value of the Sellers Notes will accrete to the stated principal amount of $44 million.

The Sellers Notes and the Short-Term Sellers Note are recorded in notes payable-related party within long-term liabilities and notes payable-related party within current liabilities, respectively.

As disclosed in the Company's 2018 Annual Report on Form 10-K, under the previous lease accounting standard, the table below reflects the future minimum lease payments, including reasonably assured renewals, due under non-cancelable leases and a financing obligation as of December 31, 2018 (in thousands):

~~For additional information regarding lease transactions between related parties, refer to~~ ~~Note~~ 15. ~~Related Party Transactions.~~

Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. Valuation techniques used to measure fair value should maximize the use of observable inputs and minimize the use of unobservable inputs. To measure fair value, the Company uses the following fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable:

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 2 – Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data by correlation or other means.

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Value is determined using pricing models, discounted cash flow methodologies, or similar techniques and also includes instruments for which the determination of fair value requires significant judgment or estimation.

The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level of classification for each reporting period. The following table sets forth the Company’s financial assets and liabilities that were measured at fair value on a recurring basis as of ~~September 30, 2019~~March 31, 2020 and December 31, ~~2018~~2019 (in thousands):

Fair Value Measurement Based on

September 30, 2019

Total

Quoted
Prices in
Active
Markets
(Level 1)

Significant
Other
Observable
Inputs
(Level 2)

Significant
Unobservable
Inputs
(Level 3)

Liabilities

Deferred Compensation Plan liabilities ⁽¹⁾

$
21,637

$
—

$
21,637

$
—

December 31, 2018

Assets

Deferred Compensation Plan asset ⁽¹⁾

$
40,101

$
—

$
40,101

$
—

Liabilities

Deferred Compensation Plan liabilities ⁽¹⁾

$
27,978

$
—

$
27,978

$
—

			Fair Value Measurement Based on
March 31, 2020	Total		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Liabilities
Interest rate swap ⁽¹⁾	$	46,285	$	—	$	46,285	$	—
Deferred compensation plan liabilities ⁽²⁾		13,854		—		13,854		—

December 31, 2019
Assets
Interest rate swap ⁽¹⁾	$	16,373	$	—	$	16,373	$	—
Liabilities
Deferred compensation plan liabilities ⁽²⁾	$	18,396	$	—	$	18,396	$	—

There were no0 transfers between levels in the fair value hierarchy during the ~~nine~~three months ended ~~September 30, 2019.~~March 31, 2020.

The carrying amounts of cash, accounts receivable and accounts payable approximate their fair values due to the short-term maturity of these instruments.

The $2.7 billion ~~term loan under the Company’s senior credit agreement entered into on May 4, 2018 (the "Term Loan")~~Term Loan falls into the Level 2 category within the fair value level hierarchy. The fair value was determined using market data for valuation. The fair value of the Term Loan at ~~September 30, 2019~~March 31, 2020 and December 31, ~~2018~~2019 was approximately $2.3 billion and ~~$2.5~~$2.4 billion, respectively.

The $180 million Rondo Term Loan entered into on January 31, 2020 falls into the Level 2 category within the fair value level hierarchy. The carrying value of $180 million at March 31, 2020 approximates fair value.

The Sellers Notes and the Short-Term Sellers Note fall into the Level 2 category within the fair value level hierarchy. At March 31, 2020, the carrying value of the Sellers Notes and the Short-Term Sellers Note of $35 million and $1 million, respectively, approximate their fair values.

There were no0 non-recurring fair value measurements during the ~~nine~~three months ended ~~September 30,~~March 31, 2020 and 2019.

The Company uses an interest rate swap to manage its exposure to market risks for changes in interest rates.

The Company is exposed to interest rate risk on its debt obligations. Interest income earned on cash and cash equivalents may fluctuate as interest rates change; however, due to their relatively short maturities, the Company does not hedge these assets or their investment cash flows because the impact of interest rate risk is not material. The Company's debt obligations consist of variable-rate and fixed-rate debt instruments (for further details, refer to Note 13. Debt). The Company's primary objective is to achieve the lowest overall cost of funding while managing the variability in cash outflows within an acceptable range. In order to achieve this objective, the Company has entered into an interest rate swap on the Term Loan.

The interest rate swap involves the periodic exchange of payments without the exchange of underlying principal or notional amounts. In October 2019, the Company entered into an interest rate lock agreement for a total notional amount of $1.3 billion to hedge part of the Company's interest rate exposure associated with the variability in future cash flows from changes in the one-month LIBOR associated with its Term Loan.

As of March 31, 2020, the total loss, net of income taxes, related to the Company’s cash flow hedge was $46 million, in which $23 million was recognized in accumulated other comprehensive loss and ~~2018.~~$23 million was recognized in non-controlling interests (NaN as of March 31, 2019).

~~13.~~A summary of the fair values of derivative instruments in the consolidated balance sheets was as follows (in thousands):

The Company continues to seek to enhance its product line and develop a balanced portfolio of differentiated products through product acquisitions and in-licensing. Accordingly, the Company, in certain instances, may be contractually obligated to make potential future development, regulatory, and commercial milestone, royalty and/or profit sharing payments in conjunction with collaborative agreements or acquisitions that the Company has entered into with third parties. The Company has also licensed certain technologies or intellectual property from various third parties. The Company is generally required to make upfront payments as well as other payments upon successful completion of regulatory or sales milestones. The agreements generally permit the Company to terminate the agreement with no significant continuing obligation. The Company could be required to make significant payments pursuant to these arrangements. These payments are contingent upon the occurrence of certain future events and, given the nature of these events, it is unclear when, if ever, the Company may be required to pay such amounts. Further, the timing of any future payment is not reasonably estimable.

The Company's legal proceedings are complex, constantly evolving and subject to uncertainty. As such, the Company cannot predict the outcome or impact of the legal proceedings set forth below. Additionally, the Company is subject to legal proceedings that are not set forth below. While the Company believes it has valid claims and/or defenses to the matters described below, the nature of litigation is unpredictable, and the outcome of the following proceedings could include damages, fines, penalties and injunctive or administrative remedies. For any proceedings where losses are probable and reasonably capable of estimation, the Company accrues for a potential loss. While these accruals have been deemed reasonable by the Company’s management, the assessment process relies heavily on estimates and assumptions that may ultimately prove inaccurate or incomplete. Additionally, unforeseen circumstances or events may lead the Company to subsequently change its estimates and assumptions. Unless otherwise indicated below, the Company is at this time unable to estimate the possible loss, if any, associated with such litigation.

The Company currently intends to vigorously prosecute and/or defend these proceedings as appropriate. From time to time, however, the Company may settle or otherwise resolve these matters on terms and conditions that it believes to be in its best interest. For the three ~~and nine~~ months ended ~~September 30, 2019,~~March 31, 2020, the Company recorded a ~~net~~ charge of ~~$15~~approximately $5 million for ~~the~~ commercial ~~and governmental~~ legal proceedings and claims. The ultimate resolution of any or all claims, legal proceedings or investigations could differ materially from our estimate and have a material adverse effect on the Company's results of operations and/or cash flow in any given accounting period, or on the Company's overall financial condition. As of ~~September 30, 2019~~March 31, 2020 and December 31, ~~2018,~~2019, the Company had liabilities for commercial and governmental legal proceedings and claims of ~~$30~~$15 million and ~~$15~~$17 million, respectively.

Additionally, the Company manufactures and derives a portion of its revenue from the sale of pharmaceutical products in the opioid class of drugs, and may therefore face claims arising from the regulation and/or consumption of such products.

Although the outcome and costs of the asserted and unasserted claims is difficult to predict, based on the information presently known to management, the Company does not currently expect the ultimate liability, if any, for such matters to have a material adverse effect on its business, financial condition, results of operations, or cash flows.

The Company is required to provide pricing information to state agencies, including agencies that administer federal Medicaid programs. Certain state agencies have alleged that manufacturers have reported improper pricing information, which allegedly caused them to overpay reimbursement costs. Other agencies have alleged that manufacturers have failed to timely file required reports concerning pricing information. Reserves are periodically established by the Company for any potential claims or settlements of overpayment.The Company intends to vigorously defend against any such claims. The ultimate settlement of any potential liability for such claims may be higher or lower than estimated.

There is substantial litigation in the pharmaceutical, biological, and biotechnology industries with respect to the manufacture, use, and sale of new products which are the subject of conflicting patent and intellectual property claims. One or more patents often cover the brand name products for which the Company is developing generic versions and the Company typically has patent rights covering the Company’s branded products.

Under federal law, when a drug developer files an Abbreviated New Drug Application ("ANDA") for a generic drug seeking approval before expiration of a patent which has been listed with the FDA as covering the brand name product, the developer must certify its product will not infringe the listed patent(s) and/or the listed patent is invalid or unenforceable (commonly referred to as a "Paragraph IV" certification). Notices of such certification must be provided to the patent holder, who may file a suit for patent infringement within 45 days of the patent holder’s receipt of such notice. If the patent holder files suit within the 45-day period, the FDA can review and tentatively approve the ANDA, but generally is prevented from granting final marketing approval of the product until a final judgment in the action has been rendered in favor of the generic drug developer, or 30 months from the date the notice was received, whichever is sooner. The Company’s Generics segment is typically subject to patent infringement litigation brought by branded pharmaceutical manufacturers in connection with the Company’s Paragraph IV certifications seeking an order delaying the approval of the Company’s ANDA until expiration of the patent(s) at issue in the litigation. Likewise, the Company’s Specialty segment is currently involved in patent infringement litigation against generic drug manufacturers that have filed Paragraph IV certifications to market their generic drugs prior to expiration of the Company’s patents at issue in the litigation.

The uncertainties inherent in patent litigation make the outcome of such litigation difficult to predict. For the Company’s Generics segment, the potential consequences in the event of an unfavorable outcome in such litigation include delaying launch of its generic products until patent expiration. If the Company were to launch its generic product prior to successful resolution of a patent litigation, the Company could be liable for potential damages measured by the profits lost by the branded product manufacturer rather than the profits earned by the Company if it is found to infringe a valid, enforceable patent, or enhanced treble damages in cases of willful infringement. For the Company’s Specialty segment, an unfavorable outcome may significantly accelerate generic competition ahead of expiration of the patents covering the Company’s branded products. All such litigation typically involves significant expense.

The Company is generally responsible for all of the patent litigation fees and costs associated with current and future products not covered by its alliance and collaboration agreements. The Company has agreed to share legal expenses with respect to third-party and Company products under the terms of certain of the alliance and collaboration agreements. The Company records the costs of patent litigation as expense in the period when incurred for products it has developed, as well as for products which are the subject of an alliance or collaboration agreement with a third-party.

Impax Laboratories, LLC. v. Zydus Pharmaceuticals USA, Inc. and Cadila Healthcare Ltd. (Rytary®)

On December 21, 2017, Impax filed suit against Zydus Pharmaceuticals USA, Inc. and Cadila Healthcare Ltd. (collectively, "Zydus") in the United States District Court for the District of New Jersey, alleging infringement of U.S. Patent No. 9,089,608, based on the filing of Zydus’s ANDA relating to carbidopa and levodopa extended release capsules, generic to Rytary ®. Zydus answered the complaint on April 27, 2018, asserting counterclaims of non-infringement and invalidity of U.S. Pat. Nos. 7,094,427; 8,377,474; 8,454,998; 8,557,283; and 9,089,607. Impax answered Zydus’s counterclaims on June 1, 2018. Zydus filed a motion for judgment on the pleadings regarding its counterclaims. On November 29, 2018, the Court granted Zydus’s motion for judgment as to its counterclaims. A case schedule ~~has~~had been set with trial anticipated in ~~February 2020.~~April 2020, but that has been postponed indefinitely due to the COVID-19 pandemic.

On February 25, 2014, Impax received a Civil Investigative Demand (“CID”) from the Federal Trade Commission (“FTC”) concerning its investigation into the drug Opana® ER and its generic equivalents. On March 30, 2016, the FTC filed a complaint against Impax, Endo Pharmaceuticals Inc. ("Endo"), and others in the United States District Court for the Eastern District of Pennsylvania, alleging that Impax and Endo violated antitrust laws when they entered into a June 2010 co-promotion and development agreement and a June 2010 settlement agreement that resolved patent litigation in connection with the submission of Impax’s ANDA for generic original Opana® ER. In July 2016, the defendants filed a motion to dismiss the complaint, and a motion to sever the claims regarding Opana® ER from claims with respect to a separate settlement agreement that was challenged by the FTC. On October 20, 2016, the Court granted the motion to sever, formally terminating the suit against Impax, with an order that the FTC re-file no later than November 3, 2016 and dismissed the motion to dismiss as moot. On October 25, 2016, the FTC filed a notice of voluntary dismissal. On January 19, 2017, the FTC filed a Part 3 Administrative complaint against Impax with similar allegations regarding Impax’s June 2010 settlement agreement with Endo that resolved patent litigation in connection with the submission of Impax’s ANDA for generic original Opana® ER. Impax filed its answer to the Administrative Complaint on February 7, 2017. Trial concluded on November 15, 2017. On May 11, 2018, the Administrative Law Judge ruled in favor of Impax and dismissed the case in its entirety. The government appealed this ruling to the FTC. On March 28, 2019, the FTC issued an Opinion & Order reversing the Administrative Law Judge’s initial dismissal decision. The FTC found that Impax had violated Section 5 of the FTC Act by engaging in an unfair method of competition, and accordingly entered an order enjoining Impax from entering into anticompetitive reverse patent settlements (or agreements with other generic original Opana® ER manufacturers) and requiring Impax to maintain an antitrust compliance program. On June 6, 2019, ~~the Company~~Impax filed a Petition for Review of the FTC’s Opinion & Order with the United States Court of Appeals for the Fifth Circuit. ~~The Company~~Impax filed its opening appellate brief with the Fifth Circuit on October 3, 2019; the FTC filed its brief in response on December 9, 2019 and Impax filed a reply brief on December 30, 2019. Oral argument before the Fifth Circuit had been scheduled for April 27, 2020, but has been postponed indefinitely due to the COVID-19 pandemic.

On July 12, 2019, the Company received a CID from the FTC concerning an August 2017 settlement agreement between Impax and Endo, which resolved a dispute between the parties regarding, and amended, the above-referenced June 2010 settlement agreement related to Opana® ER. The

Company has been cooperating and intends to continue cooperating with the FTC regarding the CID. However, no assurance can be given as to the timing or outcome of the FTC’s underlying investigation.

From June 2014 to April 2015, 14 complaints styled as class actions on behalf of direct purchasers and indirect purchasers (also known as end-payors) and several separate individual complaints on behalf of certain direct purchasers (the “opt-out plaintiffs”) were filed against the manufacturer of the brand drug Opana ER® and Impax.

The direct purchaser plaintiffs comprise Value Drug Company and Meijer Inc. The end-payor plaintiffs comprise the Fraternal Order of Police, Miami Lodge 20, Insurance Trust Fund; Wisconsin Masons’ Health Care Fund; Massachusetts Bricklayers; Pennsylvania Employees Benefit Trust Fund; International Union of Operating Engineers, Local 138 Welfare Fund; Louisiana Health Service & Indemnity Company d/b/a Blue Cross and Blue Shield of Louisiana; Kim Mahaffay; and Plumbers & Pipefitters Local 178 Health & Welfare Trust Fund. The opt-out plaintiffs comprise Walgreen Co.; The Kroger Co.; Safeway, Inc.; HEB Grocery Company L.P.; Albertson’s LLC; Rite Aid Corporation; Rite Aid Hdqtrs. Corp.; and CVS Pharmacy, Inc.

On December 12, 2014, the United States Judicial Panel on Multidistrict Litigation (the "JPML") ordered the pending class actions transferred to the United States District Court for the Northern District of Illinois (“N.D. Ill.”) for coordinated pretrial proceedings, as In Re: Opana ER Antitrust Litigation (MDL No. 2580). (Actions subsequently filed in other jurisdictions also were transferred by the JPML to the N.D. Ill. to be coordinated or consolidated with the coordinated proceedings, and the District Court likewise has consolidated the opt-out plaintiffs’ actions with the direct purchaser class actions for pretrial purposes.)

In each case, the complaints allege that Endo engaged in an anticompetitive scheme by, among other things, entering into an anticompetitive settlement agreement with Impax to delay generic competition of Opana ER® and in violation of state and federal antitrust laws. Plaintiffs seek, among other things, unspecified monetary damages and equitable relief, including disgorgement and restitution. Discovery, including expert discovery, is ongoing. On March 25, 2019, plaintiffs filed motions for class certification and served opening expert reports. Defendants’ oppositions to class certification and rebuttal expert reports were filed and served on August 29, 2019. NoOn November 5, 2019, plaintiffs filed reply briefs in further support of their motions for class certification. On January 17, 2020, defendants filed a motion for leave to file joint surreply briefs in response thereto; plaintiffs filed responses on January 24, 2020. On February 5, 2020, the court granted defendants’ motion for leave, and entered a case schedule to which the parties jointly stipulated, setting a trial date ~~has been scheduled.~~of March 15, 2021, though it will likely be delayed due to the COVID-19 pandemic. On April 15, 2020, defendants filed motions for summary judgement.

The Company believes it has substantial meritorious defenses to the claims asserted with respect to the litigation. However, any adverse outcome could negatively affect the Company and could have a material adverse effect on the Company's results of operations, cash flows and/or overall financial condition.

~~Sergeants Benevolent Association Health & Welfare Fund v. Actavis, PLC, et. al.~~

In August 2015, a complaint styled as a class action was filed against Forest Laboratories (a subsidiary of Actavis plc) and numerous generic drug manufacturers, including Amneal, in the United States District Court for the Southern District of New York involving patent litigation settlement agreements between Forest Laboratories and the generic drug manufacturers concerning generic versions of Forest’s Namenda IR product. The complaint (as amended on February 12, 2016) asserts federal and state antitrust claims on behalf of indirect purchasers, who allege in relevant part that during the class period they indirectly purchased Namenda® IR or its generic equivalents in various states at higher prices than they would have absent the defendants’ allegedly unlawful anticompetitive conduct. Plaintiffs seek, among other things, unspecified monetary damages and equitable relief, including disgorgement and restitution. On September 13, 2016, the Court stayed the indirect purchaser plaintiffs’ claims pending factual development or resolution of claims brought in a separate, related complaint by direct purchasers (in which the Company is not a defendant). On September 10, 2018, the Court lifted the stay, referred the case to the assigned Magistrate Judge for supervision of supplemental, non-duplicative discovery in advance of mediation to be scheduled in 2019. The parties thereafter participated in supplemental discovery, as well as supplemental motion-to-dismiss briefing. On December 26, 2018, the Court granted in part and denied in part motions to dismiss the indirect purchaser plaintiffs’ claims. On January 7, 2019, Amneal, its relevant co-defendants, and the indirect purchaser plaintiffs informed the Magistrate Judge that they had agreed to mediation, which occurred in April 2019. In June 2019, the Company reached a settlement with plaintiffs, subject to Court approval. On September 10, 2019, the Court entered an order preliminarily approving the settlement and indefinitely staying the case as to the settling defendants (including the Company). The amount of the settlement is not material to the Company's consolidated financial statements.

Attorney General of the State of Connecticut Interrogatories and Subpoena Duces Tecum

On July 14, 2014, Impax received a subpoena and interrogatories (the "Subpoena") from the State of Connecticut Attorney General ("Connecticut AG") concerning its investigation into sales of Impax's generic product, digoxin. According to the Connecticut AG, the investigation is to determine whether anyone engaged in a contract, combination or conspiracy in restraint of trade or commerce which has the effect of (i) fixing, controlling or maintaining prices or (ii) allocating or dividing customers or territories relating to the sale of digoxin in violation of Connecticut state antitrust law. The Company has produced documents and information in response to the Subpoena. However, no assurance can be given as to the timing or outcome of this investigation.

On November 6, 2014, Impax disclosed that one of its sales representatives received a grand jury subpoena from the Antitrust Division of the United States Department of Justice (the "DOJ"). In connection with this same investigation, on March 13, 2015, Impax received a grand jury subpoena from the DOJ requesting the production of information and documents regarding the sales, marketing, and pricing of certain generic prescription medications. In particular, the DOJ’s investigation currently focuses on ~~four~~4 generic medications: digoxin tablets, terbutaline sulfate tablets, prilocaine/lidocaine cream, and calcipotriene topical solution. The Company has been cooperating and intends to continue cooperating with the investigation. However, no assurance can be given as to the timing or outcome of the investigation.

On April 30, 2018, Impax received a CID from the Civil Division of the DOJ (the "Civil Division"). The CID requests the production of information and documents regarding the pricing and sale of Impax’s pharmaceuticals and Impax’s interactions with other generic pharmaceutical manufacturers. According to the CID, the investigation concerns allegations that generic pharmaceutical manufacturers, including Impax, engaged in market allocation and price-fixing agreements, paid illegal remuneration, and caused false claims to be submitted to the Federal government. The Company has been cooperating and intends to continue cooperating with the Civil Division’s investigation. However, no assurance can be given as to the timing or outcome of the investigation.

On May 27, 2014, a CID was served on Amneal by the Office of the Attorney General for the state of Texas (the "Texas AG") relating to products distributed by Amneal under a specific Amneal labeler code. Shortly thereafter, Amneal received a second CID with respect to the same products sold by Interpharm Holding, Inc. ("Interpharm"), the assets of which had been acquired by Amneal in June 2008. Amneal completed its production of the direct and indirect sales transaction data in connection with the products at issue and provided this information to the Texas AG in November 2015. In May 2016, the Texas AG delivered ~~two~~ 2 settlement demands to Amneal in connection with alleged overpayments made by the State of Texas for such products under its Medicaid programs. For the Amneal and Interpharm products at issue, the Texas AG’s initial demand was for an aggregate total of $36 million based on $16 million in alleged overpayments. After analyzing the Texas AG’s demand, Amneal

raised certain questions regarding the methodology used in the Texas AG’s overpayment calculations, including the fact that the calculations treated all pharmacy claims after 2012 for the products at issue as claims for over-the-counter ("OTC") drugs, even though the products were prescription pharmaceuticals. This had the effect of increasing the alleged overpayment because the dispensing fee for OTC drugs was lower than that for prescription drugs. Therefore, the Texas AG’s calculations were derived by subtracting a lower (and incorrect) OTC dispensing fee from the higher (and correct) prescription dispensing fee. The Texas AG later acknowledged this discrepancy. In March 2019, the Texas AG provided Amneal with a re-calculation of the alleged ~~overpayment, and in~~overpayment. In October 2019, Amneal reached an agreement in principle with the Texas AG to settle the matter. The parties executed a Settlement Agreement and Release as of March 5, 2020, and save for certain administrative obligations, the matter is now closed.

~~Between~~Beginning in March 2016, ~~and January 2019,~~ numerous complaints styled as antitrust class actions on behalf of direct purchasers and indirect purchasers (or end-payors) and several separate individual complaints on behalf of certain direct and indirect purchasers (the “opt-out plaintiffs”) have been filed against manufacturers of generic digoxin, lidocaine/prilocaine, glyburide-metformin, and metronidazole, including Impax.

The end-payor plaintiffs ~~comprise~~comprised Plaintiff International Union of Operating Engineers Local 30 Benefits Fund; Tulsa Firefighters Health and Welfare Trust; NECA-IBEW Welfare Trust Fund; Pipe Trade Services MN; Edward Carpinelli; Fraternal Order of Police, Miami Lodge 20, Insurance Trust Fund; Nina Diamond; UFCW Local 1500 Welfare Fund; Minnesota Laborers Health and Welfare Fund; The City of Providence, Rhode Island; Philadelphia Federation of Teachers Health and Welfare Fund; United Food & Commercial Workers and Employers Arizona Health and Welfare Trust; Ottis McCrary; Plumbers & Pipefitters Local 33 Health and Welfare Fund; Plumbers & Pipefitters Local 178 Health and Welfare Trust Fund; Unite Here Health; Valerie Velardi; and Louisiana Health Service Indemnity Company. The direct purchaser plaintiffs ~~comprise~~comprised KPH Healthcare Services, Inc. a/k/a Kinney Drugs, Inc.; Rochester Drug Co-Operative, Inc.; César Castillo, Inc.; Ahold USA, Inc.; and FWK Holdings, L.L.C. The opt-out plaintiffs ~~comprise~~comprised The Kroger Co.; Albertsons Companies, LLC; H.E. Butt Grocery Company L.P.; Humana Inc.; and United Healthcare Services, Inc.

On April 6, 2017, the JPML ordered the consolidation of all civil actions involving allegations of antitrust conspiracies in the generic pharmaceutical industry regarding 18 generic drugs in the United States District Court for the Eastern District of Pennsylvania (“E.D. Pa.”), as In Re: Generic Pharmaceuticals Pricing Antitrust Litigation (MDL No. 2724). Consolidated class action complaints were filed on August 15, 2017 for each of the 18 drugs; Impax is named as a defendant in the 2 complaints respecting digoxin and lidocaine-prilocaine. Impax also is a defendant in the class action complaint filed with the MDL court on June 22, 2018 by certain direct purchasers of glyburide-metformin and metronidazole.

Each of the various complaints alleges a conspiracy to fix, maintain, stabilize, and/or raise prices, rig bids, and allocate markets or customers for the particular drug products at issue. Plaintiffs seek, among other things, unspecified monetary damages and equitable relief, including disgorgement and restitution. On October 16, 2018, the Court denied Impax and its co-defendants’ motion to dismiss the digoxin complaint. On February 15, 2019, the Court granted in part and denied in part defendants’ motions to dismiss various state antitrust, consumer protection, and unjust enrichment claims brought by two classes of indirect purchasers in the digoxin action. The Court dismissed ~~seven~~ 7 state law claims in the end-payor plaintiffs’ complaint and ~~six~~6 state law claims in the indirect reseller plaintiffs’ complaint. Motions to dismiss the glyburide-metformin and metronidazole complaint, as well as 2 of the complaints filed by certain opt-out plaintiffs, were filed February 21, 2019. On March 11, 2019, the Court issued an order approving a stipulation withdrawing the direct purchaser plaintiffs’ glyburide-metformin claims against Impax. ~~Document discovery otherwise is proceeding.~~

On May 10, 2019, the Company was named in a civil lawsuit filed by the Attorneys General of 43 States and the Commonwealth of Puerto Rico in the United States District Court for the District of Connecticut against numerous generic pharmaceutical manufacturers, as well as certain of their current or former sales and marketing executives, regarding an alleged conspiracy to fix prices and allocate or divide customers or markets for various products, including, with respect to the Company, bethanechol chloride tablets, norethindrone acetate tablets, and ranitidine HCL tablets, in violation of federal and state antitrust and consumer protection laws. Plaintiff States seek, among other things, unspecified monetary damages (including treble damages and civil penalties), as well as equitable relief, including disgorgement and restitution. On June 4, 2019, the JPML transferred the lawsuit to the E.D. Pa. for coordination and consolidation with MDL No. 2724. On November 1, 2019, the State Attorneys General filed an Amended Complaint in their lawsuit, bringing claims on behalf of 9 additional states and territories against several defendants; the relief sought and allegations concerning the Company (including the products allegedly at issue) are unchanged from the original complaint.

On July 31, 2019, the Company and Impax were served with a Praecipe to Issue Writ of Summons and Writ of Summons filed in the Philadelphia County Court of Common Pleas by 87 health insurance companies and managed health care providers (America’s 1^st Choice of South Carolina, Inc., et al. v. Actavis Elizabeth, LLC, et al., No. 190702094), naming as defendants in the putative action the same generic pharmaceutical manufacturers and individuals named in the above-referenced State Attorneys General lawsuit. However, to date, no complaint has been filed or

served in this ~~action, and in October~~action. On December 12, 2019, the ~~parties stipulated that~~court entered an Order placing the case ~~will be placed~~ in deferred status pending further developments in MDL No. 2724.

On October 11, 2019, opt-out plaintiff United Healthcare Services, Inc. filed a second complaint, in the United States District Court for the District of Minnesota (United Healthcare Services, Inc. v. Teva Pharmaceuticals USA, Inc., et al., No. 0:19-cv-02696), following on and supplementing its original action, asserting antitrust claims against the Company and other generic pharmaceutical manufacturers arising from the facts alleged in the above-referenced State Attorneys General lawsuit. Plaintiff seeks, among other things, unspecified monetary damages and equitable relief, including disgorgement and restitution. The parties anticipate that the lawsuit will be transferred by the JPML to the E.D. Pa. for coordination and consolidation with MDL No. 2724.

On October 18, 2019, opt-out plaintiff Humana, Inc. also filed a second complaint, likewise following on supplementing its original action to assert antitrust claims against the Company and other generic pharmaceuticals manufacturers arising from the facts alleged in the above-referenced State Attorneys General lawsuit, and similarly seeking, among other things, unspecified monetary damages and equitable relief, including disgorgement and restitution. The lawsuit was filed in the E.D. Pa. (Humana Inc. v. Actavis Elizabeth, LLC, et al., No. 2:19-cv 04862), and likely will be incorporated into MDL No. 2724 for coordinated pretrial proceedings.

On November 14, 2019, the Company was named in a complaint filed in the Supreme Court of the State of New York, Nassau County, on behalf of 14 counties in the state of New York, who allege to be both direct and end-payor purchasers of generic pharmaceutical drugs (County of Nassau, et al., v. Actavis Holdco U.S., Inc., et al., No. 616029/2019). The complaint asserts antitrust claims against the Company and other generic pharmaceutical manufacturers arising from the facts alleged in the above-referenced State Attorneys General lawsuit. Plaintiff Counties seek, among other things, unspecified monetary damages and equitable relief, including disgorgement and restitution. On December 17, 2019, defendants removed the case to the United States District Court for the Eastern District of New York (No. 2:19-cv-07071) and, on January 3, 2020, the case was transferred by the JPML to the E.D. Pa. for coordination and consolidation with MDL No. 2724.

On December 11, 2019, the Company and Impax were named in a complaint filed in E.D. Pa. by Health Care Service Corp., a customer-owned health insurer opting out of the end-payor plaintiff class (Health Care Service Corp. v. Actavis Elizabeth, LLC, et al., No. 2:19-cv-05819-CMR). Plaintiff alleges a conspiracy among generic pharmaceutical manufacturers to fix prices and allocate or divide customers or markets for various products (including, with respect to the Company, bethanechol chloride tablets, norethindrone acetate tablets, and ranitidine HCL tablets; and with respect to Impax, digoxin, lidocaine-prilocaine, and metronidazole) in violation of federal and state antitrust and consumer protection laws. Plaintiff seeks, among other things, unspecified monetary damages and equitable relief, including disgorgement and restitution. The lawsuit likely will be incorporated into MDL No. 2724 for coordinated pretrial proceedings.

On December 16, 2019, a complaint was filed in the United States District Court for the District of Connecticut against Impax and against numerous generic pharmaceutical manufacturers on behalf of assignees of claims from third-party health benefit plans, opting out of the end-payor plaintiff class (MSP Recovery Claims, Series LLC, et al. v. Actavis Elizabeth, LLC, et al., No. 3:19-cv-01972-SRU), and alleging a conspiracy to fix prices and allocate or divide customers or markets for various products (including, with respect to Impax, digoxin and lidocaine-prilocaine) in violation of federal and state antitrust and consumer protection laws. Plaintiffs seek, among other things, unspecified monetary damages and equitable relief, including disgorgement and restitution. On January 10, 2020, the case was transferred by the JPML to the E.D. Pa. for coordination and consolidation with MDL No. 2724.

On December 19, 2019, the end-payor plaintiffs filed a new complaint, following on and supplementing their putative class action lawsuit pending in MDL No. 2724. Plaintiffs’ new complaint, which names as defendants the Company, Amneal, Impax, and numerous generic pharmaceutical manufacturers, alleges a conspiracy to fix prices and allocate or divide customers or markets for various products (including, with respect to the Company/Amneal, bethanechol chloride tablets, norethindrone acetate tablets, ranitidine HCL tablets, naproxen sodium tablets, oxycodone/acetaminophen tablets, phenytoin sodium capsules, and warfarin sodium tablets; and with respect to Impax, metronidazole, amphetamine salts tablets, dextroamphetamine sulfate ER capsules, cyproheptadine HCL tablets, methylphenidate tablets, and pilocarpine HCL tablets) in violation of federal and state antitrust and consumer protection laws. Plaintiffs continue to seek, among other things, unspecified monetary damages and equitable relief, including disgorgement and restitution.

On December 20, 2019, the indirect-reseller plaintiffs filed a new complaint naming the Company, following on and supplementing their putative class action lawsuit pending in MDL No. 2724. The new complaint is brought on behalf of both independent pharmacies and hospitals, and asserts antitrust claims against the Company and other generic pharmaceutical manufacturers (as well as distributors of generic pharmaceuticals, including AmerisourceBergen Corp., Cardinal Health Inc., and McKesson Corporation) arising from the facts alleged in the above-referenced State Attorneys General lawsuit. Plaintiffs continue to seek, among other things, unspecified monetary damages and equitable relief, including disgorgement and restitution.

On December 27, 2019, the Company and Impax were named in a complaint filed in the United States District Court for the Northern District of California by Molina Healthcare, Inc., a publicly traded healthcare management organization opting out of the end-payor plaintiff class (Molina Healthcare, Inc. v. Actavis Elizabeth, LLC, et al., No. 3:19-cv-08438). Plaintiff alleges a conspiracy among generic pharmaceutical manufacturers to fix prices and allocate or divide customers or markets for various products (including, with respect to the Company, bethanechol chloride tablets, norethindrone acetate tablets, and ranitidine HCL tablets; and with respect to Impax, digoxin, lidocaine-prilocaine, and metronidazole) in violation of federal and state antitrust and consumer protection laws. Plaintiff seeks, among other things, unspecified monetary

damages and equitable relief, including disgorgement and restitution. On February 5, 2020, the case was transferred by the JPML, to the E.D. Pa. for coordination and consolidation with MDL No. 2724.

On February 7, 2020, the direct purchaser plaintiffs filed a new complaint, following on and supplementing their putative class action lawsuit pending in MDL No. 2724. Plaintiffs’ new complaint, which names as defendants the Company, Amneal, Impax, and numerous generic pharmaceutical manufacturers, alleges a conspiracy to fix prices and allocate or divide customers or markets for various products (including, with respect to the Company/Amneal, bethanechol chloride tablets, ranitidine HCL tablets, naproxen sodium tablets, oxycodone/acetaminophen tablets, hydrocodone/acetaminophen tablets, phenytoin sodium capsules, and warfarin sodium tablets; and with respect to Impax, amphetamine salts tablets, dextroamphetamine sulfate ER capsules, methylphenidate tablets, and pilocarpine HCL tablets) in violation of federal and state antitrust and consumer protection laws. Plaintiffs continue to seek, among other things, unspecified monetary damages and equitable relief, including disgorgement and restitution.

On March 2, 2020, the Company, Amneal, and Amneal Pharmaceuticals of NY, LLC, were named in a complaint filed in the United States District Court for the Southern District of Texas by Harris County, Texas, which is the primary county for the Houston Metropolitan Area (Harris County, Texas v. Teva Pharmaceuticals USA, Inc., et al., No. 4:20-cv-00733). Plaintiff alleges a conspiracy among generic pharmaceutical manufacturers to fix prices and allocate or divide customers or markets for various products in violation of federal and state antitrust and consumer protection laws; specifically, plaintiff alleges that it has paid approximately $3.86 million since 2013 for products attributable to Amneal entities. On March 30, 2020, the JPML issued a conditional transfer order tagging the case for transfer to the E.D. Pa. for coordination and consolidation with MDL No. 2724.

Fact and document discovery in MDL No. 2724 are proceeding. On December 26, 2019, the MDL court entered a case management order extending by stipulation certain pretrial discovery deadlines, including leaving open-ended the date by which, after consultation with MDL court's appointed Special Master, the parties are to agree upon bellwether claims or cases for, inter alia, class certification and/or trials. On February 20, 2020, the Special Master issued a Report & Recommendation and Proposed Order providing for the establishment of two bellwether trial tracks; Track One would involve a jury trial of the overarching conspiracy claims presented in the States Attorneys General’s May 10, 2019 complaint (in which the Company and Amneal are defendants), and Track Two would consist of a second round of trials on one of three different individual drug conspiracy complaints (none of which involve the Company or any Amneal entities). Briefing in support of and in opposition to the Special Master’s proposal is underway.

The Company and certain of its affiliates have been named as defendants in various matters relating to the promotion and sale of prescription opioid pain relievers. The Company is aware that other individuals and states and political subdivisions are filing comparable actions against, among others, manufacturers and parties that have promoted and sold prescription opioid pain relievers, and additional suits may be filed.

The complaints, asserting claims under provisions of different state and Federal law, generally contend that the defendants allegedly engaged in improper marketing of opioids, and seek a variety of remedies, including restitution, civil penalties, disgorgement of profits, treble damages, attorneys’ fees and injunctive relief. None of the complaints specifies the exact amount of damages at issue. The Company and its affiliates that are defendants in the various lawsuits deny all allegations asserted in these complaints and have filed or intend to file motions to dismiss where possible. Each of the opioid-related matters described below is in its early stages. The Company intends to continue to vigorously defend these cases. In light of the inherent uncertainties of civil litigation, the Company is not in a position to predict the likelihood of an unfavorable outcome or provide an estimate of the amount or range of potential loss in the event of an unfavorable outcome in any of these matters.

On August 17, 2017, plaintiff Linda Hughes, as the mother of Nathan Hughes, decedent, filed a complaint in Missouri state court naming Amneal Pharmaceuticals of New York LLC, Impax, ~~five~~5 other pharmaceutical company defendants, and ~~three~~3 healthcare provider defendants. Plaintiff alleges that use of defendants’ opioid medications caused the death of her son, Nathan Hughes. The complaint alleges causes of action against Amneal and Impax for strict product liability, negligent product liability, violation of Missouri Merchandising Practices Act and fraudulent misrepresentation. The case was removed to federal court on September 18, 2017. It was transferred to the United States District Court for the Northern District of Ohio on February 2, 2018 and is part of the multidistrict litigation pending as In Re National Prescription Opiate Litigation, MDL No. 2804 (the “MDL”). Plaintiff has filed a motion to remand the case to Missouri state court. That motion remains pending before the MDL court. All activity in the case is stayed by order of the MDL court.

On March 15, 2018, plaintiff Scott Ellington, purporting to represent the State of Arkansas, more than ~~sixty~~60 counties and a dozen cities, filed a complaint in Arkansas state court naming Gemini Laboratories, LLC and ~~fifty-one~~NaN other pharmaceutical companies as defendants. Plaintiffs allege that Gemini and the other pharmaceutical company defendants improperly marketed, sold, and distributed opioid medications and failed to adequately warn about the risks of those medications. Plaintiffs allege causes of actions against Gemini and the other pharmaceutical company defendants for negligence and nuisance and alleged violations of multiple Arkansas statutes. Plaintiffs request past damages and restitution for monies allegedly spent by the State of Arkansas and the county and city plaintiffs for “extraordinary and additional services” for responding to

what plaintiffs term the “Arkansas Opioid Epidemic.” Plaintiffs also seek prospective damages to allow them to “comprehensively intervene in the Arkansas Opioid Epidemic,” punitive and treble damages as provided by law, and their costs and fees. The complaint does not include any specific damage amounts. Gemini filed a general denial and, on June 28, 2018, it joined the other pharmaceutical company defendants in moving to dismiss plaintiffs’ complaint. On January 29, 2019, the Court granted without prejudice Gemini’s motion to dismiss and dismissed Gemini from the litigation on March 22, 2019.

On March 27, 2018, plaintiff American Resources Insurance Company, Inc. filed a complaint in the United States District Court for the Southern District of Alabama against Amneal, Amneal Pharmaceuticals of New York, LLC, Impax, and ~~thirty-five~~ NaN other pharmaceutical company defendants. Plaintiff seeks certification of a class of insurers that since January 1, 2010, allegedly have been wrongfully required to: (i) reimburse for prescription opioids that allegedly were promoted, sold, and distributed illegally and improperly by the pharmaceutical company defendants; and (ii) incur costs for treatment of overdoses of opioid medications, misuse of those medications, or addiction to them. The complaint seeks compensatory and punitive damages, but plaintiff’s complaint does not include any allegation of specific damage amounts. On or about May 2, 2018, the case was transferred to the MDL. All activity in the case is stayed by order of the MDL court.

On May 30, 2018, plaintiff William J. Comstock filed a complaint in Washington state court against Amneal Pharmaceuticals of New York, LLC, and ~~four~~ 4 other pharmaceutical company defendants. Plaintiff alleges he became addicted to opioid medications manufactured and sold by the pharmaceutical company defendants, which plaintiff contends caused him to experience opioid-induced psychosis, prolonged hospitalizations, pain, and suffering. Plaintiff asserts causes of action against Amneal and the other pharmaceutical company defendants for negligence, fraudulent misrepresentation, and violations of the Washington Consumer Protection Act. On July 12, 2018, Amneal and other defendants removed the case to the United States District Court for the Eastern District of Washington. On August 17, 2018, the case was transferred to the MDL. All activity in the case is stayed by order of the MDL court.

On June 18, 2018, a Subpoena and CID issued by the Office of the Attorney General of Kentucky, Office of Consumer Protection was served on Amneal. The CID contains ~~eleven~~11 requests for production of documents pertaining to opioid medications

manufactured and/or sold by Amneal, or for which Amneal holds an Abbreviated New Drug Application. The Company is evaluating the CID and has been in communication with the Office of the Attorney General about the scope of the CID, the response to the CID, and the timing of the response. It is unknown if the Office of the Attorney General will pursue any claim or file a lawsuit against Amneal.

On July 9, 2018, the Muscogee (Creek) Nation filed a First Amended Complaint in its case pending in the MDL against the Company and 55 other defendants consisting of pharmaceutical companies, wholesalers, distributors, and pharmacies. Plaintiff alleges it has been damaged by the Company and the other pharmaceutical company defendants as a result of alleged improper marketing, including off-label marketing, failure to adequately warn of the risks of opioid medications, and failure to properly monitor and control diversion of opioid medications within the Nation. The case has been designated as a bellwether motion to dismiss case for the MDL, meaning it is a test case for arguments directed at the complaints filed by Indian tribes in the MDL cases. On August 31, 2018, the Company moved to dismiss the First Amended Complaint, and also joined in separate motions to dismiss filed by different defense subgroups. Plaintiff opposed these motions. Additionally, on September 28, 2018, plaintiff filed a motion to add Amneal and Amneal Pharmaceuticals of New York, LLC, and to dismiss the Company from the complaint. The Company opposed that motion, and plaintiff filed a reply on October 19, 2018. On April 1, 2019, the MDL court's designated magistrate judge issued a Report and Recommendation as to the Company’s motion to dismiss, recommending dismissal of plaintiff’s Lanham Act claims and state-law claims based on an alleged duty to correct alleged misrepresentations of brand-name manufacturers, but recommending denial of relief as to all other claims. On April 12, 2019, the magistrate judge overruled the Company’s objection to adding Amneal and Amneal Pharmaceuticals of New York, LLC, but dismissed the Company. Amneal and Amneal Pharmaceuticals of New York, LLC, filed an objection to the magistrate’s Report and Recommendation as to the Company’s motion to dismiss on April 29, 2019. On June 13, 2019, the MDL court denied the objections and subsequently ordered the defendants to file Answers to the First Amended Complaint. On August 16, 2019, Amneal and Amneal Pharmaceuticals of New York, LLC filed their respective answers. Further activity in the case is stayed by order of the MDL court.

On July 18, 2018, the County of Webb, Texas requested waivers of service from Amneal and Amneal Pharmaceuticals of New York, LLC, in its case pending in the MDL. Plaintiff’s Amended Complaint, filed against Amneal and ~~forty-one~~ NaN other defendants consisting of pharmaceutical companies, wholesalers, distributors, and pharmacy benefit managers, alleges damages as a result of Amneal’s and the pharmaceutical company defendants’ improper marketing, failure to adequately warn of the risks of opioid medications, and failure to properly monitor and control diversion of opioid medications in or affecting Webb County. Amneal and Amneal Pharmaceuticals of New York, LLC have returned the requested waivers. All activity in the case is stayed by order of the MDL court.

On August 24, 2018, the Tucson Medical Center filed a complaint against the Company and 18 other defendants consisting of pharmaceutical companies, distributors, and unidentified John Doe defendants, in the Superior Court of the State of Arizona, Pima County. Plaintiff alleges damages as a result of Amneal’s and the pharmaceutical company defendants’ improper marketing, failure to adequately warn of the risks of opioid medications, and failure to properly monitor and control diversion of opioid medications. Plaintiff seeks economic damages related to its purchase of opioid medications and for the costs of unreimbursed healthcare it has provided as a result of the opioid epidemic over and above ordinary healthcare services. In addition, plaintiff seeks compensatory damages, treble damages, punitive damages, awards of attorney’s fees, and abatement of the alleged public nuisance, as provided by law. On September 24, 2018, the distributor defendants removed the case to the United States District Court for the District of Arizona. Plaintiff filed a motion to remand on September 25, 2018, which the distributor defendants opposed. The Company filed a motion to dismiss on October 1, 2018. On October 8, 2018, following the Court’s denial of its remand motion, plaintiff voluntarily dismissed its Complaint without prejudice. Plaintiff re-filed its Complaint on October 9, 2018, in the Superior Court of the

State of Arizona, Pima County, along with a motion to designate the case as “complex.” The distributor defendants filed a notice of removal on October 29, 2018. Plaintiff filed an Emergency Motion to Remand on October 30, 2018. On December 19, 2018, the Court granted plaintiff’s motion and remanded the case to the Superior Court of Pima County, Arizona. On February 13, 2019, the Company again filed a motion to dismiss the complaint. The defendants (including the Company) also moved for a discovery stay pending resolution of their motions to dismiss. The Court entered an order on April 8, 2019 staying discovery until the earlier of June 25, 2019 or when the Court rules on the defendants’ separate motions to dismiss. On June 12, 13, and 14, 2019, the Court held hearings on all pending motions to dismiss. Immediately prior to the hearing on Amneal’s Motion to Dismiss, plaintiff agreed to a voluntary dismissal without prejudice of Amneal, which the parties then entered on the record. The co-defendants removed the case to federal court, but the federal court re-remanded the case to state court. Plaintiff ~~is attempting to amend~~initially amended its complaint in state court and ~~will attempt~~attempted to ~~add~~name Amneal as a defendant; however, plaintiff did not serve that complaint on Amneal. On February 7, 2020, plaintiff filed a second amended complaint that did not name Amneal as a defendant. Accordingly, Amneal is not presently a defendant in this lawsuit.

On October 4, 2018, the City of Martinsville, Virginia, filed a complaint in Virginia state court, naming the Company, Amneal, Amneal Pharmaceuticals of New York, LLC, Impax, and 45 other pharmaceutical companies and other entities as defendants. Plaintiff alleges that the defendants are liable for the economic and non-economic injuries allegedly suffered by resident doctors, health care payors, and opioid-addicted individuals, as well as for the costs incurred in addressing the opioid epidemic. Plaintiff requests an unspecified amount of damages against the defendants. The case was removed to federal court on December 13, 2018and was conditionally transferred to the MDL on December 27, 2018. Plaintiff opposed the transfer to the MDL and moved to remand the case to Virginia state court. On February 14, 2019, the United States District Court for the Western District of Virginia, Roanoke Division, remanded the case to the Martinsville Circuit Court in Martinsville, Virginia. Nine other Virginia municipalities have filed identical complaints naming the same defendants, but none have been served on the Company or its affiliates. The unserved Virginia cases ~~have been~~were removed ~~and are in~~to federal court ~~though plaintiffs have filed motions to remand~~ and ~~are opposing transfer of those cases~~subsequently transferred to the ~~MDL court.~~MDL. On April 24, 2019, the ~~Court in~~ Martinsville ~~Virginia,~~Circuit Court stayed this case until it is determined whether the other Virginia cases that were removed to federal court will be remanded, or until the parties or the court may determine whether consolidation of this case with others is possible in Virginia state court. The removed cases were transferred to the MDL, but this case remains stayed in state court.

In October and November 2018, the SouthEast Alaska Regional Health Consortium, the Kodiak Area Native Association, and the Norton Sound Health Corporation requested that the Company execute waivers of service in their cases pending in the MDL. Plaintiffs’ complaints name the Company and 37 other entities as defendants. Plaintiffs allege damages and seek injunctive relief, compensatory and statutory damages, “as well as the means to abate the epidemic” that they allege was “created by Defendants’ wrongful and/or unlawful conduct.” All activity in these cases is stayed by order of the MDL court.

On December 3, 2018, Appalachian Regional Healthcare, Inc., filed a complaint in Kentucky state court, naming Amneal and 32 other pharmaceutical companies and other entities as defendants. Plaintiff alleges that the defendants are liable for the economic and non-economic injuries allegedly suffered by Kentucky’s hospitals and others. Plaintiff requested an unspecified amount of damages against the defendants. The case has now been removed to federal court, and all activity in these cases is stayed by order of the MDL court.

On January 23, 2019, Indian Health Council, Inc., requested that the Company execute a waiver of service in its case pending in the MDL. Plaintiff’s complaint names the Company and 18 other pharmaceutical companies and other entities as defendants. Plaintiff, an intertribal health organization which provides healthcare services to its consortium’s member tribes, alleges that the defendants are liable for the economic injuries it allegedly suffered as a result of its role in responding to an alleged “epidemic of opioid abuse”. Plaintiff requests an unspecified amount of damages against the defendants. The case has been transferred to the MDL. All activity in the case is stayed by order of the MDL court.

On February 7, 2019, Kentucky River District Health Department requested that the Company execute a waiver of service in its case pending in the MDL. Plaintiff’s putative class action complaint names Amneal and 20 other pharmaceutical companies and other entities as defendants. Plaintiff alleges that the defendants are liable for the economic injuries it suffered, on behalf of itself and similarly situated Kentucky health departments, as a result of their role in responding to an alleged “opioid epidemic.” Plaintiff requests an unspecified amount of damages against the defendants. All activity in the case is stayed by order of the MDL court.

In February and March 2019, the Aleutian Pribilof Islands Association and Alaska Native Tribal Health Consortium requested that the Company execute waivers of service in their cases pending in the MDL. Plaintiffs’ complaints name the Company and 37 other entities as defendants. Plaintiffs allege damages and seek injunctive relief, compensatory and statutory damages, “as well as the means to abate the epidemic” that they allege was “created by Defendants’ wrongful and/or unlawful conduct.” All activity in these cases is stayed by order of the MDL court.

In March 2019, Glynn County, Georgia, requested waivers of service from the Company and Amneal in its case pending in the MDL. Plaintiff’s second amended short-form complaint, filed against Amneal and 39 other defendants consisting of pharmaceutical companies, wholesalers, retailers, and distributors, alleges damages as a result of defendants’ alleged improper marketing, fraud, including RICO violations, failure to adequately warn of the risks of opioid medications, failure to properly monitor and control diversion of opioid medications in or affecting Glynn County, negligence, public nuisance, and unjust enrichment. All activity in the case is stayed by order of the MDL court.

On March 14, 2019, the City of Concord, New Hampshire, filed a short-form amendment to its Second Amended Complaint in the MDL court adding the Company, Amneal, and Impax, to 31 other defendants, including pharmaceutical companies, corporate officers of certain brand manufacturer pharmaceutical companies, and distributors. As to the Company, Amneal, and Impax, plaintiff asserts claims for violation of the New Hampshire Consumer Protection Act, public nuisance, unjust enrichment, and violation of RICO. Plaintiff alleges that defendants are liable

for economic injuries experienced by plaintiff, including unspecified restitution, civil penalties, disgorgement of unjust enrichment and attorneys’ fees, as well as for injunctive relief as to defendants’ further false or misleading statements as to opioids, and for exemplary damages. Amneal was served on April 25, 2019. All activity in the case is stayed by order of the MDL court.

On March 15, 2019, the International Union of Painters and Allied Trades, District Council No. 21 Welfare Fund, and, separately, the International Brotherhood of Electrical Workers Local 98 Health & Welfare Fund, and International Brotherhood of Electrical Workers Local 98 Sound and Communications Health and Welfare Fund, filed complaints in the Philadelphia County Common Pleas Court, naming Amneal, Impax, Amneal Pharmaceuticals of New York, LLC, and 29 other pharmaceutical companies as defendants. In each, plaintiffs allege that the defendants are liable for economic injuries allegedly suffered by the respective funds to the extent those funds paid for long term treatment of their benefit members with opioids, and for the costs incurred in addressing an alleged “opioid epidemic.” Plaintiffs request an unspecified amount of damages against the defendants. On April 17, 2019, Amneal and Amneal Pharmaceuticals of New York, LLC were served with both complaints. ~~Both~~On January 7, 2020, Karen Davidson, individually and as administratrix of the estate of John C. Davidson, filed a complaint in the Philadelphia County Common Pleas Court, naming the Company and Amneal, among other parties, as defendants. All three cases have been transferred to Delaware County, Pennsylvania, where numerous other opioid cases currently are pending. The cases are now stayed by order of the Delaware County court.

In March 2019, the State of New Mexico filed a Second Amended Complaint in its case pending against numerous generic drug manufacturers and distributors in the First District Court of Santa Fe County, naming as defendants Amneal and Amneal Pharmaceuticals of New York, LLC. Plaintiff seeks unspecified damages, and injunctive relief, “to eliminate the hazard to public health and safety caused by the opioid epidemic, to abate the nuisance, ~~in [the state],~~ and to recoup State monies that have been spent” on account of defendants’ alleged “false, deceptive and unfair marketing and/or unlawful diversion of prescription opioids.” On July 17, 2019, the Amneal entities moved to dismiss for lack of personal jurisdiction and failure to state a claim upon which relief can be granted. On October 15, 2019, the court entered an order dismissing the plaintiff’s negligence per se claims, but declining to dismiss the Amneal entities for lack of personal jurisdiction. ~~Responsive pleadings~~The Amneal entities timely filed answers and moved for reconsideration of their jurisdictional motion on January 21, 2020. On March 27, 2020, the court held oral argument and denied the motion for reconsideration from the bench. The court entered an order denying the motion for reconsideration, without explanation, on April 6, 2020. The parties are ~~presently due to be filed on November 29, 2019.~~now engaged in discovery.

In April 2019, several Virginia municipalities (the County Board of Arlington, Dinwiddie County, and Mecklenburg County) filed Complaints in their respective local circuit courts against the Company, Amneal, Amneal Pharmaceuticals of New York, LLC, and Impax along with numerous additional generic drug manufacturers, distributors, and pharmacies. In each Complaint, plaintiffs seek unspecified damages and equitable relief, alleging that defendants were negligent and/or grossly negligent in flooding the relevant municipalities with prescription opioid medications and engaged in civil conspiracies to do so. Each case had been removed to the United States District Court for the Eastern District of Virginia, but all three since have been remanded back to Virginia state court. The Company was nonsuited (dismissed) from the Arlington case. Amended Complaints ~~are expected to be~~were filed in the Dinwiddie and Mecklenburg cases ~~before~~at the end of November ~~2019. There are no deadlines presently in those cases, and no responsive pleadings are due until after~~2019, but they did not include the ~~Amended Complaints are filed.~~ Amneal entities as defendants.

On June 10, 2019, in their cases currently pending in the MDL, West Virginia municipal-entity plaintiffs Cabell County Commission and the City of Huntington were granted leave to file, then filed, a Joint and Third Amended Complaint naming approximately 20 additional defendants, including the Company, Amneal, Amneal Pharmaceuticals of New York, LLC, and Impax. The plaintiff municipalities, seek unspecified actual, treble, and punitive damages and disgorgement “to eliminate the hazard to public health and safety, to abate the public nuisance caused by the opioid epidemic in the City and County and to compensate both for abatement measures undertaken or underway and damages sustained as a result of the opioid epidemic” they allege the defendants “proximately caused.” These actions have been designated “Track Two” bellwether cases by the MDL court (intended to be adjudicated following the “Track One” cases for which bellwether trials had been scheduled for October 2019). On December 31, 2018, the MDL court entered an Order directing the then-parties in these Track Two actions to work with one of the MDL court's appointed Special Masters to prepare case management deadlines. On May 12, 2019, the Special Master entered an Order acknowledging that the press of issues surrounding ongoing litigation of the Track One cases had prevented both the parties and the MDL court from acting on the directives of the prior Track Two Order, and setting deadlines of June 10, 2019 for plaintiffs to amend their complaints, and June 14, 2019 for the submission of proposals for case management by the then-parties to the cases (the Amneal entities were not served with plaintiffs’ Third Amended Complaints until June 25, 2019). ~~However,~~On December 16, 2019, the MDL court granted plaintiffs’ motion to ~~date, none of~~sever all defendants from the ~~existing parties to the cases have filed or submitted any case management proposals to the Special Master. Accordingly, the case management aspect of these~~ Track Two cases ~~remains pending.~~except certain distributor defendants (AmerisourceBergen Drug Corporation, Cardinal Health, Inc., and McKesson Corporation). On January 3, 2020, the MDL court ordered that plaintiffs cannot take discovery of any severed Track Two defendant. On January 14, 2020, the Track Two cases were remanded to the United States District Court for the Southern District of West Virginia, without the severed defendants. To the extent Amneal entities were defendants in the Track Two cases but have been severed, the cases are now stayed by order of the MDL court.

In October 2019, the Company, Amneal, Amneal Pharmaceuticals of New York, LLC, and Impax were served with a putative class action complaint, which also names as defendants numerous manufacturers of opioid products (and certain corporate officers thereof), filed in the United States District Court for the Middle District of Tennessee by several individuals who allegedly purchased prescription opioid medication in cash and/or with an insurance co-payment (Rhodes, et al., v. Rhodes Technologies, Inc., et al., No. 3:19-cv-00885). Plaintiffs claim that they would not have purchased these prescription opioid products had defendants not allegedly misrepresented the products’ “addiction propensities,” and thereby suffered economic loss. Plaintiffs purport to represent a nationwide class of all individuals who directly or indirectly purchased prescription opioid medication from January 2008 to the present in 31 different states, allege causes of action for violations of those states’

antitrust laws and consumer protection statutes (and unjust enrichment), and seek, in addition to class certification, unspecified monetary damages (including actual, statutory, and punitive or treble damages) and equitable relief, including declaratory judgment and restitution. ~~Responsive pleadings~~

There are currently 26 cases brought by various West Virginia and Kentucky hospitals that have been consolidated in the state-court West Virginia Opioid Litigation Multi-Litigation Panel (the “MLP”). On November 20, 2019, the manufacturer defendants collectively filed a motion to dismiss, in which Amneal joined, and the Company filed its own individual motion to dismiss. The MLP has denied the manufacturer defendants’ motion to dismiss, but has not yet ~~due~~ruled on the Company’s separate motion. There also are 5 additional cases brought by West Virginia municipalities against the Company, Amneal, Amneal Pharmaceuticals of New York, LLC, and Impax which have been transferred to ~~be filed.~~the MLP. The Amneal entities’ responsive pleading deadline is May 18, 2020, and we intend to file motions to dismiss in those cases. The MLP also ordered an early mediation on February 26 and 27, 2020, during which plaintiffs did not make a settlement demand. The MLP has ordered a public nuisance bench trial to occur beginning on March 22, 2021. Defendants have filed a motion for reconsideration of the order denying a jury trial.

Including the above-referenced cases, the Company and certain of its affiliates recently have been named in approximately ~~800~~915 cases now pending in the MDL court or in various state and territorial courts, including cases brought by:

Requests for waivers for service of process have been transmitted by plaintiffs’ counsel to defense counsel in relation to the Company and certain of its affiliates in most of these cases. In each case where service on the Company or its affiliates has been perfected, and the case is not stayed, responsive pleadings or pre-answer motions have been filed.

On April 17, 2017, ~~Lead Plaintiff~~lead plaintiff New York Hotel Trades Council & Hotel Association of New York City, Inc. Pension Fund filed an amended class action complaint in the United States District Court for the Northern District of California on behalf of itself and others similarly situated against Impax and four current or former Impax officers alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule ~~10b-5.~~10b-5 (Fleming v. Impax Laboratories Inc., et al., No. 4:16-cv-06557-HSG). Plaintiff asserts claims regarding alleged misrepresentations about three generic drugs. Its principal claim alleges that Impax concealed that it colluded with competitor Lannett Corp. to fix the price of generic drug digoxin, and that its digoxin profits stemmed from this collusive pricing. Plaintiff also alleges that Impax concealed from the market anticipated erosion in the price of generic drug diclofenac and that Impax overstated the value of budesonide, a generic drug that it acquired from Teva. On June 1, 2017, Impax filed its motion to dismiss the amended complaint. On September 7, 2018, the Court granted Impax’s motion, dismissing plaintiff’s claims without prejudice and with leave to amend the complaint. Plaintiff filed a second amended complaint October 26, 2018. Impax filed a motion to dismiss the second amended complaint on December 6, 2018; plaintiffs’ opposition thereto was filed on January 17, 2019; and Impax’s reply in support of its motion to dismiss was filed on February 7, 2019. A hearing before the Court on the motion to dismiss took place on May 2, 2019. On August 12, 2019, the Court entered an order granting Impax’s motion, dismissing plaintiff’s second amended complaint with prejudice. On September 5, 2019, plaintiff filed a notice of appeal from both dismissal orders with the United States Court of Appeals for the Ninth Circuit.

~~On February 15, 2017, plaintiffs Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals Curacao N.V. ("Teva") filed a Praecipe to Issue Writ~~By order of ~~Summons and Writ of Summons in~~ the Philadelphia County Court of Common Pleas against Impax alleging that Impax breached the Strategic Alliance Agreement between the parties by not indemnifying Teva in its two litigations with GlaxoSmithKline LLC regarding Wellbutrin ® XL (and therefore that Impax is liable to Teva for the amounts it paid to settle those litigations). Impax filed a Motion to Disqualify Teva’s counsel related to the matter, and on August 23, 2017, the trial court denied Impax's motion. Following the trial court’s order, Teva filed its complaint. On September 6, 2017, Impax appealed the trial court’s decision to the Pennsylvania Superior Court. On September 20, 2017, the Superior Court stayed the trial court action pending the outcome of Impax’s appeal. OnNinth Circuit dated November 2, 2018, the Superior Court affirmed the trial court’s decision. On November 16, 2018, Impax filed an application for reargument with the Superior Court, which was denied on December 28, 2018. On February 13,26, 2019, the Superior Court remitted the record to the trial court. On February 15, 2019, Impax filed its answer with new matter to Teva’s complaint. On February 19, 2019, the trial court issued a revised case management order providing that, absent any extensions or amendments thereto, discovery was to have closed on July 1, 2019 and the case is expected to be ready for trial by February 3, 2020. On or about March 4, 2019, Teva filed a motion for judgment on the pleadings. Impax filed its answer andplaintiff’s opening brief in opposition to Teva’s motion for judgment on the pleadings on March 25, 2019. On April 4, 2019, the trial court denied Teva’s motion. On April 16, 2019, Impax filed a motion to stay the proceedings and compel Teva to arbitrate the dispute pursuant to an Indemnification Release Agreement negotiated and executed by the parties in 2012. Teva’s opposition to the motionpresently was filed on February 14, 2020, with Impax’s answering brief due on May ~~7, 2019.~~ 15, 2020.

On ~~June 11,~~December 18, 2019, the trial court denied Impax’s motion. On June 24, 2019, Impax noticed its intent to appeal to the Superior Court the trial court’s denial of the motion to compel arbitration, and moved both to stay the trial court proceedings pending that appeal and for an extension of case management deadlines. On July 12, 2019, the trial court denied both motions. On July 24, 2019, Impax moved the Superior Court to stay all trial court proceedings pending the outcome of Impax’s appeal of the trial court’s denial of the motion to compel arbitration and, on August 13, 2019, the Superior Court granted Impax’s motion. Impax filed its opening appellate brief with the Superior Court on September 3, 2019 and Teva filed its response brief on October 3, 2019. In October 2019, the parties reached an agreement in principle to resolve the matter, subject to finalized documentation.

~~On August 3, 2017, plaintiff Emielou Williams~~Cambridge Retirement System filed a class action complaint in the Superior Court ~~for the State~~ of ~~California in the~~New Jersey, Somerset County, ~~of Alameda~~ on behalf of ~~herself~~itself and others similarly situated against the Company and fourteen current or former officers alleging violations of Sections 11, 12(a)(2) and 15 of the Securities Act of 1933 (Cambridge Retirement System v. Amneal Pharmaceuticals, Inc., et al., No. SOM-L-001701-19). Plaintiff principally alleges that the amended registration statement and prospectus issued on May 7, 2018 in connection with the Amneal/Impax ~~alleging violation of California Business~~business combination was materially false and/or misleading, insofar as it purportedly failed to disclose that Amneal was an active participant in an alleged antitrust conspiracy with several other pharmaceutical manufacturers to fix generic drug prices, and ~~Professions Code section 17200 by violating various California wage and hour laws, and seeking,~~that this secret collusion improperly bolstered Amneal’s financial results reflected in the registration statement. Plaintiff seeks, among other things, ~~declaratory judgment, restitution~~certification of ~~allegedly unpaid wages,~~a class and disgorgement. On October 10, 2017, Impax filed a Demurrer and Motion to Strike Class Allegations. On December 12, 2017, the Court overruled Impax’s Demurrer to Plaintiff’s individual claims. However, it struck all of plaintiff’s class allegations.unspecified compensatory and/or recessionary damages. On March ~~13, 2018, plaintiff filed her First Amended Complaint once again including~~31, 2020, the ~~same class allegations. The~~ Company filed a ~~Demurrer and Motion~~motion to ~~Strike Class Allegations on April 12, 2018. On September 20, 2018,~~dismiss the ~~Court again struck plaintiff’s class allegations; plaintiff~~complaint.

The Company believes it has ~~appealed this most recent order~~substantial meritorious defenses to the California State Court of Appeal. Plaintiff filed her opening appellate brief on February 22, 2019; Impax’s brief in response was filed on April 18, 2019; plaintiff filed her reply brief on May 7, 2019;claims asserted with respect to the litigation. However, any adverse outcome could negatively affect the Company and ~~Impax filed~~could have a ~~surreply on May 22, 2019. The appeal has now been fully submitted~~material adverse effect on the ~~briefs.~~Company's results of operations, cash flows and/or overall financial condition.

On July 7, 2017, Amneal Pharmaceuticals of New York, LLC received an administrative subpoena issued by the Long Island, NY District Office of the Drug Enforcement Administration (the “DEA”) requesting information related to compliance with certain recordkeeping and reporting requirements pursuant to regulations promulgated by the DEA. The Company is cooperating with this request for information and has provided relevant information responsive to the request. The Company and the U.S. Attorney for the Eastern District of New York (“E.D.N.Y.”) have entered into a tolling agreement (and several amendments thereto) with respect to the investigation. The material provisions of the tolling agreement (as amended) provide that the investigation is ongoing, that the U.S. Attorney will not file a claim against the Company on or before ~~December 19, 2019,~~November 11, 2020, and requests that the Company agree that the applicable statute(s) of limitations be tolled during the period from January 19, 2018 through ~~December 20, 2019.~~November 12, 2020. The Company cannot predict at this time whether the U.S. Attorney will file a lawsuit or other claims against the Company with respect to the investigation.

On March 14, 2019, Amneal received a subpoena (the “Subpoena”) from an Assistant U.S. Attorney (“AUSA”) for the Southern District of Florida. The Subpoena requests information and documents generally related to the marketing, sale, and distribution of oxymorphone. The Company has been cooperating and intends to continue to cooperate with the AUSA regarding the Subpoena. However, no assurance can be given as to the timing or outcome of its underlying investigation.

On May 28, 2019, Amneal received a subpoena (the “Subpoena”) from an AUSA for the E.D.N.Y. requesting information and documents generally related to the Company’s compliance with Controlled Substances Act regulations. The Company intends to cooperate with the AUSA regarding the Subpoena. The Company and the U.S. Attorney for the E.D.N.Y. have entered into a tolling agreement (and several amendments thereto) with respect to the investigation. The material provisions of the tolling agreement (as amended) provide that the E.D.N.Y. has made no decision as yet as to the appropriate resolution of its pending investigation, that the Company’s time to present evidence and arguments to the E.D.N.Y. concerning the investigation is extended to November 12, ~~2019,~~2020, and that the Company agrees that the applicable statute(s) of limitations are tolled during the period from April 12, 2019 through November 12, ~~2019.~~2020. The Company cannot predict at this time whether the U.S. Attorney will file a lawsuit or other claims against the Company with respect to the investigation.

On January 27, 2020, the Company and Amneal were named in a putative class action complaint filed in the United States District Court for the Northern District of Illinois by several named plaintiffs on behalf of consumers who purchased Zantac® (ranitidine) and have not been diagnosed with, but “live in constant fear of developing,” cancer, alleging that the defendants, comprising various entities alleged to have manufactured or sold brand-name Zantac® or generic ranitidine, failed to disclose and/or concealed the product’s “dangerous propensities” in respect of the alleged presence in the product of N-Nitrosodimethylamine (or NDMA) (White, et al., v. GlaxoSmithKline plc, et al., No. 1:19-cv-07773). The complaint purports to state claims for violations of state consumer protection acts, breaches of implied warranties, negligence/gross negligence, and fraudulent concealment (and seeks the certification of corresponding nationwide classes and subclasses). In addition to class certification, plaintiffs seek, among other things, unspecified monetary damages and equitable relief, including the implementation and funding of a medical monitoring program. The complaint is one of hundreds of similar putative class actions and personal injury/product liability lawsuits filed in federal courts nationwide. In November 2019, the JPML established In re Zantac/Ranitidine NDMA Litigation (MDL No. 2924) for coordinated or consolidated pretrial proceedings and, on February 6, 2020, ordered the MDL centralized in the Southern District of Florida. On February 24, 2020 this lawsuit was transferred to and consolidated with MDL No. 2924. On March 2, 2020, plaintiffs voluntarily dismissed their claims without prejudice against the generic ranitidine manufacturers named as defendants (including the Company and Amneal).

On March 6, 2020, plaintiff Kathy McMillian filed a personal injury / products liability complaint in the United States District Court for the Southern District of Alabama against brand and generic ranitidine product manufacturers (including Amneal), as well as Walmart, Inc., alleging that she developed kidney cancer as a result of her use of Zantac®, Equate®, and/or generic ranitidine, and that defendants knew about but failed to warn regarding an alleged “NDMA defect” in those products (McMillian v. Sanofi-Aventis U.S. LLC, et al., No. 1:20-cv-00141-N). Plaintiff seeks unspecified amounts of both compensatory and punitive damages, as well as attorneys’ fees and other costs. On March 31, 2020, the case was transferred to and consolidated with MDL No. 2924 and, accordingly, responsive pleading deadlines are stayed.

On March 13, 2020, plaintiff Walter Jones, on behalf of decedent Sue Jones, filed an amended complaint naming the Company, Amneal, and Amneal Pharmaceuticals of New York, LLC, in his personal injury / products liability lawsuit against brand and generic ranitidine product manufacturers pending in the United States District Court for the Western District of Tennessee (Jones v. Boehringer Ingelheim Pharmaceuticals, Inc., et al., No. 1:20-cv-2157-JDB-JAY). Plaintiff alleges that his decedent spouse developed liver cancer and died as a result of six years of use with Zantac®, and that defendants knew about but failed to warn regarding an alleged “NDMA defect” in their ranitidine products. Plaintiff seeks unspecified amounts of both compensatory and punitive damages, as well as attorneys’ fees and other costs. On March 31, 2020, the case was transferred to and consolidated with MDL No. 2924 and, accordingly, responsive pleading deadlines are stayed.

The Company believes it has substantial meritorious defenses to the claims asserted with respect to these lawsuits. However, any adverse outcome could negatively affect the Company and could have a material adverse effect on the Company's results of operations, cash flows and/or overall financial condition.

On April 14, 2020, Amneal received a letter from counsel on behalf of Mohammed Rahman and a putative class of purchasers of prescription metformin, providing notice of alleged breaches of express and implied warranties and violations of state consumer protection laws regarding the quality and safety of the metformin allegedly purchased. Specifically, the letter alleges that because the metformin Mr. Rahman and the putative class purchased “contain[ed] NDMA,” the product is “worthless,” “unusable and unfit for human consumption.” The letter demands that Amneal cease and desist from selling “defective metformin” and make full restitution to all purchasers of “defective metformin.” The Company anticipates that it will be served with the putative class action lawsuit that was filed by Mr. Rahman and his counsel on April 7, 2020 in the United States District Court for the District of New Jersey (Rahman v. Amneal Pharmaceuticals LLC, No. 2:20-cv-03757-BRM-JAD).

The Company believes it has substantial meritorious defenses to the claims asserted with respect to this matter. However, any adverse outcome could negatively affect the Company and could have a material adverse effect on the Company's results of operations, cash flows and/or overall financial condition.

~~The~~As a result of the Acquisitions, the Company ~~has two~~added a third reportable segment, AvKARE, to its existing reportable segments, Generics and Specialty. Generics develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals across a broad range of therapeutic categories. ~~The Company's~~Generics’ retail and institutional portfolio contains approximately ~~200~~250 product families, many of which represent difficult-to-manufacture products or products that have a high barrier-to-entry, such as oncologics, anti-infectives and supportive care products for healthcare providers.

Specialty delivers proprietary medicines to the U.S. market. The Company offers a growing portfolio in core therapeutic categories including central nervous system disorders, endocrinology, parasitic infections and other therapeutic areas. The Company's specialty products are marketed through skilled specialty sales and marketing teams, who call on neurologists, movement disorder specialists, endocrinologists and primary care physicians in key markets throughout the U.S.

Specialty also has a number of product candidates that are in varying stages of development.

AvKARE provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, primarily focused on serving the Department of Defense and the Department of Veterans Affairs. AvKARE is also a wholesale distributor of bottle and unit dose pharmaceuticals under the registered names of AvKARE and AvPAK, as well as medical and surgical products. AvKARE is also a packager and wholesale distributor of pharmaceuticals and vitamins to its retail and institutional customers who are located throughout the United States focused primarily on offering 340b-qualified entities products to provide consistency in care and pricing.

The Company’s chief operating decision maker evaluates the financial performance of the Company’s segments based upon segment operating income (loss). Items below income (loss) from operations are not reported by segment, since they are excluded from the measure of segment profitability reviewed by the Company’s chief operating decision maker. Additionally, general and administrative expenses, certain selling expenses, certain litigation settlements, and non-operating income and expenses are included in "Corporate and Other." The Company does not report balance sheet information by segment since it is not reviewed by the Company’s chief operating decision maker.

The tables below present segment information reconciled to total Company financial results, with segment operating income or loss including gross profit less direct selling expenses, research and development expenses, and other operating expenses to the extent specifically identified by segment (in thousands):

Three Months Ended September 30, 2019	Generics ⁽¹⁾			Specialty ⁽¹⁾		Corporate and Other			Total Company
Three Months Ended March 31, 2020												Generics ^{(1) (2)}		Specialty ⁽²⁾		AvKARE ⁽¹⁾		Corporate and Other			Total Company
Net revenue	$	291,021		$	87,262	$	—		$	378,283		$	352,586	$	87,977	$	57,970	$	—		$	498,533
Cost of goods sold		217,773			49,944		—			267,717			218,865		47,818		46,895		—			313,578
Cost of goods sold impairment charges		49,115			7,017		—			56,132			1,456		—		—		—			1,456
Gross profit		24,133			30,301		—			54,434			132,265		40,159		11,075		—			183,499
Selling, general and administrative		14,256			20,228		29,313			63,797			16,623		20,942		10,788		29,623			77,976
Research and development		34,316			3,809		—			38,125			29,034		7,345		—		—			36,379
In-process research and development impairment charges		23,382			—		—			23,382			960		—		—		—			960
Charges (gains) related to legal matters, net		14,750			—		—			14,750
Intellectual property legal development expenses		2,586			—		—			2,586			1,265		5		—		—			1,270
Acquisition, transaction-related and integration expenses		502			2,455		174			3,131
Restructuring and other charges		14,702			213		6,022			20,937
Operating (loss) income	$	(80,361	)	$	3,596	$	(35,509	)	$	(112,274	)
Charges related to legal matters													2,500		2,000		—		—			4,500
Other operating expenses													46		—		—		4,577			4,623
Operating income (loss)												$	81,837	$	9,867	$	287	$	(34,200	)	$	57,791

Nine Months Ended September 30, 2018	Generics			Specialty		Corporate and Other			Total Company
Three Months Ended March 31, 2019												Generics			Specialty		Corporate and Other			Total Company
Net revenue	$	1,028,134		$	137,329	$	—		$	1,165,463		$	382,477		$	63,643	$	—		$	446,120
Cost of goods sold		572,179			62,474		—			634,653			278,878			30,865		—			309,743
Cost of goods sold impairment charges		7,815			—		—			7,815			53,297			—		—			53,297
Gross profit		448,140			74,855		—			522,995			50,302			32,778		—			83,080
Selling, general and administrative		51,854			33,265		71,491			156,610			24,148			21,327		38,961			84,436
Research and development		129,762			7,131		—			136,893			50,151			3,707		—			53,858
In-process research and development impairment charges		650			—		—			650			22,787			—		—			22,787
Intellectual property legal development expenses		12,509			515		—			13,024			3,121			1,045		—			4,166
Acquisition, transaction-related and integration expenses		114,622			—		102,251			216,873
Restructuring and other charges		21,912			2,394		18,003			42,309
Charges (gains) related to legal matters, net		(3,000	)		—		2,589			(411	)
Operating income (loss)	$	119,831		$	31,550	$	(194,334	)	$	(42,953	)
Other operating expenses													4,678			2,062		5,453			12,193
Operating (loss) income												$	(54,583	)	$	4,637	$	(44,414	)	$	(94,360	)

The Company has various business agreements with certain third-party companies in which there is some common ownership and/or management between those entities, on the one hand, and the Company, on the other hand. The Company has no direct ownership or management in any of such related party companies. The related party relationships that generated income and/ or expense in the respective reporting periods are described below.

The Company has a financing lease for ~~two~~2 buildings located in Long Island, New York, that are used as an integrated manufacturing and office facility. For annual payments required under the terms of the non-cancelable lease agreement over the next five years and thereafter, refer to Note ~~11.~~12. Leases.in the Company’s 2019 Annual Report on Form 10-K.

Lease costs and interest expense related to this lease were each approximately $1 million for the three months ended March 31, 2020. Lease costs and interest expense related to this lease were each approximately $1 million for the three months ended March 31, 2019.

Kanan, LLC ("Kanan") is an independent real estate company which owns Amneal’s manufacturing facilities located at 65 Readington Road, Branchburg, New Jersey, 131 Chambers Brook Road, Branchburg, New Jersey and 1 New England Avenue, Piscataway, New Jersey. Amneal leases these facilities from Kanan under ~~two~~2 separate triple-net lease agreements that expire in 2027 and 2031, respectively, at an annual rental cost of approximately $2 million combined, subject to CPI rent escalation adjustments as provided in the lease agreements. Rent expense paid to the related party for both of the three months ended ~~September 30,~~March 31, 2020 and 2019 ~~and 2018~~ was $0.5 ~~million. Rent expense paid to the related party for both of the nine months ended September 30, 2019 and 2018 was $1.5~~ million.

Asana Biosciences, LLC (“Asana”) is an early stage drug discovery and research and development company focusing on several therapeutic areas, including oncology, pain and inflammation. Amneal provided research and development services to Asana under a development and manufacturing agreement. The total amount of income earned from this arrangement for the three ~~and nine~~ months ended ~~September 30,~~March 31, 2019 was ~~nil~~$0.3 million (NaN in 2020). At both March 31, 2020 and ~~$1.4 million, respectively. The total amount of income earned from this arrangement for both the three and nine months ended September 30, 2018 was $0.2 million. At September 30,~~December 31, 2019 receivables of approximately $1 million were due from the related party for research and development related services.

Industrial Real Estate Holdings NY, LLC ~~("IRE")~~ is an independent real estate management entity, which ~~among other activities,~~ is the landlord of Amneal’s leased manufacturing facility located at 75 Adams Avenue, Hauppauge, New York. The lease expires in March ~~2021.~~2026. Rent ~~expense~~ paid to the related party for both the three months ended ~~September 30,~~March 31, 2020 and 2019 ~~and 2018~~ was $0.3 ~~million and $0.5 million, respectively. Rent expense paid for the related party for the nine months ended September 30, 2019 and 2018 was $0.8 million and $1.0 million, respectively.~~million.

Kashiv BioSciences, LLC ("Kashiv") is an independent contract development organization focused primarily on the development of 505(b) (2) NDA products. Amneal has various business agreements with Kashiv.

~~In May 2013, Amneal~~The parties entered into a ~~sublease agreement with Kashiv~~lease for ~~a portion~~parking spaces in Piscataway, NJ. The total amount of one of its research and development facilities. The sublease automatically renews annually if not terminated and has an annual base rent of $2 million. On January 15, 2018, Amneal and Kashiv entered into an Assignment and Assumption of Lease Agreement. The lease was assignedexpense paid to Kashiv ~~and Amneal was relieved of all obligations. Rental expense~~ from ~~the related party sublease~~this agreement for ~~the nine months ended September 30, 2018 was $0.4 million (none for both~~ the three months ended ~~September 30, 2019 and 2018 and nine months ended September 30,~~March 31, 2020 was less than $0.1 million (NaN in 2019).

Amneal has also entered into various development and commercialization arrangements with Kashiv to collaborate on the development and commercialization of certain generic pharmaceutical products. The total reimbursable expenses associated with these arrangements for the ~~nine months ended September 30, 2019 was $1 million, (none for the~~ three months ended ~~September 30,~~March 31, 2020 and 2019 were $0.2 million and ~~for the three and nine months ended September 30, 2018).~~$0.8 million, respectively. Kashiv receives a percentage of net profits with respect to Amneal’s sales of these products. The total profit share ~~paid to Kashiv~~ for the three months ended ~~September 30,~~March 31, 2020 and 2019 ~~and 2018~~ was ~~$0.6~~$3 million and ~~$0.8~~$0.7 million, respectively. The total profit share paid to Kashiv for the nine months ended September 30, 2019 and 2018 were $2 million and $3 million, respectively. At September 30, 2019 and December 31, 2018 payables of approximately $0.6 million and $0.8 million, respectively, were due to the related party for royalty-related transactions. Additionally, as of September 30, 2019 a receivable of $0.7 million was due from the related party.

In June 2017, Amneal and Kashiv entered a product acquisition and royalty stream purchase agreement. The aggregate purchase price was $25 million on the closing, which has been paid, plus two potential future $5 million earn outs related to the Estradiol Product. The contingent earn outs were to be recorded in the period in which they are earned. The first and second $5 million earn outs were recognized in March 2018 and June 2018, respectively, as an increase to the cost of the Estradiol product intangible asset and amortized on a straight-line basis over the remaining life of the Estradiol intangible asset. The first earn out was paid in July 2018 and the second earn out was paid in September 2018.

Pursuant to a product development agreement, Amneal and Kashiv agreed to collaborate on the development and commercialization of Oxycodone HCI ER Oral Tablets. Under the agreement, this product is owned by Kashiv, with Amneal acting as the exclusive marketing partner and as Kashiv’s agent for filing the product ANDA. Under the agreement, Amneal was also responsible for assuming control of and managing all aspects of the patent litigation arising from the filing of the ANDA, including selecting counsel and settling such proceeding (subject to Kashiv’s consent). In December 2017, Amneal and Kashiv terminated the product development agreement and pursuant to the termination and settlement of the agreement, Kashiv agreed to pay Amneal $8 million, an amount equal to the legal costs incurred by Amneal related to the defense of the ANDA. The cash payment was received in February 2018.

Pursuant to a product development agreement, Amneal and Kashiv agreed to collaborate on the development and commercialization of Levothyroxine Sodium. Under the agreement, the IPintellectual property and ANDA for this product is owned by Amneal and Kashiv is to receive a profit share for all sales of the product made by Amneal. Amneal is precluded from selling the product made by Kashiv during the term of the license and supply agreement with JSP. Under the terms of the amended agreement with Kashiv, Amneal paid $2 million in July 2019 and may be required to pay up to an additional $18 million upon certain regulatory milestones being met.

In November 2019, Amneal and Kashiv entered into a licensing agreement for the development and commercialization of Kashiv’s orphan drug K127 (pyridostigmine) for the treatment of Myasthenia Gravis. Under the terms of the agreement, Kashiv will be responsible for all development and clinical work required to secure Food and Drug Administration approval and Amneal will be responsible for filing the NDA and commercializing the product. The Company made an upfront payment of approximately $2 million to Kashiv in December 2019, which was recorded in research and development, and Kashiv is eligible to receive development and regulatory milestones totaling approximately $17 million. Kashiv is also eligible to receive tiered royalties from the low double-digits to mid-teens on net sales of K127. For the ~~nine~~three months ended ~~September 30, 2019,~~March 31, 2020, the Company recorded a $2 million (NaN in 2019), as research and development expense to compensate Kashiv for costs incurred to develop the product.

~~Adello is an independent clinical stage company engaged in~~On February 20, 2020, the ~~development of biosimilar pharmaceutical products. Amneal~~Company and ~~Adello are parties to~~Kashiv entered into a master services agreement ~~pursuant to which, from time to time, Amneal~~covering certain services that Kashiv provides ~~human resources~~the Company for commercial product support for EluRyng and product quality assurance services on behalf of Adello. The parties are also party to a license agreement for parking spaces in Piscataway, NJ. The total amount of income received from Adello from these agreements was less than $0.1 million for bothother products, including ranitidine and nitrofurantoin. For the three ~~and nine~~ months ended ~~September 30, 2019. The total amount~~March 31, 2020, the Company recorded $1 million (NaN in 2019), as cost of ~~net expense paid~~goods sold to ~~Adello from these agreements~~compensate Kashiv for services performed.

At March 31, 2020 and December 31, 2019 payables of approximately $10 million and $6 million, respectively, were due to the related party for the aforementioned transactions. Additionally, at both ~~the three~~March 31, 2020 and ~~nine months ended September 30, 2018 was less than $0.1 million. At September 30,~~December 31, 2019 a receivable of ~~approximately~~ $0.1 million was due from the related party.

In March 2017, Amneal entered into a product development agreement with Adello. The collaboration extended the remaining development process to Adello for a complex generic product, while Amneal retained its commercial rights upon approval. Pursuant to the agreement, Adello paid Amneal $10 million for reimbursement of past development costs, which Amneal deferred as a liability and will pay royalties upon commercialization.

In October 2017, Amneal and Adello terminated their product development agreement pursuant to which Amneal and Adello had been collaborating to develop and commercialize Glatiramer Acetate products. Pursuant to the termination agreement, Amneal owed Adello $11 million for the up-front payment plus interest. This amount was paid in January 2018.

On October 1, 2017, Amneal and ~~Adello~~Kashiv, entered into a license and commercialization ~~agreement pursuant~~agreement. Kashiv granted Amneal an exclusive license, under its New Drug Application, to ~~which the parties have agreed to cooperate with respect to certain development activities in connection with~~distribute and sell two ~~biologic pharmaceutical products. In addition, under the agreement, Adello has appointed Amneal as its exclusive marketing partner for such~~bio-similar products in the ~~United States.~~ U.S. Kashiv is responsible for development, regulatory

filings, obtaining FDA approval, and manufacturing, and Amneal is responsible for marketing, selling and pricing activities. The term of the agreement is 10 - years from the respective product’s launch date.

In connection with the agreement, Amneal paid an upfront amount of $2 million in October 2017 for execution of the agreement which was ~~recorded within~~expensed in research and ~~development expenses.~~development. The agreement also provides for potential future milestone payments to ~~Adello.~~

Kashiv of (i) up to $21 million relating to regulatory approval, (ii) up to $43 million for successful delivery of commercial launch inventory, (iii) between $20 million and $50 million relating to number of competitors at launch for one product, and (iv) between $15 million and $68 million for the achievement of cumulative net sales for both products. The milestones are subject to certain performance conditions which may or may not be achieved, including FDA filing, FDA approval, launch activities and commercial sales volume objectives. In ~~October 2017,~~addition, the agreement provides for Amneal ~~purchased~~to pay a ~~building from Adello in Ireland~~profit share equal to ~~further support its inhalation dosage form. Amneal issued a promissory note~~50% of net profits, after considering manufacturing and marketing costs. The research and development expenses under this agreement for ~~13 million euros ($15 million based on exchange rate as of December~~the three months ended March 31, ~~2017) which accrues interest at a rate of 2% per annum, due on or before July 1, 2019. The promissory note was paid in full in the second quarter of 2018. Refer to~~ ~~Note 5. Alliance~~2020 and ~~Collaboration~~ ~~for further information on collaboration agreements with Adello.~~ 2019 were immaterial.

PharmaSophia, LLC ("PharmaSophia") is a joint venture formed by Nava Pharma, LLC ("Nava") and Oakwood Laboratories, LLC for the purpose of developing certain products. Currently PharmaSophia is actively developing two injectable products. PharmaSophia and Nava are parties to a research and development agreement pursuant to which Nava provides research and development services to PharmaSophia. Nava subcontracted this obligation to Amneal, entering into a subcontract research and development services agreement pursuant to which Amneal provides research and development services to Nava in connection with the products being developed by PharmaSophia. The total amount of income earned from these agreements for the three months ended ~~September 30,~~March 31, 2020 and 2019 ~~and 2018~~ was ~~$0.3~~$0.2 million and ~~$0.2 million, respectively. The total amount of income earned from these agreements for the nine months ended September 30, 2019 and 2018 was $0.9 million and $0.5~~$0.3 million, respectively. At ~~September 30, 2019~~March 31, 2020 and December 31, ~~2018~~2019 receivables of ~~$0.3~~$0.6 million and ~~$0.1~~$0.7 million, respectively, were due from the related party.

~~Prior~~ Additionally, as of December 31, 2019 a payable of less than $0.1 million was due to the ~~Company's acquisition of Gemini~~related party, which was settled in May 2018, Amneal and Gemini were parties to various agreements. Total gross profit earned from the sale of inventory to Gemini for the nine months ended September 30, 2018 (through the acquisition date) was $0.1 million. The total profit share paid by Gemini for the nine months ended September 30, 2018 (through the acquisition date) was $5 million.February 2020.

Fosun International Limited (“Fosun”) is a Chinese international conglomerate and investment company that is a shareholder of the Company. On June 6, 2019, the Company entered into a license and supply agreement with a subsidiary of Fosun, which is a Chinese pharmaceutical company. Under the terms of the agreement, the Company will hold the imported drug license required for pharmaceutical products manufactured outside of China and will supply Fosun with finished, packaged products for Fosun to then sell in the China market. Fosun will be responsible for obtaining regulatory approval in China and for shipping the product from Amneal’s facility to Fosun’s customers in China. In consideration for access to the Company's U.S. regulatory filings to support its ~~China~~ regulatory filings in China and for the supply of product, Fosun paid the Company a $1 million non-refundable fee, net of tax, in July 2019 and will be required to pay the Company $0.3 million for each of 8 products upon the first commercial sale of each in China in addition to a supply price and a profit share. For the three ~~and nine~~ months ended ~~September 30, 2019,~~March 31, 2020, the Company has ~~not~~0t recognized any revenue from this agreement.

Apace KY, LLC d/b/a Apace Packaging LLC (“Apace”) provides packaging solutions pursuant to an exclusive packaging agreement. Apace markets its services which include bottling and blistering for the pharmaceutical industry. The total amount of expenses from this arrangement for the three months ended March 31, 2020 was $2 million (NaN in 2019). At March 31, 2020, payables of approximately $1 million were due to the related party for packaging services.

R&S leases operating facilities, office and warehouse space from Tracy Properties LLC. The total amount of expenses from this arrangement for the three months ended March 31, 2020 was $0.1 million (NaN in 2019). At March 31, 2020, payables of approximately less than $0.1 million were due to the related party for lease expenses.

R&S purchases inventory from AzaTech Pharma LLC for resale. The total amount of expenses from this arrangement for the three months ended March 31, 2020 was $0.8 million (NaN in 2019). At March 31, 2020, payables of approximately less than $0.5 million were due to the related party for inventory purchases.

AvKARE LLC leases its operating facilities from AvPROP, LLC. Rent expense from this arrangement for the three months ended March 31, 2020 was $0.1 million.

Tarsadia Investments, LLC (“Tarsadia”) is a private investment firm that provides financial services and is a shareholder of the Company. Tarsadia offers capital and strategic support for companies with substantial growth potential primarily in the healthcare, financial services, real estate, and clean technology sectors. The Company entered into an agreement in which Tarsadia will provide financial consulting services. The services are not expected to have a material impact to the Company’s financial statements.

Under the terms of the Limited Liability Company Agreement, Amneal is obligated to make tax distributions to its members, which are also holders of non-controlling interests in the Company. For further details, refer to Note ~~19.~~21. Stockholders' ~~Equity/ Members' Deficit~~ ~~contained~~Equity in the ~~Company's 2018~~Company’s 2019 Annual Report on Form 10-K.

The sellers of AvKARE, LLC and R&S hold the ~~Company acquired~~remaining 34.9% interest in Rondo (“Rondo Class B Units”). Certain holders of the ~~non-controlling interests in one~~Rondo Class B Units are also holders of ~~Amneal's non-public subsidiaries for approximately $3 million. As of December 31, 2018,~~ the ~~Company recorded a $3 million related party payable for this transaction which was paid in full as of September 30, 2019.~~Sellers Notes and the Short-Term Sellers Note. For additional information, refer to Note 13. Debt.

The changes in goodwill for the ~~nine~~three months ended ~~September 30, 2019~~March 31, 2020 and for the year ended December 31, ~~2018~~2019 were as follows (in thousands):

As of ~~September 30,~~March 31, 2020, $361 million, $89 million, and $65 million of goodwill was allocated to the Specialty, Generics, and AvKARE segments, respectively. As of December 31, 2019, $361 million and $59 million of goodwill was allocated to the Specialty and Generics segment, respectively. ~~As of~~For the year ended December 31, ~~2018, $360 million and $66 million of goodwill was allocated to the Specialty and Generics segment, respectively. For the nine months ended September 30,~~ 2019, goodwill divested was associated with the sale of the Company's operations in the United ~~Kingdom and Germany.~~Kingdom. For the year ended December 31, ~~2018,~~2019, the adjustment to goodwill ~~acquired~~ was associated with the ~~Impax and Gemini acquisitions.~~Combination. Refer to Note 3. Acquisitions and Divestitures for additional information about the ~~acquisition of Impax~~Acquisitions and the divestiture of the Company's operations in the United ~~Kingdom and Germany.~~

~~In light of the continued decline in the Company’s share price and financial performance,~~ the Company performed an interim goodwill impairment test during the three months ended September 30, 2019 by evaluating its two reporting units, which are the same as the Company’s two reportable segments. The fair values of the reporting units were determined by combining both the income and market approaches. In performing this test, the Company utilized long-term growth rates for its reporting units ranging from no growth to 1.0% and discount rates ranging from 9.0% to 11.5% in its estimation of fair value. The assumptions used in evaluating goodwill for impairment are subject to change and are tracked against historical performance by management.

Based on the results of the interim test performed as of August 31, 2019 and updated on September 30, 2019, the Company determined that the estimated fair values of the Generics and Specialty reporting units exceeded their respective carrying amounts; therefore, the Company did not record a goodwill impairment charge during the three months ended September 30, 2019. ~~The Generics reporting unit was in excess of its carrying value by approximately 15% and the Specialty reporting unit was in excess of its carrying value by approximately 9%.~~

While management believes the assumptions used were reasonable and commensurate with the views of a market participant, changes in key assumptions for these reporting units, including increasing the discount rate, lowering forecasts for revenue, operating margin or lowering the long-term growth rate, could result in a future impairment.Kingdom.

Intangible assets at ~~September 30, 2019~~March 31, 2020 and December 31, ~~2018~~2019 are comprised of the following (in thousands):

	September 30, 2019								December 31, 2018							March 31, 2020								December 31, 2019
	Weighted-Average Amortization Period (in years)	Cost		Accumulated Amortization			Net		Cost		Accumulated Amortization			Net		Weighted-Average Amortization Period (in years)	Cost		Accumulated Amortization			Net		Cost		Accumulated Amortization			Net
Amortizing intangible assets:
Product rights	9.9	$	1,213,195	$	(161,969	)	$	1,051,226	$	1,282,011	$	(88,081	)	$	1,193,930	9.7	$	1,191,135	$	(229,959	)	$	961,176	$	1,197,535	$	(198,857	)	$	998,678
Customer relationships			—		—			—		7,005		(1,955	)		5,050
Other intangible assets	10.3		3,000		(950	)		2,050		5,620		(1,561	)		4,059	6.1		140,400		(7,530	)		132,870		3,000		(1,000	)		2,000
Total		$	1,216,195	$	(162,919	)	$	1,053,276	$	1,294,636	$	(91,597	)	$	1,203,039		$	1,331,535	$	(237,489	)	$	1,094,046	$	1,200,535	$	(199,857	)	$	1,000,678
In-process research and development			382,525		—			382,525		451,930		—			451,930			381,115		—			381,115		382,075		—			382,075
Total intangible assets		$	1,598,720	$	(162,919	)	$	1,435,801	$	1,746,566	$	(91,597	)	$	1,654,969		$	1,712,650	$	(237,489	)	$	1,475,161	$	1,582,610	$	(199,857	)	$	1,382,753

The Company evaluated assets for potential impairment by comparing estimated future undiscounted net cash flows to the carrying amount of the asset. For the three months ended ~~September 30, 2019,~~March 31, 2020, the Company recognized a total of ~~$79~~$2 million of intangible asset impairment charges, of which ~~$56~~$1 million was recognized in cost of goods sold impairment charges and ~~$23~~$1 million was recognized in in-process research and development impairment charges. For the nine months ended September 30, 2019, the Company recognized a total of $158 million of intangible asset impairment charges, of which $112 million was recognized in cost of goods sold impairment charges and $46 million was recognized in in-process research and development expense.

The impairment charges for the three months ended ~~September 30, 2019~~March 31, 2020 are primarily related to 42 currently marketed products and 4 2 in-process research and development (“IPR&D&D”) products, all acquired as part of the Combination. For the currently marketed products, ~~the impairment charges were the result of~~2 products experienced significant price erosion during ~~the three months ended September 30, 2019,~~2020, without an offsetting increase in customer demand, resulting in significantly lower than

expected future cash ~~flows. For~~flows and negative margins. The IPR&D charges are associated with two products, one of which experienced a delay in its estimated launch date and the ~~IPR&D products,~~other was canceled due to the ~~impairment charges were the result~~withdrawal of ~~expected significant price erosion for the products resulting in significantly lower than expected future cash flows.~~our development partner.

~~The impairment charges for~~During the ~~nine~~three months ended ~~September 30, 2019 are primarily related to twelve products, six~~March 31, 2020, the Company recognized $137 million of intangible assets associated with the Acquisitions, of which all are ~~currently marketed products~~classified in other intangible assets in the table above. These intangible assets consist of government licenses, government contracts, national contracts, customer relationships and ~~six of which~~a trade name and are IPR&D products, all acquired as part of the Combination. For the currently marketed products, the impairment charges were the result of significant price erosion during 2019, without an offsetting increase in customer demand, resulting in significantly lower than expected future cash flows. ~~For one IPR&D product, the impairment charge was the result of increased competition at launch resulting in significantly lower than expected future cash flows.~~ ~~For one IPR&D product, the impairment charge was the result of a strategic decision~~amortized to ~~no longer pursue approval of the product. For the other four IPR&D products, the impairment charges were the result of expected significant price erosion~~selling, general, and administrative over their estimated useful lives. Refer to Note 3.Acquisitions and Divestitures for ~~the products resulting in significantly lower than expected future cash flows.~~additional information.

During the ~~nine~~three months ended ~~September 30,~~March 31, 2019, the Company recognized a $50 million product rights intangible asset for the exclusive rights to sell Levothyroxine in the U.S. market under a license and supply agreement with JSP. Refer to Note 5. Alliance and Collaboration for additional information.

For the ~~nine~~three months ended ~~September 30,~~March 31, 2019, included in the Company's divested United Kingdom operations were a net customer relationship intangible asset and a net trade name intangible asset of $5 million and $2 million, respectively. Refer to Note 3. Acquisitions and Divestitures for additional information.

Amortization expense related to intangible assets recognized is as follows (in thousands):

The following table presents future amortization expense for the next five years and thereafter, excluding ~~$383~~$381 million of IPR&D intangible assets (in thousands):

~~17. Acquisition, Transaction-Related~~21. Stockholders’ Equity and ~~Integration Expenses~~Redeemable Non-Controlling Interests

The following table sets forth the components of the Company’s acquisition, transaction-related and integration expenses for the three and nine months ended September 30, 2019 and 2018 (in thousands):Non-Controlling Interests

Amneal’s historical capital structure included several classifications of membership and profit participation units. During the second quarter of 2018, the board of managers of Amneal Pharmaceuticals LLC approved a discretionary modification to certain profit participation units concurrent with the Combination that immediately caused the vesting of all profit participation units that were previously issued to certain current or former employees for service prior to the Combination. The modification entitled the holders to 6,886,140 shares of Class A Common Stock with a fair value of $126 million on the date of the Combination and $33 million of cash. The cash and shares were distributed by Holdings with no additional shares issued by the Company. As a result of this transaction, the Company recorded a charge in acquisition, transaction-related and integration expenses and a corresponding capital contribution of $159 million for the three and nine months ended September 30, 2018.

~~On May 4, 2018, the Company completed the Combination, as described in~~ ~~Note 1. Nature of Operations~~. For the nine months ended September 30, 2018, transaction costs associated with the Impax acquisition were $23 million (none for the three months ended September 30, 2018) were recorded in acquisition, transaction-related and integration expenses (none in 2019).

Effective October 31 2019, the Company entered into an interest rate lock agreement for a total notional amount of $1.3 billion, with a maturity date of May 2025. The hedge will be accounted for as a cash flow hedge.

On October 10, 2019, the Compensation Committee of the Board of Directors of the Company, subject to the approval of the stockholders of the Company, approved a one-time stock option repricing (the “Option Repricing”). Pursuant to the Option Repricing, the exercise price of each relevant option will be amended to reduce such exercise price to the closing price of a share of the Company’s Class A Common Stock as reported on the New York Stock Exchange on or around November 13, 2019. The Company does not expect that the Option Repricing will have a material impact on its statement of operations.

The Company has entered into a definitive licensing agreement with Kashiv for the development and commercialization of Kashiv’s orphan drug K127 (pyridostigmine) for the treatment of Myasthenia Gravis. Through this agreement, the Company has an exclusive license within the United States to market and sell the K127 product under a New Drug Application (“NDA”).

Under the terms of the ~~agreement, Kashiv will be responsible~~Limited Liability Company Agreement, Amneal is obligated to make tax distributions to its members. For the three months ended March 31, 2020 and 2019, 0 tax distribution was recorded due to tax losses incurred. As of March 31, 2019, 0 liability was included in related-party payables for ~~all development~~the tax distribution.

During December 2018, the Company acquired the non-controlling interests in 1 of Amneal's non-public subsidiaries for approximately $3 million. As of December 31, 2018, the Company recorded a $3 million related party payable for this transaction which was paid in full in 2019.

As discussed in Note 3. Acquisitions and ~~clinical work required~~Divestitures, the Company acquired a 65.1% interest in Rondo on January 31, 2020. The sellers of AvKARE, LLC and R&S hold the remaining 34.9% interest as Rondo Class B Units. Beginning on January 1, 2026, the holders of the Rondo Class B Units have the right (“Put Right”) to ~~secure Food~~require the Company to acquire the Rondo Class B Units for a purchase price that is based on a multiple of Rondo’s earnings before income taxes, depreciation, and ~~Drug Administration (“FDA”) approval~~amortization (EBITDA) if certain financial targets and ~~Amneal will be responsible for filing~~other conditions are met. Additionally, beginning on January 31, 2020, the ~~NDA~~Company has the right to acquire the Rondo Class B Units based on the same value and ~~commercializing~~conditions as the ~~product. Kashiv will receive an upfront payment~~Put Right. The Rondo Class B Units are also redeemable by the holders upon a change in control.

Since the redemption of ~~approximately $2 million and~~the Rondo Class B Units is ~~eligible to receive development and regulatory milestones totaling approximately $17 million. Kashiv is also eligible to receive tiered royalties from~~outside of the ~~low double-digits to mid-teens~~Company's control, the units have been presented outside of stockholders' equity as redeemable non-controlling interests. Upon closing of the Acquisitions on ~~net sales of K127.~~

~~On September 13, 2019, the FDA announced that ranitidine may potentially contain NDMA, which is classified~~January 31, 2020, the redeemable non-controlling interests were recorded as a ~~probable human carcinogen. As a precautionary measure,~~component of the fair value of consideration transferred at an estimated fair value of $11 million. The fair value of the redeemable non-controlling interests was estimated using the Monte-Carlo simulation approach under the option pricing framework, which considers the redemption rights of both the Company ~~immediately halted shipments~~and the holders of ~~ranitidine-based products and began evaluation~~the Rondo Class B Units.

The Company will attribute 34.9% of ~~its externally sourced ranitidine active pharmaceutical ingredient.~~ B~~ased on~~ the ~~FDA’s November 1, 2019 statement summarizing their NDMA results~~net income of Rondo to ~~date for numerous ranitidine products on~~ the ~~market,~~redeemable non-controlling interests. The Company will also accrete the ~~Company~~ ~~has made~~redeemable non-controlling interests to redemption value upon an event that makes redemption probable.

As the ~~decision~~financial markets stabilized following a period of high volatility due to ~~conduct a voluntary recall of its ranitidine-based products. As of September 30, 2019,~~the COVID-19 pandemic, the Company ~~had approximately $6~~repaid $200 million of ~~ranitidine-based product inventory. The Company is currently testing~~ the ~~impacted inventory and is unable to estimate~~ $300 million of borrowings under the ~~possible loss, if any, at this time.~~

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Amneal Pharmaceuticals, Inc. (the "Company," "we," "us," or "our") is a pharmaceutical company specializing in developing, manufacturing, marketing and distributing high-value generic pharmaceutical products across a broad array of dosage forms and therapeutic areas, as well as branded products. We were formed on October 4, 2017, under the name Atlas Holdings, Inc. for the purpose of facilitating the combination (the "Combination") of Impax Laboratories, Inc. ("Impax") and Amneal Pharmaceuticals LLC ("Amneal"), which closed on May 4, 2018.

The following discussion and analysis for the three ~~and nine~~ months ended ~~September 30, 2019~~March 31, 2020 should be read in conjunction with the consolidated financial statements and related notes of thereto included elsewhere in this Quarterly Report on Form 10-Q and with our audited consolidated financial statements for the year ended December 31, ~~2018~~2019 included in our ~~2018~~2019 Annual Report on Form 10-K.

On January 31, 2020, we acquired a 65.1% controlling interest in both AvKARE Inc., a Tennessee corporation now a limited liability company (“AvKARE, LLC”), and Dixon-Shane, LLC d/b/a R&S Northeast LLC, a Kentucky limited liability company (“R&S”). As a result of the AvKARE, LLC and R&S acquisitions (the “Acquisitions”), we now have three reportable segments, Generics, Specialty, and AvKARE.

Our Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products, with a focus on products addressing central nervous system ("CNS") disorders, including migraine and Parkinson’s disease. Our portfolio of products includes Rytary®, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. In addition to Rytary®, our promoted Specialty portfolio includes Zomig® (zolmitriptan) products, for the treatment of migraine headaches, which is sold under a license agreement with AstraZeneca UKU.K. Limited, Emverm® (mebendazole) 100 mg chewable tablets, for the treatment of pinworm, whipworm, common roundworm, common hookworm and American hookworm in single or mixed infections, and Unithroid® (levothyroxine sodium), for the treatment of hypothyroidism, which is sold under a license and distribution agreement with JSP.

For Specialty products, the majority of the product’s commercial value is usually realized during the period in which the product has market exclusivity. In the U.S. and some other countries, when market exclusivity expires and generic versions of a product are approved and marketed, there can often be very substantial and rapid declines in the branded product’s sales.

~~The Company’s~~Our Generics segment includes ~~over 200~~approximately 250 product families covering an extensive range of dosage forms and delivery systems, including both immediate and extended release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, ophthalmics (which are sterile pharmaceutical preparations administered for ocular conditions), films, transdermal patches and topicals (which are creams or gels designed to administer pharmaceuticals locally through the skin). We focus on developing products with substantial barriers-to-entry resulting from complex drug formulations or manufacturing, or legal or regulatory challenges. Generic products, particularly in the U.S., generally contribute most significantly to revenues and gross margins at the time of their launch, and even more so in periods of market exclusivity, or in periods of limited generic competition. As such, the timing of new product introductions can have a significant impact on the Company’s financial results. The entrance into the market of additional competition generally has a negative impact on the volume and pricing of the affected products. Additionally, pricing is often affected by factors outside of the Company’s control.

AvKARE provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, primarily focused on serving the Department of Defense and the Department of Veterans Affairs. AvKARE is a wholesale distributor of bottle and unit dose pharmaceuticals under the registered names of AvKARE and AvPAK, as well as medical and surgical products. AvKARE is also a packager and wholesale distributor of pharmaceuticals and vitamins to its retail and institutional customers who are located throughout the United States of America focused primarily on offering 340b-qualified entities products to provide consistency in care and pricing.

The pharmaceutical industry is highly competitive and highly regulated. As a result, we face a number of industry-specific factors and challenges, which can significantly impact our results. For a more detailed explanation of our business and its risks, refer to our ~~2018~~2019 Annual Report on Form 10-K.

~~In 2019, our Generics segment has experienced both industry-wide~~COVID-19 Pandemic

On March 11, 2020, the World Health Organization designated the outbreak of a novel strain of coronavirus (“COVID-19”) as a global pandemic. Governments and ~~company-specific challenges that resulted~~businesses around the world have taken unprecedented actions to mitigate the spread of COVID-19, including imposing restrictions on movement and travel such as quarantines and shelter-in-place requirements, and restricting or prohibiting outright some or all commercial and business activity, including the manufacture and distribution of certain goods and the provision of non-essential services. These measures, though currently temporary in ~~our financial performance falling short of our expectations since~~nature, may become more severe and continue indefinitely depending on the ~~beginning~~evolution of the ~~year. Such challenges include increased competition~~outbreak.

The Company did not observe significant impacts on ~~certain key generic products, the uncertainty~~its business or results of supply of epinephrine auto-injector (generic Adrenaclick®) from our third-party supplier, and delays in key product approvals and launches, including generic NuvaRing®. We expect these challenges and others to persist at leastoperations for the ~~remainder~~three months ended March 31, 2020 due to the global emergence of ~~2019.~~

~~To address these challenges, we have,~~COVID-19. However, during March and April 2020, as the infection rate of COVID-19 spread throughout New York and New Jersey, the governors of those states issued executive orders requiring residents, among other things, ~~conducted~~to remain at home with limited exceptions such as working at an essential business. Although as a pharmaceutical manufacturer Amneal is an essential business, we may experience increased manufacturing and packaging delays at our New York and New Jersey facilities during April and May 2020. These potential manufacturing and packaging delays may significantly impact our second quarter results of operations and cash flows. To mitigate any potential

overall market liquidity constraints, we borrowed $300 million under our revolving credit facility in ~~depth, company wide review~~March 2020 as a precautionary measure. As the financial markets stabilized following a period of high volatility due the COVID-19 pandemic, the Company repaid $200 million of the $300 million of borrowings under the Revolving Credit Facility in May 2020. (Refer to Note 13.Debt, for further details). As noted in our 2019 Annual Report on Form 10-K, several of our ~~organizational structures, operational budgets, current~~key domestic manufacturing, packaging, and R&D facilities are located in New York and New Jersey, the two states with the highest confirmed cases of COVID-19. To offset any potential decreased second quarter output, we will increase production during the third and fourth quarters, if necessary.

To the extent that COVID-19 continues or worsens, national, state, and local governments may impose additional restrictions or extend the restrictions already in place. The continuing spread of COVID-19 and the related safety and business operating restrictions could result in a number of adverse impacts to our business, including, but not limited to, additional disruption to the economy and our customers, additional work restrictions, and supply chains being interrupted or slowed. Also, governments may impose other laws, regulations, or taxes that could adversely impact our business, financial condition, or results of operations. Further, depending on the extent to which our customers are affected, they could delay or reduce purchases of services we provide. The potential effects of COVID-19 also could impact us in a number of other ways including, but not limited to, reductions to our profitability, fluctuations in foreign currency markets, the availability of future ~~capital projects~~borrowings, the cost of borrowings, credit risks of our customers and ~~existing capability~~counterparties, and ~~infrastructure alignments, resulting~~potential impairment of the carrying amount of goodwill or other definite-lived assets.

We will continue to actively monitor the situation and may take further precautionary and preemptive actions as may be required by national, state, or local authorities or that we determine are in the ~~comprehensive restructuring plan~~best interests of our employees, customers, partners, suppliers, and shareholders. To the extent the pandemic worsens, we ~~announced~~cannot predict the effects it may have on our business, in ~~July 2019. The revised restructuring plan is designed~~particular with respect to ~~reduce costs, optimize~~demand for our ~~organizational~~services, our strategy, and ~~manufacturing infrastructure, which we expect~~our prospects, the effects on our customers, or the impact on our financial results. Refer to ~~reduce costs by approximately $40 million per year once the plan has been executed. For additional information, refer to~~ ~~Note 6, Restructuring and Other Charges, to the unaudited financial statements in~~ Part I, II, Item 11A "Risk Factors" of this ~~report.~~

~~Our current year results continue to be impacted by our Combination with Impax as a result of our continued actions to adjust our operations and cost structure. The historical financial results~~Quarterly Report on Form 10-Q for further discussion of the ~~Company for the periods prior the May 4, 2018 closing~~potential impact of the Combination are the historical financial results of Amneal, and thus the current period results, and balances, may not be comparable to prior years as the current year includes the results of Impax from May 4, 2018.COVID-19 pandemic on our business.

The following table sets forth our summarized, consolidated results of operations for the three ~~and nine~~ months ended ~~September 30,~~March 31, 2020 and 2019 ~~and 2018~~ (in thousands):

	Three Months Ended September 30,						Nine Months Ended September 30,						Three Months Ended March 31,
	2019			2018			2019			2018			2020			2019
Net revenue	$	378,283		$	476,487		$	1,229,045		$	1,165,463		$	498,533		$	446,120
Cost of goods sold		267,717			268,567			873,841			634,653			313,578			309,743
Cost of goods sold impairment charges		56,132			7,815			112,441			7,815			1,456			53,297
Gross profit		54,434			200,105			242,763			522,995			183,499			83,080
Selling, general and administrative		63,797			75,486			215,514			156,610			77,976			84,436
Research and development		38,125			42,349			139,999			136,893			36,379			53,858
In-process research and development impairment charges		23,382			650			46,169			650			960			22,787
Charges (gains) related to legal matters, net		14,750			2,589			14,750			(411	)
Intellectual property legal development expenses		2,586			4,401			9,263			13,024			1,270			4,166
Acquisition, transaction-related and integration expenses		3,131			2,231			12,682			216,873			2,575			6,032
Charges related to legal matters														4,500			—
Restructuring and other charges		20,937			(2,156	)		29,933			42,309			2,048			6,161
Operating (loss) income		(112,274	)		74,555			(225,547	)		(42,953	)
Gain from reduction of tax receivable agreement liability		192,844			—			192,844			—
Other expense, net		(54,294	)		(51,981	)		(130,428	)		(144,963	)
Total other income (expense), net		138,550			(51,981	)		62,416			(144,963	)
Operating income (loss)														57,791			(94,360	)
Total other expense, net														(44,447	)		(38,820	)
Income (loss) before income taxes		26,276			22,574			(163,131	)		(187,916	)		13,344			(133,180	)
Provision for (benefit from) income taxes		389,668			5,109			375,539			(6,943	)
Net (loss) income	$	(363,392	)	$	17,465		$	(538,670	)	$	(180,973	)
Benefit from income taxes														(108,173	)		(8,428	)
Net income (loss)													$	121,517		$	(124,752	)

Net revenue for the three months ended ~~September 30, 2019 decreased~~March 31, 2020 increased by ~~21%~~12%, or ~~$98~~$53 million, to ~~$378~~$499 million as compared to ~~$476~~$446 million for the three months ended ~~September 30, 2018.~~March 31, 2019. The ~~decrease~~increase over the prior year is primarily attributable to ~~price and volume erosion of $132~~$58 million ~~mainly~~from the newly acquired AvKARE segment, $62 million from new product launches after March 31, 2019 in our Generics segment ~~$12~~and $11 million ~~in divestitures of our international businesses and $15 million in the loss of exclusivity on Albenza~~primarily from volume increases in our Specialty segment, which were partially offset by ~~a $40 million contribution from Levothyroxine sodium tablets ("Levothyroxine") which launched in the fourth quarter 2018, and $19 million from new product launches in our Generics segment.~~

Net revenue for the nine months ended September 30, 2019 increased by 5%, or $64 million, to $1,229 million compared to $1,165 million for the nine months ended September 30, 2018. The increase over the prior year period is primarily attributable to a $211 million timing impact from the Combination and the acquisition of Gemini, a $135 million contribution from Levothyroxine, and $36 million from new product launchesprice erosion in our Generics segment ~~which were partially offset by price~~ and ~~volume erosion of $240~~a $15 million ~~mainly in our Generics segment, $38 million from the loss of exclusivity on Albenza in our Specialty segment and $27 million~~decline from the divestitures of our international businesses primarily in the UKU.K. and Germany.

Cost of goods sold, including impairment charges, ~~increased 17%~~decreased 13%, or ~~$47~~$48 million, to ~~$324~~$315 million for the three months ended ~~September 30, 2019~~March 31, 2020 as compared to ~~$276~~$363 million for the three months ended ~~September 30, 2018.~~March 31, 2019. The ~~increase~~decrease in cost of goods sold was primarily attributable to ~~$48~~a $52 million of impairment charges on intangible assets primarily in our Generics segment, $14 million in inventory charges, and $13 million in amortization of intangible assets, partially offset by a year over year decline in Generics volume.

Accordingly, gross profit for the three months ended September 30, 2019 was $54 million (14% of total revenues) as compared to gross profit of $200 million (42% of total revenues) for the three months ended September 30, 2018. Our gross profit as a percentage of sales declined compared to the prior year period primarily as a result of the impairment charges as well as price and volume erosion in the Generics segment.

Cost of goods sold, including impairment charges, increased 54%, or $344 million, to $986 million for the nine months ended September 30, 2019 as compared to $642 million for the nine months ended September 30, 2018. The increase in cost of goods sold was primarily attributable to higher product sales due to the Combination and Gemini acquisition, $105 milliondecrease in intangible ~~impairment~~asset impairments mainly in our Generics segment, incremental expenses related to the Combination and the acquisition of Gemini, including amortization of intangible assets of $61 million and royalties of $22 million, $47 million of inventory charges in our Generics segment anda $36 million ofdecrease in expenses related to the Levothyroxine transition agreement with Lannett Company ("Lannett"). and a $6 million decline associated with the divestitures of our international businesses primarily in the U.K. and Germany, which were partially offset by a $47 million increase associated with the Acquisitions.

Accordingly, gross profit for the ~~nine~~three months ended ~~September 30, 2019~~March 31, 2020 was ~~$243~~$183 million ~~(20%~~(37% of total ~~revenues)~~net revenue) as compared to gross profit of ~~$523~~$83 million ~~(45%~~(19% of total ~~revenues)~~net revenue) for the ~~nine~~three months ended ~~September 30, 2018.~~March 31, 2019. Our gross profit as a percentage of ~~sales declined~~net revenue increased compared to the prior year ~~period~~ primarily as a result of the $52 million decline in intangible impairment charges, ~~increased inventory related charges, and price erosion in our Generics segment~~ as well as other factors described above.

~~Selling, general, and administrative ("~~ (“SG~~&A"~~&A”) expenses for the three months ended ~~September 30, 2019~~March 31, 2020 were ~~$64~~$78 million, as compared to ~~$75~~$84 million for the three months ended ~~September 30, 2018.~~March 31, 2019. The ~~$11~~$6 million decrease ~~from the prior year period was primarily due to post Combination synergies.~~

~~SG&A expenses for the nine months ended September 30, 2019 were $216 million, as compared to $157 million for the nine months ended September 30, 2018. The $59 million increase~~ from the prior year was primarily due to ~~the timing of the Combination and Gemini acquisition, including selling expenses~~cost savings associated with our ~~Specialty segment, stock-based compensation~~restructuring and ~~higher Corporate functions spend including public company costs that did not exist prior to the Combination.~~integration programs. These ~~increases~~decreases were partially offset by ~~post Combination synergies.~~an $11 million increase associated with the Acquisitions.

Research and development (“R&D”) expenses for the three months ended ~~September 30, 2019~~March 31, 2020 were ~~$38~~$36 million, as compared to ~~$42~~$54 million for the three months ended ~~September 30, 2018.~~March 31, 2019. The $4$18 million decrease ~~is primarily attributable to post Combination synergies.~~

~~Research and development expenses for the nine months ended September 30, 2019 were $140 million, as compared to $137 million for the nine months ended September 30, 2018. The $3 million increase~~ compared to the prior year is primarily attributable to ~~the timing of the Combination and increased milestone payments~~cost savings in our Generics segment ~~partially offset by post Combination synergies.~~associated with the Company’s restructuring programs and the timing of expenses in 2020 due to delayed spending as a result of COVID-19.

~~For the three months ended September 30, 2019, we~~We recognized in-process research and development (“IPR&D”) impairment charges of ~~$23~~$1 million in our Generics segment for the three months ended March 31, 2020. The charges are primarily associated with ~~four intangible assets that were acquired as part~~two products. One of the ~~Combination. The impairment charges were~~products experienced a delay in its estimated launch date and the ~~result~~other product was canceled due to the withdrawal of ~~expected significant price erosion for the products resulting in significantly lower than expected future cash flows.~~our development partner.

We recognized IPR&D impairment charges for the three months ended ~~September 30, 2018 were less than $1~~March 31, 2019 of $23 million.

~~We recognized IPR&D impairment charges of $46 million for the nine months ended September 30, 2019.~~ The charges are primarily associated with ~~six~~two products in our Generics segment that were acquired as part of the Combination. The impairment charges were the result of expected significant price erosion for the products resulting in significantly lower than expected future cash flows. IPR&D impairment charges for nine months ended September 30, 2018 were less than $1 million.Combination.

Intellectual property legal development expenses for the three months ended ~~September 30, 2019~~March 31, 2020 were $3$1 million as compared to $4 million for the three months ended September 30, 2018. Intellectual property legal development expenses for the nine months ended September 30, 2019 were $9 million as compared to $13 million for the nine months ended September 30, 2018.March 31, 2019. These costs include, but are not limited to, formulation assessments, patent challenge opinions and strategy, and litigation expenses to defend the intellectual property.

For the three and nine months ended September 30, 2019, the Company recorded a net charge of $15 million primarily associated with an agreement in principle with Teva Pharmaceuticals. For further details, see ~~Note 13. Commitments and Contingencies.~~

We recognized approximately $3 million of acquisition, transaction-related and integration expenses for the three months ended ~~September 30, 2019~~March 31, 2020 as compared to $2$6 million for the three months ended September 30, 2018. We recognized approximately $13 million of acquisition, transaction-related and integration expenses for the nine months ended September 30, 2019 as compared to $217 million for the nine months ended September 30, 2018.March 31, 2019.

Expenses for the three ~~and nine~~ months ended ~~September 30, 2019~~March 31, 2020 were primarily related to the ~~ongoing integration and site closure expenses associated with Impax and Gemini. During~~Acquisitions. The decrease from the prior year ~~period, expenses were~~is primarily ~~for transaction-related costs associated with pre and post Combination activities.~~related to substantial completion of integration activities related to the Combination.

For the three months ended March 31, 2020, we recorded charges of $5 million for commercial legal proceedings and claims, approximately $3 million of which was recorded in our Generics segment and $2 million in our Specialty segment.

On July 10, 2019, ~~the Company~~we announced a plan to restructure ~~its~~our operations that is intended to reduce costs and optimize ~~its~~our organizational and manufacturing infrastructure. Pursuant to the restructuring plan as revised, ~~the Company expects~~we expect to reduce ~~its~~our headcount by approximately 300 to 350, primarily by ~~closing its~~ceasing manufacturing ~~facility located in~~at our Hauppauge, ~~NY. As a result~~NY facility.

Restructuring and other charges were $2 million for the three months ended March 31, 2020, and primarily consisted of ~~the restructuring plan, the Company estimates that it will incur a pre-tax restructuring charge of approximately $6~~charges associated with cash severance and other benefits provided pursuant to ~~$8 million of cash expenditures related to~~our severance ~~benefits.~~programs for former senior executives.

~~We recorded $21 million of restructuring~~Restructuring and other charges for the three months ended ~~September 30,~~March 31, 2019 ~~which~~were $6 million and primarily consisted of $11 million of property plant and equipment and right of use asset impairment charges in connection with the planned closure of the Company’s Hauppauge, NY facility. Restructuring and other charges also consisted of employee restructuring separation charges of approximately $6$2 million for cash and other severance provided pursuant to our severance programs for employees at our ~~Hauppauge, NY,~~ Hayward, CA facility and other facilities and ~~approximately~~ $4 million for cash severance charges associated with the cost of ~~other employee severance charges. The restructuring and other charges~~benefits for former senior executives.

Other expense, net was $44 million for the three months ended ~~September 30, 2018 were a benefit of $2~~March 31, 2020, as compared to $39 million ~~which was primarily related to changes in estimates~~ for ~~certain employee-related separation liabilities associated with employees who exited early.~~

We recorded $30 million of restructuring and other charges for the nine months ended September 30, 2019, which primarily consisted of $11 million of property plant and equipment and right of use asset impairment charges in connection with the planned closure of the Company’s Hauppauge, NY facility. Restructuring and other charges also consisted of employee restructuring separation charges of approximately $9 million for severance provided pursuant to our severance programs for employees at our Hauppauge, NY, Hayward, CA and other facilities and $9 million of other employee severance charges. The restructuring and other charges for the nine months ended September 30, 2018 were $42 million, which were primarily associated with a reduction in workforce resulting from the Combination.

~~During~~ the three months ~~and nine months~~ ended September 30, 2019, we recorded a $372 million valuation allowance to reduce our deferred tax assets (“DTAs”). For further discussion, see Provision For (Benefit From) Income Taxes below. In conjunction with the valuation allowance of our DTAs, we reversed the accrued TRA liability, which resulted in a $193 million gain to our statement of operations.

~~Other expense, net was $54 million for the quarter ended September 30, 2019, as compared to $52 million for the quarter ended September 30, 2018.~~March 31, 2019. The increase of $2 million was primarily attributable to $7 million of additional expense from the change in foreign exchange rates, primarily as a result of the impact of fluctuations in the Swiss Franc, Indian Rupee and Euro on intercompany loans, partially offset by $3 million decline in loss on the sale of international businesses and a $1 million savings on interest expense.

~~Other expense, net was $130 million for the nine months ended September 30, 2019, as compared to $145 million for the nine months ended September 30, 2018. The decrease of $15~~$5 million was primarily attributable to a ~~$20~~$9 million ~~decline~~gain from the divestiture of our U.K. business in ~~loss from extinguishment of debt,~~the prior year, partially offset by a ~~$13~~$3 million decrease in interest expense as reductions in interest rates offset increased borrowings.

For the three months ended March 31, 2020 and 2019, the Company's benefit for income taxes and effective tax rates were $108 million and (810.6%) and $8 million and 6.3%, respectively. The year over year change is primarily associated with the $110 million benefit from the ~~change~~carryback of U.S. Federal deferred tax assets under the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”), which the Company expects to receive in ~~foreign exchange rates, primarily as a result of the impact of fluctuations~~cash in the Swiss Franc, Indian Rupee and Euro on intercompany loans and a $10 million beneficial impact from the divestitures of our international businesses. These decreases were partially offset by $29 million of additional interest expense associated withyear ending December 31, 2020. The CARES Act is an ~~increase~~emergency economic stimulus package in ~~long-term debt related~~response to the ~~Combination~~coronavirus outbreak which, among other things, includes provisions relating to income and ~~the acquisition~~non-income-based tax laws. These deferred tax assets had a 100% valuation allowance as of ~~Gemini.~~December 31, 2019.

~~The provision for~~We recognized net income ~~taxes was $390 million~~ for the three months ended ~~September 30, 2019 as compared to the provision for income taxes~~March 31, 2020 of $5 million for the three months ended September 30, 2018. The provision for income taxes was $376 million for the nine months ended September 30, 2019, as compared to the benefit from income taxes of $7 million for the nine months ended September 30, 2018.

The change in income tax provision for the three and nine months ended September 30, 2019 is primarily impacted by a $372 million valuation allowance against our DTAs. We recorded valuation allowances against our various DTAs on a jurisdictional basis after it was determined that it is more likely than not that our deferred tax assets will not be realized. The provision for the nine months ended September 30, 2019 compared to the prior year period was also impacted by the company structure. Prior to the Combination, as a limited liability company, income taxes were only provided for the international subsidiaries as all domestic taxes flowed to the members. Subsequent to May 4, 2018, domestic income taxes were also provided for our allocable share of income or losses from Amneal at the prevailing U.S. federal, state, and local corporate income tax rates.

We recognized a net loss for the three months ended September 30, 2019 of $363 million as compared to net income of $17 million for the three months ended September 30, 2018. For the three months ended September 30, 2019, we recorded a $98 million decline in net revenues from the prior year period, a tax provision of $390 million, impairment charges of $79 million on intangible assets, $21 million in restructuring and other charges and $15 million in charges for legal matters, which were partially offset by $193 million from the gain in reduction of TRA liability.

~~We recognized a net loss for the nine months ended September 30, 2019 of $539~~$122 million as compared to net loss of ~~$181~~$125 million for the ~~nine~~three months ended ~~September 30, 2018.~~March 31, 2019. The year over year increase of ~~$358~~$246 million is primarily attributable to a ~~$382~~$100 million ~~unfavorable~~favorable impact from income ~~tax expense,~~taxes, a ~~$150~~$74 million decline of intangible asset impairment charges, a ~~$15~~$36 million ~~unfavorable impact on legal matters and incremental~~decrease in expenses related to the ~~Combination~~Levothyroxine transition agreement with Lannett, and ~~acquisition of Gemini.~~a $18 million decline in R&D expenses. These ~~increases~~beneficial net income factors were partially offset by a ~~$204~~$9 million decline ~~in acquisition, transaction~~ related ~~and integration expenses associated with the Combination and Gemini acquisition,~~to a ~~$20 million decline in loss on extinguishment~~gain from sale of ~~debt, a $13 million benefit from the change in foreign exchange rates, primarily as a result of the impact of fluctuations~~our U.K. business in the ~~Swiss Franc, Indian Rupee and Euro on intercompany loans and a $12 million decline in restructuring and other charges.~~prior year

The following table sets forth results of operations for our Generics segment for the three ~~and nine~~ months ended ~~September 30,~~March 31, 2020 and 2019 ~~and 2018~~ (in thousands):

Generics net revenue was ~~$291~~$353 million for the three months ended ~~September 30, 2019,~~March 31, 2020, a decrease of ~~$100~~$29 million or ~~26%~~8% when compared with the same period in 2018. Volume and pricing erosion of $132 million in our existing business as well as a $17 million decline from the reclassification of Oxymorphone to the Specialty segment (where it is sold as a non-promoted product), and a $12 million decline in international revenues from divestitures were partially offset by $40 million in sales of Levothyroxine which launched in the fourth quarter 2018 and $19 million from new product launches. Favorable volume growth increased revenue in Levothyroxine, Abiraterone Acetate, Chlorpromazine HCI, Guanfacine and Hydroxyprogesterone Caproate Injection, which was partially offset by price and volume declines in revenue of Yuvafem, Diclofenac Gel and Aspirin Dipyridamole ER Capsules.

~~Generics net revenue was $1,009 million for the nine months ended September 30, 2019, a decrease of $20 million or 2% when compared with the same period in 2018.~~2019. The year over year decrease was primarily driven by price ~~and volume declines of $249 million~~erosion in our existing business primarily ~~in Yuvafem, Aspirin Dipyridamole ER Capsules,~~from Levothyroxine and Diclofenac Gel ~~(price only) and Oseltamavir,~~generic competition, a ~~$27~~$13 million decline ~~in international revenues from divestitures and $17 million~~ from the reclassification of Oxymorphone to our Specialty segment, and a $15 million decline from the divestitures of our international businesses primarily in the U.K. and Germany, partially offset by ~~$135 million in sales of Levothyroxine, a $113 million impact from the timing of the Combination, and $36~~$62 million from new product ~~launches.~~launches after March 31, 2019, which included EluRyng and Sucralfate Oral Suspension.

Generics cost of goods sold, including impairment charges, for the three months ended ~~September 30, 2019~~March 31, 2020 was ~~$267~~$220 million, ~~an increase~~a decrease of ~~12%~~34% or ~~$29~~$112 million compared to the three months ended ~~September 30, 2018.~~March 31, 2019. The year over year ~~increase is~~decrease was primarily associated with ~~$41 million of impairment charges, $14 million in inventory charges, amortization of intangible assets of $5 million and $5 million of royalties partially offset by~~ a ~~$16 million decline of purchase accounting adjustments, a $7~~$52 million decline in ~~acquisition and site closure expenses and a year over year decline in volume.~~ ~~The~~intangible asset impairment charges are associated with four products that experienced significant price erosion during the three months ended September 2019, without an offsetting increase in customer demand, resulting in significantly lower than expected future cash flows.

Generics gross profit for the three months ended September 30, 2019 was $24 million (8% of total revenues) as compared to gross profit of $153 million (39% of total revenues) for the three months ended September 30, 2018. Our Generics gross profit as a percentage of sales declined compared to the prior year period primarily as a result of $41 million of incremental impairment charges and price erosion in addition to the other factors noted above.

Generics cost of goods sold, including impairment charges, for the nine months ended September 30, 2019 was $865 million, an increase of 49% or $286 million compared to the nine months ended September 30, 2018. The year over year increase is primarily associated with sales of Impax products added to portfolio with the Combination, $98 million in impairment charges primarily associated with six marketed products acquired as part of the Combination and $47 million in inventory charges. ~~The impairment charges are associated with six products that experienced~~ ~~significant price erosion during 2019, without an offsetting increase in customer demand, resulting in significantly lower than expected future cash flows~~. Cost of goods sold was also ~~unfavorably~~favorably impacted by a $36 million decline of expenses related to the Levothyroxine transition agreement with Lannett and ~~incremental expenses related to~~a $6 million decline associated with the ~~Combination, including amortization~~divestitures of ~~intangible assets of $22 million, royalties of $17 million~~our international businesses primarily in the U.K and ~~site closure costs of $5 million. These increases were partially offset by a $29 million decrease in purchase accounting adjustments.~~Germany.

Generics gross profit for the ~~nine~~three months ended ~~September 30, 2019~~March 31, 2020 was ~~$143~~$132 million ~~(14%~~(38% of ~~total~~Generics net revenue) as compared to gross profit of ~~$448~~$50 million ~~(44%~~(13% of ~~total~~Generics net revenue) for the ~~nine~~three months ended ~~September 30, 2018.~~March 31, 2019. Our Generics gross profit as a percentage of sales ~~declined~~increased compared to the prior year period primarily as a result of the ~~$98~~$52 million ~~of incremental~~decline in impairment charges ~~price erosion~~ and the other factors described above.

Generics SG&A ~~expenses~~expense for the three months ended ~~September 30, 2019 were $14~~March 31, 2020 was $17 million, as compared to ~~$21~~$24 million for the three months ended ~~September 30, 2018.~~March 31, 2019. The ~~$7 million~~year over year decrease ~~from the prior year period~~ was primarily ~~due to post Combination synergies~~associated with cost savings initiatives associated with our restructuring and ~~the divesting of our UK~~integration programs and ~~Germany businesses.~~

~~Generics SG&A expense for the nine months ended September 30, 2019 were $53 million, as compared to $52 million for the nine months ended September 30, 2018. The impact from~~ the timing of ~~the Combination was offset by post Combination synergies and the divesting~~expenses in 2020 due to delayed spending as a result of ~~our UK and Germany businesses.~~COVID-19.

Generics research and development expenses for the three months ended ~~September 30, 2019 were $34~~March 31, 2020 was $29 million, asa decrease of 42% or $21 million compared to ~~$38 million for~~ the three months ended ~~September 30, 2018.~~March 31, 2019. The year over year decrease is primarily ~~attributable to post Combination synergies.~~associated with cost savings associated with our restructuring programs.

Generics research and development expenses remained consistent for the nine months ended September 30, 2019 and 2018 at $130 million. The impact from the timing of the Combination was offset by post Combination synergies.

We recognized IPR&D impairment charges of $1 million for the three months ended March 31, 2020. The charges are primarily associated with two products. One of the products experienced a delay in its estimated launch date and the other product was canceled due to the withdrawal of our development partner.

We recognized IPR&D impairment charges for the three months ended March 31, 2019 of $23 million. The charges are primarily associated with two products in our Generics segment that were acquired as part of the Combination.

For the three months ended ~~September 30, 2019,~~March 31, 2020, we ~~recognized IPR&D impairment~~recorded charges of ~~$23 million associated with four intangible assets that were partially impaired and one intangible asset that was fully impaired.~~

~~For the nine months ended September 30, 2019, we recognized IPR&D impairment charges of $46 million in the Generics segment.~~ The impairment charges are primarily related to six products, all acquired as part of the Combination. For one IPR&D product, the impairment charge was the result of increased competition at launch resulting in significantly lower than expected future cash flows. For one IPR&D product, the impairment charge was the result of a strategic decision to no longer pursue approval of the product. For the other four IPR&D products, the impairment charges were the result of expected significant price erosion for the products resulting in significantly lower than expected future cash flows.

~~The IPR&D charges for the three and nine months ended September 30, 2018 were less than $1 million.~~

~~Gains for legal matters of~~approximately $3 million for ~~the nine months ended September 30, 2018 were primarily related to settlements with several innovators of branded pharmaceutical products (none for the three months ended September 30, 2018).~~commercial legal claims.

Generics intellectual property legal development expenses for the three months ended ~~September 30, 2019~~March 31, 2020 were $3$1 million as compared to $4$3 million for the prior year period. Generics intellectual property legal development expenses for the nine months ended September 30, 2019 were $8 million as compared to $13 million for the prior year period. For both the three and nine month periods, theseThese costs include, but are not limited to, formulation assessments, patent challenge opinions and strategy, and litigation expenses to defend the intellectual property.

For the three ~~and nine~~ months ended ~~September 30,~~March 31, 2020, other operating expenses were immaterial. For the three months ended March 31, 2019, we recorded $5 million of other ~~expenses of $15 million and $21 million, respectively.~~ operating expenses. These ~~charges~~expenses were primarily attributable to ~~restructuring, severance, and~~ integration expenses associated with the ~~Combination.~~

For the three and nine months ended September 30, 2018, we recorded $3 million of other operating income and $137 million of other operating expenses, respectively. For the three months ended September 30, 2018, the $3 million of other operating income was a result of changes in estimates on restructuring charges. For the nine months ended September 30, 2018, the charges were primarily attributable to acquisition, integration and restructuring expenses associated with the Combination.Combination.

The following table sets forth results of operations for our Specialty segment for the three ~~and nine~~ months ended ~~September 30,~~March 31, 2020 and 2019 ~~and 2018~~ (in thousands):

Our Specialty segment is comprised of the Impax Specialty business acquired on May 4, 2018 and the Gemini business acquired on May 7, 2018. Prior to these two transactions, we did not have a Specialty segment. Refer to ~~Note 3. Acquisitions and Divestitures~~ ~~in our 2018 Annual Report on Form 10-K and in this Quarterly Report on Form 10-Q for further information related to these two transactions.~~

Specialty net revenue for the three months ended ~~September 30, 2019~~March 31, 2020 was ~~$87~~$88 million, an increase of 2%38% or $2$24 million compared to the three months ended ~~September 30, 2018.~~March 31, 2019. The increase from the prior year period was primarily due to ~~$17~~$13 million from the reclassification of Oxymorphone from ~~the~~our Generics segment ~~to the Specialty segment (where it is sold~~ as ~~a non-promoted product), which was partially offset by a $15~~well as an $8 million ~~decline~~increase in our existing business primarily associated with ~~the loss~~volume increases in Rytary and Unithroid.

Specialty ~~net revenue~~cost of goods sold, for the ~~nine~~three months ended ~~September 30, 2019~~March 31, 2020 was ~~$220~~$48 million, an increase of ~~61%~~$17 million or ~~$83 million~~55% compared to the ~~nine~~three months ended ~~September 30, 2018.~~March 31, 2019. The increase from the prior year period was primarily due to ~~a $99 million timing impact from the Combination and Gemini acquisition, and $17 million from~~ the reclassification of Oxymorphone, ~~which was partially offset by~~$9 million of incremental royalty expense associated with the reclassification of Oxymorphone and $5 million of incremental amortization expense, as well as a ~~$29 million decline~~volume increase in our existing ~~business primarily associated with the loss of exclusivity on Albenza.~~business.

Specialty cost of goods sold, including impairment charges, for the three months ended September 30, 2019 was $57 million, an increase of 48% or $19 million compared to the three months ended September 30, 2018. The increase from the prior year period was primarily due to $8 million of amortization expense and $7 million of impairment charges associated with one marketed product.

Accordingly, Specialty gross profit for the three months ended ~~September 30, 2019~~March 31, 2020 was ~~$30~~$40 million ~~(35%~~(46% of ~~total revenues) as compared to gross profit of $47 million (55% of total revenues) for the three months ended September 30, 2018.~~

Specialty cost of goods sold, including impairment charges, for the nine months ended September 30, 2019 was $121 million, an increase of $58 million or 93% compared to the nine months ended September 30, 2018. The increase from the prior year period was primarily due to $37 million of amortization expense, increased volume associated with the timing of the Combination and Gemini acquisition and $7 million of impairment charges associated with one marketed product.

~~Accordingly, Specialty gross profit for the nine months ended September 30, 2019 was $100 million (45% of total~~net revenue) as compared to gross profit of ~~$75~~$33 million ~~(55%~~(52% of ~~total revenues) for the nine months ended September 30, 2018.~~

Specialty ~~SG&A expenses remained consistent~~net revenue) for the three months ended ~~September 30, 2019 at $20 million compared to the prior year period.~~March 31, 2019.

Specialty SG&A expense ~~for the nine months ended September 30, 2019 was $58 million, as compared to $33~~of $21 million for the ~~nine~~three months ended ~~September 30, 2018. The $25 million increase from~~March 31, 2020 was flat with the prior ~~period was primarily due to the timing of the Combination partially offset by post-Combination operating synergies.~~year.

~~Specialty research and development expenses remained consistent for the three month period ended September 30, 2019 at $4 million when compared to the prior year period of $4 million.~~

Specialty research and development expenses for the ~~nine~~three months ended ~~September 30, 2019~~March 31, 2020 were ~~$10~~$7 million, as compared to $7$4 million for the ~~nine~~three months ended ~~September 30, 2018.~~March 31, 2019. The $3 million increase from the prior year period was primarily due to ~~clinical costs associated with~~a $2 million milestone achievement of one of our ~~bio studies.~~development partners.

For the three months ended ~~September 30,~~March 31, 2020, we recorded a charge of $2 million for commercial legal proceedings.

For the three months ended March 31, 2019, ~~we recognized~~ other operating expenses of $3$2 million were primarily attributable to integration expenses associated with the Combination (none in ~~the Specialty~~2020).

The following table sets forth results of operations for our AvKARE segment ~~compared to none~~ for the three months ended ~~September 30, 2018. For~~March 31, 2020 (in thousands):

Our AvKARE segment consists of the ~~nine months ended September 30, 2019,~~businesses we ~~recognized other operating expenses of $6 million~~acquired in the ~~Specialty segment compared~~Acquisitions on January 31, 2020. Prior to ~~$2 million for~~ the ~~nine months ended September 30, 2018. For the three~~Acquisitions, we did not have an AvKARE segment. Refer to Note 3. Acquisitions and ~~nine month periods, these expenses were primarily attributable to acquisition, site closure and integration expenses associated with the Combination.~~Divestitures.

Our primary source of liquidity is cash generated from operations, available cash and borrowings under debt financing arrangements, including ~~$433~~$394 million of available additional capacity on our ~~asset backed revolving credit facility ("ABL").~~Revolving Credit Facility as of May 11, 2020, as defined below. We believe these sources are sufficient to fund our planned operations, meet our interest and contractual obligations and provide sufficient liquidity over the next 12 months. However, our ability to satisfy our working capital requirements and debt obligations will depend upon economic conditions and demand for our products, which are factors that may be out of our control.

Our primary uses of capital resources are to fund operating activities, including research and development expenses associated with new product filings, and pharmaceutical product manufacturing expenses, license payments, and spending on production facility expansions and capital equipment items.

On March 27, 2020, President Trump signed into law the CARES Act. The CARES Act is an emergency economic stimulus package in response to the coronavirus outbreak which, among other things, includes provisions relating to income and non-income-based tax laws. We anticipate receiving approximately $110 million in cash from U.S. federal tax refunds associated with the CARES Act (refer to Note 8.Income Taxes). Other non-income-based tax provisions include deferral of the employer share of Social Security payroll taxes due from the CARES Act date of enactment through December 31, 2020, and a potential 50% credit on qualified wages against employment taxes each quarter with any excess credits eligible for refunds The Company continues to carefully analyze eligibility and application of both the income tax and non-income-based tax provisions.

Over the next 12 months, we will make substantial payments for monthly interest and quarterly principal amounts due on our term ~~loan under our senior secured credit facility (the "Term Loan"), any future borrowings under the ABL,~~loans, Revolving Credit Facility, severance and capital expenditures. We ~~made a $50 million payment~~expect that we will continue to ~~JSP on April 22, 2019 pursuant~~have sufficient cash resources to ~~the terms of a license~~support our debt service payments and ~~supply agreement, as described in~~ ~~Note 5. Alliance and Collaboration. Given the magnitude of projected expenditures, we may require additional funds from our ABL to meet these increased cash needs in~~all other financial obligations over the next ~~year.~~12 months.

We are party to a tax receivable agreement that requires us to make cash payments to APHC Holdings LLC (formerly known as Amneal Holdings LLC) ("Holdings") in respect of certain tax benefits that we may realize or may be deemed to realize as a result of redemptions or exchanges of Amneal common units by Holdings. The tax receivable agreement also requires that we make an accelerated payment to Holdings equal to the present value of all future payments due under the agreement upon certain change of control and similar transactions. The timing of any payments under the tax receivable agreement will vary depending upon a number of factors, but payments could be substantial, and could be in excess of the tax savings that we ultimately realize. Because of the foregoing, our obligations under the tax receivable agreement could have a substantial negative impact on our liquidity. For further details, see Item 1A. Risk Factors and Note 8. Income Taxes in our ~~2018~~2019 Annual Report on Form 10-K.

In addition, pursuant to the limited liability operating agreement of Amneal, in connection with any tax period, Amneal will be required to make distributions to its members, on a pro rata basis in proportion to the number of Amneal Common Units held by each member, of cash until each member (other than the Company) has received an amount at least equal to its assumed tax liability and the Company has received an amount sufficient to enable it to timely satisfy all of its U.S. federal, state and local and non-U.S. tax liabilities, and meet its obligations pursuant to the tax receivable agreement. For the ~~nine months ended September 30, 2019, Amneal made an aggregate of $13 million in tax distributions to Holdings (none for the~~ three months ended ~~September 30, 2019). The amount due~~March 31, 2020, no tax distributions were made to ~~Holdings as of September 30, 2019 is immaterial.~~Holdings.

At ~~September 30, 2019,~~March 31, 2020, our cash and cash equivalents consist of cash on deposit and highly liquid investments. A portion of our cash flows are derived outside the United States. As a result, we are subject to market risk associated with changes in foreign exchange rates. We maintain cash balances at both U.S. based and foreign country based commercial banks. At various times during the year, our cash balances held in the United States may exceed amounts that are insured by the Federal Deposit Insurance Corporation (FDIC). We make our investments in accordance with our investment policy. The primary objectives of our investment policy are liquidity and safety of principal.

Net cash provided by operating activities was ~~$53~~$49 million for the ~~nine~~three months ended ~~September 30, 2019~~March 31, 2020 compared to net cash used in operating activities of $9$108 million for the ~~nine~~three months ended ~~September 30, 2018.~~March 31, 2019. The change was primarily attributed to favorable timing ofimpacts from the collections of trade receivables and payments of accounts ~~receivable~~payable and ~~decreased transaction~~accrued expenses, and ~~integration costs~~a decrease in payments of employee separation benefits and interest, which were partially offset by ~~increased interest due to additional debt of the combined company and~~ an ~~increase in restructuring and severance related payments.~~unfavorable impact from income taxes paid.

The ~~decrease~~increase in cash used in investing activities of ~~$387~~$241 million for the ~~nine~~three months ended ~~September 30, 2019~~March 31, 2020 compared to the ~~nine~~three months ended ~~September 30, 2018,~~March 31, 2019, was primarily related to ~~a decrease~~an increase in cash paid for ~~acquisitions, an increase~~the Acquisitions, partially offset by a decrease in ~~proceeds from corporate owned life insurance~~purchases of property, plant and ~~an increase in the proceeds received on the sale of international businesses.~~equipment.

Net cash ~~used in~~provided by financing activities was ~~$39~~$468 million for the ~~nine~~three months ended ~~September 30, 2019~~March 31, 2020 compared to net cash ~~provided~~used by financing activities of ~~$507~~$22 million for the ~~nine~~three months ~~September 30, 2018.~~ended March 31, 2019. The change was primarily attributable to ~~a decrease in~~the net proceeds from a $300 million borrowing on our ~~Term Loan~~Revolving Credit Facility to mitigate the uncertainty surrounding overall market liquidity due to COVID-19, net proceeds from a $180 million term loan associated with the Acquisitions and ~~an increase~~a decrease in tax distributions to non-controlling ~~interests partially offset by a decrease in distributions to members.~~interests.

~~On March 30, 2019, Amneal sold 100%~~As the impact of the ~~stock of its Creo Pharma Holding Limited subsidiary, which comprised substantially all of~~COVID-19 pandemic on the economy and our operations inevolves, we will continue to assess our liquidity needs. A continued worldwide disruption could materially affect our future access to sources of liquidity, particularly our cash flows from operations, and financial condition. In the ~~United Kingdom,~~event of a sustained market deterioration, we may need additional liquidity, which would require us to ~~AI Sirona (Luxembourg) Acquisition S.a.r.l for net cash consideration of approximately $32 million which was received in April 2019.~~

On May 3, 2019, the Company sold 100% of the stock of its Amneal Deutschland GmbH subsidiary, which compromised substantially all of our operations in Germany, to EVER Pharma Holding Ges.m.b.H. for net cash consideration of approximately $3 million which was received in May 2019.evaluate available alternatives and take appropriate actions.

The contractual obligations of the Company are set forth in Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in the Company’s ~~2018~~2019 Annual Report on Form 10-K. WeOther than the contractual obligations noted below, there have been no material changes to the disclosure presented in our 2019 Annual Report on Form 10-K.

The foregoing table does not include ~~herein certain updates~~the $45 million of aggregate principal and the related interest due on the long-term promissory notes (“Sellers Notes”) and the short-term promissory note (“Short-Term Sellers Note”) issued in connection with the Acquisition because of the uncertainty as to when those ~~obligations.~~amounts will be repaid. Refer to the section Acquisition Financing – Notes Payable-Related Party below for additional information. The ~~$50 million Levothyroxine license and supply contract liability outstanding at March 31, 2019 was paid~~foregoing table also does not include interest due on the Revolving Credit Facility drawn in ~~April 2019.~~connection with COVID-19 because of uncertainty as to when the amount will be repaid.

On August 16, 2018, the Company entered into a license and supply agreement with Jerome Stevens Pharmaceuticals, Inc. ("JSP") for Levothyroxine. This agreement designated the Company as JSP's exclusive commercial partner for Levothyroxine in the U.S. market for a 10-year term commencing on March 22, 2019. Under this license and supply agreement with JSP, the Company accrued the up-front license payment of $50 million on March 22, 2019, which was paid in April 2019. The agreement also provides for the Company to pay a profit share to JSP based on net profits of the Company's sales of Levothyroxine, after considering product costs.

On November 9, ~~201 8,~~2018, the Company entered into a transition agreement ("Transition Agreement") with Lannett and JSP. Under the terms of the Transition Agreement, the Company assumed the distribution and marketing of Levothyroxine from Lannett beginning December 1, 2018 through March 22, 2019, ahead of the commencement date of the license and supply agreement with JSP described above.

In accordance with the terms of the Transition Agreement, the Company made $47 million of non-refundable payments to Lannett. For the ~~nine~~three months ended ~~September 30,~~March 31, 2019, ~~and the year ended December 31, 2018,~~ $37 million ~~and $ 10 million, respectively,~~(none in 2020) were expensed to cost of goods sold, as the Company sold Levothyroxine. As of December 31, 2018, the Company had a $4 million transition contract liability, which was fully settled in February 2019.

Additionally, during the year ended December 31, 2019, the Company recorded $1 million in cost of sales related to reimbursement due to Lannett for certain of its unsold inventory at the end of the Transition Period, which was fully settled in March 2020.

On May 4, 2018 we entered into a senior credit agreement that provided ~~the~~ a term loan (“Term ~~Loan~~Loan”) with a principal amount of $2.7 billion and ~~the ABL~~an asset backed revolving credit facility (“Revolving Credit Facility”) under which loans and letters of credit up to a principal amount of $500 million, on which $394 million are available (principal amount of up to $25 million is available for letters of credit) (collectively, the "Senior Secured Credit Facilities"). The Term Loan is repayable in equal quarterly installments at a rate of 1.00% or the original principal amount annually, with the balance payable at maturity on May 4, 2025. The Term Loan bears a variable annual interest rate, which is one-month LIBOR plus 3.5% at ~~September 30, 2019.~~March 31, 2020. The ~~ABL~~Revolving Credit Facility bears an annual interest rate of one-month LIBOR plus ~~1.5%~~1.25% at ~~September 30, 2019~~March 31, 2020 and matures on May 4, 2023. ~~As of September 30, 2019, the~~The annual interest rate for the ~~ABL~~Revolving Credit Facility may be reduced or increased by 0.25% based on step-downs and step-ups determined by the average historical excess availability. ~~At September 30, 2019, we had no outstanding borrowings under the ABL.~~

The proceeds of any loans made under the Senior Secured Credit ~~Facility~~Facilities can be used for capital expenditures, acquisitions, working capital needs and other general purposes, subject to covenants as described below. We pay a commitment fee based on the average daily unused amount of the ~~ABL~~Revolving Credit Facility at a rate based on average historical excess availability, between 0.25% and 0.375% per annum. At ~~September 30, 2019,~~March 31, 2020, the ~~ABL~~Revolving Credit Facility commitment fee rate is 0.375% per annum.

During March 2020, as a precautionary measure to mitigate the uncertainty surrounding overall market liquidity due to COVID-19, we borrowed $300 million on the Revolving Credit Facility all of which is outstanding at March 31, 2020. During May 2020, $200 million was repaid.

The Senior Secured Credit Facilities contain a number of covenants that, among other things, create liens on Amneal's and its subsidiaries' assets. The Senior Secured Credit Facilities contain certain negative covenants that, among other things and subject to certain exceptions, restrict Amneal’s and its subsidiaries' ability to incur additional debt or guarantees, grant liens, make loans, acquisitions or other investments, dispose of assets, merge, dissolve, liquidate or consolidate, pay dividends or other payments on capital stock, make optional payments or modify certain debt instruments, modify certain organizational documents, enter into arrangements that restrict the ability to pay dividends or grant liens, or enter into or consummate transactions with affiliates. The ~~ABL~~Revolving Credit Facility also includes a financial covenant whereby Amneal must maintain a minimum fixed charge coverage ratio if certain borrowing conditions are met. The Senior Secured Credit Facilities contain customary events of default, subject to certain exceptions. Upon the occurrence of certain events of default, the obligations under the Senior Secured Credit Facilities may be accelerated and the commitments may be terminated. At ~~September 30, 2019,~~March 31, 2020, Amneal was in compliance with all covenants under the Senior Secured Credit Facilities.

On January 31, 2020, in connection with the Acquisitions, Rondo Intermediate Holdings, LLC (“Rondo Holdings”), a wholly-owned subsidiary of Rondo, entered into a revolving credit and term loan agreement (“Rondo Credit Facility”) that provided a term loan ("Rondo Term Loan") with a principal amount of $180 million and a revolving credit facility (“Rondo Revolving Credit Facility”) which loans up to a principal amount of $30 million. The Rondo Term Loan is repayable in equal quarterly installments at a rate of 5.0% of the original principal amount annually, with the balance payable at maturity on January 31, 2025. The Rondo Credit Facility bears a variable annual interest rate, which is one-month LIBOR plus 3.0% at March 31, 2020 and matures on January 31, 2025. The annual interest rate for borrowing under the Rondo Credit Facility may be reduced or increased by 0.25% based on step-downs and step-ups determined by the total net leverage ratio, as defined in that agreement. At March 31, 2020, the Company had no outstanding borrowings under the Rondo Revolving Credit Facility.

The Sellers Notes with a stated principal amount of $44 million and the Short-Term Sellers Note with a stated principal amount of $1 million were issued by Rondo or its subsidiary, Rondo Top Holdings, LLC, on January 31, 2020, the closing date of the Acquisitions. The Sellers Notes are unsecured and accrue interest at a rate of 5% per annum, not compounded, until June 30, 2025. The Sellers Notes are subject to prepayment at the option of Rondo, as the obligor, without premium or penalty. Mandatory payment of the outstanding principal and interest is due on June 30, 2025 if certain financial targets are achieved, the borrowers’ cash flows are sufficient (as defined in the Sellers Notes) and repayment is not prohibited by senior debt. If repayment of all outstanding principal and accrued interest on the Sellers Notes is not made on June 30, 2025, the requirements for repayment are revisited on June 30 of each subsequent year until all principal and accrued interest on the Sellers Notes are satisfied no later than January 31, 2030 or earlier, upon a change in control. The Short-Term Sellers Note is also unsecured and accrues interest at a rate of 1.6% and is due on January 31, 2020.

The Sellers Notes were recorded at a fair value of $35 million, which was estimated using the Monte-Carlo simulation approach under the option pricing framework. The Short-Term Sellers Note of $1 million was recorded at the stated principal amount of $1 million, which approximates fair value. The $9 million discount on the Sellers Notes will be amortized to interest expense using the effective interest method from January 31, 2020 to June 30, 2025 as the carrying value of the Sellers Notes will accrete to the stated principal amount of $44 million.

We did not have any off-balance sheet arrangements as of ~~September 30, 2019.~~March 31, 2020.

For a discussion of the Company’s critical accounting policies, see Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations in our ~~2018~~2019 Annual Report on Form 10-K. ~~Other than as set forth below, there~~There have been no material changes to the disclosure presented in our ~~2018~~2019 Annual Report on Form 10-K.

~~In January 2017, the Financial Accounting Standards Board issued ASU 2017-04,~~ ~~Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment~~ that eliminates the requirement to calculate the implied fair value of goodwill (i.e., Step 2 of today’s goodwill impairment test) to measure a goodwill impairment charge. We adopted ASU 2017-04 as of April 1, 2019 on a prospective basis and have updated our critical accounting policy accordingly.

Goodwill, which represents the excess of purchase price over the fair value of net assets acquired, is carried at cost. Goodwill is not amortized; rather, it is subject to a periodic assessment for impairment by applying a fair value based test. We review goodwill for possible impairment annually during the fourth quarter, or whenever events or circumstances indicate that the carrying amount may not be recoverable.

In order to test goodwill for impairment, an entity is permitted to first assess qualitative factors to determine whether a quantitative assessment of goodwill is necessary. The qualitative factors considered by us may include, but are not limited to, general economic conditions, our outlook, market performance of our industry and recent and forecasted financial performance. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that a reporting unit’s fair value is less than its carrying amount. Otherwise, no further impairment testing is required. If a quantitative assessment is required, we determine the fair value of the reporting unit using a discounted cash flow analysis. If the net book value of the reporting unit exceeds its fair value, we recognize a goodwill impairment charge for the reporting unit equal to the lesser of (i) the total goodwill allocated to that reporting unit and (ii) the amount by which that reporting unit’s carrying amount exceeds its fair value.

Goodwill is allocated and evaluated for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment. We have two reportable segments, Generics and Specialty, which are the same as the respective operating segments and reporting units. As of September 30, 2019, $361 million and $59 million of goodwill was allocated to our Specialty and Generics segments, respectively.

In light of the decline in our share price and financial performance, we performed an interim goodwill impairment test during the three months ended September 30, 2019 by evaluating our two reporting units, which are the same as our two reportable segments. The fair values of each of our reporting units were determined by combining both the income and market approaches. In performing this test, the Company utilized long-term growth rates for its reporting units ranging from no growth to 1.0% and discount rates ranging from 9.0% to 11.5% in its estimation of fair value. The assumptions used in evaluating goodwill for impairment are subject to change and are tracked against historical performance by management.

Based on the results of the interim test performed as of August 31, 2019 and updated on September 30, 2019, we determined that the estimated fair values of the Generics and Specialty reporting units exceeded their respective carrying amounts; therefore, the Company did not record a goodwill impairment charge for the three months ended September 30, 2019. ~~The Generics reporting unit was in excess of its carrying value by approximately 15% and the Specialty reporting unit was in excess of its carrying value by approximately 9%.~~

~~A 50-basis point increase in the assumed discount rates utilized in each test would have not created a goodwill impairment charge in our Generics reporting unit or our Specialty reporting unit.~~

Significant judgment is employed in determining the assumptions utilized as of the acquisition date and for each subsequent measurement period. Accordingly, changes in assumptions described above, could have a material impact on our consolidated results of operations.

For each of our reporting units, there are a number of future events and factors that may impact future results and the outcome of subsequent goodwill impairment testing. For a list of these factors, see ~~Item 1A. Risk Factors.~~

Recently issued accounting standards are discussed in Note 2. Summary of Significant Accounting Policies.

~~For a discussion~~There has not been any material change in our assessment of ~~the Company’s quantitative and qualitative disclosures about~~ market ~~risks, see~~ risk as set forth in Item 7A. Quantitative and Qualitative Disclosures About Market Risk, in our ~~2018~~2019 Annual Report on Form 10-K.

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")) that are designed to ensure information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Co-Chief Executive Officers and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Our management, with the participation of our Co-Chief Executive Officers and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based upon that evaluation, our Co-Chief Executive Officers and Chief Financial Officer concluded that our disclosure controls and procedures, as defined in Rule 13a-15(e) of the Exchange Act, were effective as of ~~September 30, 2019~~March 31, 2020 at the reasonable assurance level.

During the quarter ended ~~September 30, 2019,~~March 31, 2020, there were no changes in the Company’s internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) which materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

Systems of disclosure controls and internal controls over financial reporting and their associated policies and procedures, no matter how well conceived and operated, are designed to provide a reasonable, but not an absolute, level of assurance that the objectives of the system of control are achieved. Further, the design of a control system must be balanced against resource constraints, and therefore the benefits of controls must be considered relative to their costs. Given the inherent limitations in all systems of controls, no evaluation of controls can provide absolute assurance all control issues and instances of fraud, if any, within a company have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Accordingly, given the inherent limitations in a cost-effective system of internal control, financial statement misstatements due to error or fraud may occur and may not be detected. Our disclosure controls and procedures are designed to provide a reasonable assurance of achieving their objectives. We conduct periodic evaluations of our systems of controls to enhance, where necessary, our control policies and procedures.

Information pertaining to legal proceedings can be found in Note ~~13.~~17. Commitments and Contingencies and is incorporated by reference herein.

Other than as set forth below, there have been no material changes to the ~~disclosure~~disclosures presented in our ~~2018~~2019 Annual Report on Form 10-K under Item 1A. Risk Factors.

The spread of the novel coronavirus (“COVID-19”) and other adverse public health developments could adversely affect our business and results of operations.

On March 11, 2020, the World Health Organization designated the outbreak of a novel strain of coronavirus (“COVID-19”) as a global pandemic. Governments and businesses around the world have taken unprecedented actions to mitigate the spread of COVID-19, including imposing restrictions on movement and travel such as quarantines and shelter-in-place requirements, and restricting or prohibiting outright some or all commercial and business activity, including the manufacture and distribution of certain goods and the provision of non-essential services. These measures, though currently temporary in nature, may become more severe and continue indefinitely depending on the evolution of the outbreak. To date, no fully effective vaccines or treatments have been developed and effective vaccines or treatments may not be discovered soon enough to protect against a worsening of the outbreak or to prevent COVID-19 from becoming endemic.

Our business and results of operations could be adversely affected by the ~~Amneal Group.~~COVID-19 outbreak. In particular, the continued global spread of COVID-19 could adversely impact the Company's operations, including, among other things, its manufacturing operations, supply chain, sales and marketing and clinical trial operations. Any of these factors could adversely affect the Company's business, operating results or financial condition. The ~~interests~~United States and China, two countries particularly hard hit by the outbreak, represent vital aspects of our direct and indirect supply chain and the United States is the largest end market for our products, representing the geographic source of almost our entire 2019 net revenue. We have taken precautionary measures intended to help minimize the risk of the ~~Amneal Group~~virus to our employees, including requiring non-production employees to work remotely, suspending all non-essential travel worldwide, and restricting or prohibiting attendance at industry events and in-person work-related meetings. While these measures are temporary, they may ~~differ from~~continue until the ~~interests~~outbreak is contained. The spread of COVID-19 could also negatively affect the operations of the third parties with whom we do business, including our raw material providers, aspects of our supply chain and our development, collaboration and commercial partners, for the same or different reasons that it is impacting our business directly. We expect the foregoing and other ~~stockholders.~~

~~As of September 30, 2019,~~unanticipated challenges will cause delays or disruptions in the ~~group of shareholders who owned Amneal prior to the Combination (the "Amneal Group") controlled approximately 55% of the voting power of all~~manufacture, supply and availability of our ~~outstanding shares~~products, particularly those in New York and New Jersey and more generally will make it more difficult to operate our business.

~~Through its control of a majority of~~COVID-19 could also adversely affect our ~~voting power~~clinical trial operations and other R&D activities in the ~~provisions set forth in~~United States and elsewhere, including our ~~charter, bylaws and the Second Amended and Restated Stockholders Agreement dated December 16, 2017 (the "Stockholders Agreement"), the Amneal Group has the~~ ability to ~~designate~~recruit and ~~elect~~retain volunteers, principal investigators and ~~has designated~~site staff who, as patients and elected a majority of our board of directors. The Amneal Group has control over all matters submitted to our stockholders for approval, including changes in capital structure, transactions requiring stockholder approval under Delaware law and corporate governance, subject to the terms of the Stockholders Agreement relating to the Amneal Group's agreement to vote in favor of directors not designated by the Amneal Group and such other matters that are set forth in the Stockholders Agreement. The Amneal Grouphealthcare providers, may have ~~different interests than~~heightened exposure risks and sensitivities to COVID-19. Further, some patients may be unable to comply with clinical trial protocols if quarantines or travel restrictions impede patient movement or interrupt healthcare services or may become infected with COVID-19 themselves, any of which would delay our ~~other stockholders and~~ability to conduct clinical trials or release clinical trial results. COVID-19 may ~~make decisions adverse such interests.~~

~~Among other things, the Amneal Group's control could delay, defer, or prevent a sale~~also affect employees of ~~the Company~~third-party contract research organizations that ~~the Company’s other stockholders support, or, conversely, this control~~we rely upon to carry out our clinical trials, which could result in inefficiencies due to reductions in staff and disruptions to work environments. The outbreak could impact the ~~consummation~~day-to-day operations of ~~such a transaction that our~~the FDA and other ~~stockholders do not support. This concentrated control~~health authorities in their ability to respond to non-emergency matters, which could ~~discourage a potential investor from seeking to acquire Class A Common Stock~~delay reviews and ~~as a result, might harm the market price~~approvals of ~~that Class A Common Stock.~~product candidates.

The ~~Amneal Group could transfer control~~continued spread of usCOVID-19 has adversely affected many industries as well as the economies and financial markets of many countries, including the United States and China, resulting in a significant deceleration of economic activity. This slowdown has reduced production, decreased the level of trade, and led to widespread corporate downsizing, causing a ~~third party by transferring its shares. In addition,~~sharp increase in unemployment. In recent weeks, we have also seen significant disruption of and extreme volatility in the Company believes members of the Amneal Group have pledged Amneal Common Units and the corresponding shares of Class B Common Stock to secure borrowings, and other members of the Amneal Group could enter into similar arrangements. In connection with these arrangements, the Company has entered into agreements with certain Amneal Group members and the lending institutions to whom their securities may be pledged. Because of the recent drop in our stock price, the value of pledged Amneal securities has decreased,global capital markets, which could increase the ~~likelihood~~cost of, ~~a margin call on a pledge of Amneal securities. The voluntary~~ or ~~forced sale of some or all these units or shares pursuant~~entirely restrict access to, ~~a margin call or otherwise could cause~~capital. This volatility and uncertainty have adversely affected our stock price and may continue to ~~decline~~do so. The impact of this outbreak on the U.S., Chinese and ~~negatively impact our business. Similarly, a voluntary or forced sale~~world economies is uncertain and, unless the outbreak is contained, these adverse impacts could cause the Company to lose its “controlled company” status under the New York Stock Exchange listing requirements, which would require us to comply over a transition period with certain corporate governance requirements from which we are currently exempt, including having a fully independent compensation committee. Ifworsen, impacting all segments of the ~~Amneal Common Units~~global economy, and ~~corresponding shares of Class B stock were pledged to secure borrowings, a complete foreclosure could~~ result in a ~~change~~significant recession or worse.

Considerable uncertainty still surrounds the COVID-19 virus and its potential effects, and the extent of ~~control.~~

~~Our future success depends~~and effectiveness of any responses taken on a local, national and global level. Infections may become more widespread and that could accelerate or magnify one or more of the risks described above. While we expect the coronavirus outbreak and related events will have a negative effect on our business, the full extent and scope of the impact on national, regional and global markets and economies, and therefore our business and industry, is highly uncertain and cannot be predicted. Accordingly, our ability to ~~attract~~conduct our business in the manner and ~~retain talented employees~~on the timelines presently planned could be materially and ~~consultants.~~

~~Our future success depends, to a substantial degree, upon the continued service~~negatively affected, any of ~~the members of our management team. The loss of the services of members of our management team, or their inability to perform services on our behalf,~~which could have a material adverse ~~effect~~impact on our business ~~condition (financial~~ and otherwise), prospects and results of operations. On August 5, 2019, we announced that President and Chief Executive Officer Robert A. Stewart was leaving the Company and resigning as a director, effective immediately, and would be replaced by Amneal’s co-founders Chirag Patel, who will serve as President and Co-Chief Executive Officer, and Chintu Patel, who will serve as Co-Chief Executive Officer. Each of Chirag Patel and Chintu Patel is a member of the Amneal Group. In connection with this transition, among other changes to the Company's board of directors, Executive Chairman Paul M. Bisaro also resigned from the Company and the board and was replaced on the board by Paul Meister, who will serve as non-executive Chairman of the Board. Any change in senior management involves significant inherent risk, and any failure to effect a smooth transition process could hinder our strategic planning, execution and future performance. While we endeavor to minimize any negative impact associated with changes such as these, there may be uncertainty among investors, employees and others regarding our future direction and performance. Any disruption in our operations, uncertainty regarding our future or negative public perception regarding the change could have a material adverse effect on our business, financial condition, operating results and cash flows.

Our success also depends, to a large extent, upon the contributions of our sales, marketing, scientific and quality assurance staff. We compete with brand and generic pharmaceutical manufacturers for qualified personnel, and our competitors may offer more favorable employment opportunities than we do. If we are not able to attract and retain the necessary personnel to accomplish our business objectives we could experience constraints that would adversely affect our ability to sell and market our products effectively, to meet the demands of our strategic partners in a timely fashion, and to support our research and development programs. In particular, our sales and marketing efforts depend on the ability to attract and retain skilled and experienced sales, marketing and quality assurance representatives. Although we believe that we have been successful in attracting and retaining skilled personnel in all areas of our business, we cannot provide assurance that we can continue to attract, train and retain such personnel. Any failure in this regard could limit the rates at which we generate sales and develop or acquire new products.

~~If we determine that our goodwill has become impaired, we may record significant impairment charges, which would adversely affect our financial condition and results of operations.~~

Goodwill represents a significant portion of our assets. Goodwill is the excess of cost over the fair market value of net assets acquired in business combinations. In the future, goodwill may increase as a result of future acquisitions. We review our goodwill and indefinite lived intangible assets at least annually for impairment. Impairment may result from, among other things, deterioration in the performance of acquired businesses, adverse market conditions and adverse changes in applicable laws or regulations, including changes that restrict the activities of an acquired business.

Generic pharmaceuticals have faced regular and increasing price erosion each year, placing even greater importance on our ability to continually introduce new products. If these trends continue or worsen, or if we experience further difficulty in this market or the Specialty market, this may continue to adversely affect our revenues and profits in our Generics and Specialty segments. Furthermore, during the first three quarters of 2019, the Company's market capitalization decreased significantly. Additional decline in our market capitalization, even if due to macroeconomic or industry-wide factors, could put pressure on the carrying value of our goodwill in both our Generics and Specialty segments and cause the Company to conduct an interim impairment test. A determination that all or a portion of our goodwill is impaired, although a non-cash charge against earnings, could have a material adverse effect on our results of ~~operations~~operation and financial condition.

If we determine in the future that we will not be able to fully utilize all or part of our deferred tax assets, we would record a valuation allowance through earnings in the period the determination was made, which could have an adverse effect on our results of operations and earnings.

We record valuation allowances against our DTAs when it is more likely than not that all or a portion of a DTA will not be realized. We routinely evaluate the realizability of our DTAs by assessing the likelihood that our deferred tax assets will be recovered based on all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, estimates of future taxable income, tax planning strategies and results of operations. Estimating future taxable income is inherently uncertain and requires judgment. In projecting future taxable income, we consider our historical results and incorporate certain assumptions, including projected new product launches, revenue growth, and operating margins, among others.

In assessing the need for a valuation allowance in the third quarter of fiscal 2019, we considered all available objective and verifiable evidence both positive and negative, including historical levels of pre-tax income (loss) both on a consolidated basis and tax reporting entity basis, legislative developments, expectations and risks associated with estimates of future pre-tax income, and prudent and feasible tax planning strategies. We currently estimate that as of September 30, 2019 we will have generated a cumulative consolidated three-year pre-tax loss. As a result of this analysis, we considered it more likely than not that we will not realize the benefits of our gross DTAs and therefore, for the three and nine months ended September 30, 2019, we have recorded a valuation allowance of $372 million to reduce the carrying value of these gross DTAs, net of the impact of the reversal of taxable temporary differences, to zero.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Delaware		32-0546926
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)
Amneal Pharmaceuticals, Inc. 400 Crossing Boulevard, Bridgewater, NJ		08807
(Address of principal executive offices)		(Zip Code)


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class A Common Stock, par value $0.01 per share	AMRX	New York Stock Exchange

Large accelerated filer	☐☒	Accelerated filer	☐
Non-accelerated filer	☒☐	Smaller reporting company	☐
		Emerging growth company	☐








Cautionary Note Regarding Forward-Looking Statements			1

PART I - FINANCIAL INFORMATION
	Item 1.	Financial Statements (Unaudited)	12
		Consolidated Statements of Operations	12
		Consolidated Statements of Comprehensive Income (Loss) ~~Income~~	23
		Consolidated Balance Sheets	34
		Consolidated Statements of Cash Flows	45
		Consolidated Statements of Stockholders' Equity ~~/ Members' Deficit~~	56
		Notes to Consolidated Financial Statements	97
	Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	4142
	Item 3.	Quantitative and Qualitative Disclosures About Market Risk	5521
	Item 4.	Controls and Procedures	52

PART II - OTHER INFORMATION
	Item 1.	Legal Proceedings	53
	Item 1A.	Risk Factors	53
	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	5453
	Item 3.	Defaults Upon Senior Securities	54
	Item 4.	Mine Safety Disclosures	54
	Item 5.	Other Information	54
	Item 6.	Exhibits	55

Signatures			56

Cash	$	254,000
Sellers Notes ⁽¹⁾		35,033
Settlement of Amneal trade accounts receivable from R&S ⁽²⁾		7,440
Short-Term Seller Note ⁽³⁾		1,000
Working capital adjustment ⁽⁴⁾		(2,640	)
Fair value consideration transferred	$	294,833


☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

	Class A Common Stock				Class B Common Stock						Class B-1 Common Stock						Additional Paid-in		Stockholders' Accumulated			Accumulated Other Comprehensive			Non- Controlling			Total
	Shares		Amount		Shares			Amount			Shares			Amount			Capital		Deficit			(Loss) Income			Interests			Equity
Balance at January 1, 2019		115,047	$	1,151		171,261		$	1,713			12,329		$	123		$	530,438	$	(20,920	)	$	(7,755	)	$	391,613		$	896,363
Net loss		—		—		—			—			—			—			—		(329,789	)		—			(208,881	)		(538,670	)
Cumulative-effective adjustment from adoption of Topic 842		—		—		—			—			—			—			—		4,957			—			8,604			13,561
Foreign currency translation adjustment		—		—		—			—			—			—			—		—			1,759			2,255			4,014
Stock-based compensation		—		—		—			—			—			—			16,666		—			—			—			16,666
Exercise of stock options		205		2		—			—			—			—			922		—			(7	)		468			1,385
Restricted stock unit vesting, net of shares withheld to cover payroll taxes		253		2		—			—			—			—			10		—			(5	)		(933	)		(926	)
Redemption of Class B Common Stock		6,256		62		(6,256	)		(62	)								17,605		—			(332	)		(17,273	)		—
Conversion of Class B-1 Common Stock		12,329		123		—			—			(12,329	)		(123	)		—		—			—			—			—
Tax distribution		—		—		—			—			—			—			—		—			—			(82	)		(82	)
Reclassification of foreign currency translation adjustment included in net loss		—		—		—			—			—			—			—		—			1,461			1,952			3,413
Balance at September 30, 2019		134,090	$	1,340		165,005		$	1,651			—		$	—		$	565,641	$	(345,752	)	$	(4,879	)	$	177,723		$	395,724

	Members'			Members' Accumulated			Class A Common Stock				Class B Common Stock						Class B-1 Common Stock				Additional Paid-in			Stockholders' Accumulated			Accumulated Other Comprehensive			Non- Controlling			Total			Redeemable Non- Controlling
	Equity			Deficit			Shares		Amount		Shares			Amount			Shares		Amount		Capital			Deficit			(Loss) Income			Interests			Equity			Interest
Balance at January 1, 2018	$	2,716		$	(382,785	)		—	$	—		—		$	—			—	$	—	$	8,562		$	—		$	(14,232	)	$	10,157		$	(375,582	)	$	—
Period Prior to the Combination
Net (loss) income		—			(148,806	)		—		—		—			—			—		—		—			—			—			97			(148,709	)		—
Cumulative-effective adjustment from adoption of ASU 2014-09 (Topic 606)		—			4,977			—		—		—			—			—		—		—			—			—			—			4,977			—
Capital contribution from non- controlling interest		—			—			—		—		—			—			—		—		—			—			—			360			360			—
Distributions to members		—			(182,998	)		—		—		—			—			—		—		(8,562	)		—			—			—			(191,560	)		—
PPU expense		158,757			—			—		—		—			—			—		—		—			—			—			—			158,757			—
Foreign currency translation adjustment		—			—			—		—		—			—			—		—		—			—			1,721			—			1,721			—
Capital contribution by Amneal Holdings for employee bonuses		27,742			—			—		—		—			—			—		—		—			—			—			—			27,742			—
Period Subsequent to the Combination
Effect of the Combination		(189,215	)		709,612			73,289		733		224,996			2,250			—		—		323,589			—			9,437			626,737			1,483,143			—
Redemption of Class B Common Stock for PIPE		—			—			34,520		345		(46,849	)		(468	)		12,329		123		165,180			—			(1,965	)		(130,501	)		32,714			—
Redemption of Class B Common Stock for distribution to PPU Holders		—			—			6,886		69		(6,886	)		(69	)		—		—		24,293			—			(289	)		(19,181	)		4,823			—
Net (loss) income		—			—			—		—		—			—			—		—		—			(10,976	)		—			(21,355	)		(32,331	)		67
Foreign currency translation adjustment		—			—			—		—		—			—			—		—		—			—			(4,554	)		(6,131	)		(10,685	)		—
Stock-based compensation		—			—			—		—		—			—			—		—		5,234			—			—			—			5,234			—
Exercise of stock options		—			—			279		3		—			—			—		—		3,610			—			(7	)		(444	)		3,162			—
Reclassification of redeemable non- controlling interest		—			—			—		—		—			—			—		—		—			(1,176	)		—			(10,532	)		(11,708	)		11,708
Non-controlling interests from acquisition of Gemini		—			—			—		—		—			—			—		—		—			—			—			2,518			2,518			—
Acquisition of redeemable non- controlling interest		—			—			—		—		—			—			—		—		—			—			—			—			—			(11,775	)
Tax distribution		—			—			—		—		—			—			—		—		—			—			—			(35,543	)		(35,543	)		—
Other		—			—			—		—		—			—			—		—		(1,746	)		—			—			(1,968	)		(3,714	)		—
Balance at September 30, 2018	$	—		$	—			114,974	$	1,150		171,261		$	1,713			12,329	$	123	$	520,160		$	(12,152	)	$	(9,889	)	$	414,214		$	915,319		$	—

	Preliminary Fair Values As of March 31, 2020
Restricted cash	$	375
Trade accounts receivable, net		52,223
Inventories		72,615
Prepaid expenses and other current assets		33,525
Related party receivables		61
Property, plant and equipment		5,278
Goodwill		95,955
Intangible assets, net		137,400
Operating lease right-of-use assets - related party		5,544
Total assets acquired		402,976
Accounts payable and accrued expenses		89,592
Related party payables		1,532
Operating lease liabilities - related party		5,544
Total liabilities assumed		96,668
Redeemable non-controlling interests		11,475
Fair value of consideration transferred	$	294,833

	Preliminary Fair Values		Weighted-Average Useful Life
Government licenses	$	66,700	7 years
Government contracts		28,600	4 years
National contracts		28,600	5 years
Customer relationships		13,000	10 years
Trade name		500	6 years
	$	137,400

	Nine Months Ended September 30, 2018
Net revenue	$	1,341,555
Net loss	$	(143,585	)
Net loss attributable to Amneal Pharmaceuticals, Inc.	$	(21,502	)

Segment	Product Family	Three Months Ended September 30, 2018
		$		%
Generics	Yuvafem-Estradiol	$	48,466	10%
Specialty	Rytary®		33,073	7%
Generics	Epinephrine Auto-Injector (generic Adrenaclick®)		30,259	6%
Generics	Diclofenac Sodium Gel		26,455	6%
Generics	Aspirin; Dipyridamole ER Capsule	$	22,777	5%

Segment	Product Family	Nine Months Ended September 30, 2019
		$		%
Generics	Levothyroxine Sodium	$	135,220	11%
Specialty	Rytary®		95,538	8%
Generics	Diclofenac Sodium Gel		67,741	6%
Generics	Epinephrine Auto-Injector (generic Adrenaclick®)		53,841	4%
Specialty⁽¹⁾	Oxymorphone	$	45,191	4%

	Contract Charge- backs and Sales Volume Allowances			Cash Discount Allowances			Accrued Returns Allowance			Accrued Medicaid and Commercial Rebates			Contract Charge - Backs and Sales Volume Allowances			Cash Discount Allowances			Accrued Returns Allowance			Accrued Medicaid and Commercial Rebates
Balance at December 31, 2018	$	829,596		$	36,157		$	154,503		$	74,202
Balance at December 31, 2019													$	829,807		$	34,308		$	150,361		$	114,960
Impact from the Acquisitions														15,292			944			15,229			10
Provision related to sales recorded in the period		3,413,718			101,285			71,126			143,145			1,080,290			32,947			47,163			36,472
Credits/payments issued during the period		(3,444,048	)		(109,309	)		(85,666	)		(110,319	)		(1,244,302	)		(35,371	)		(26,301	)		(40,067	)
Balance at September 30, 2019	$	799,266		$	28,133		$	139,963		$	107,028
Balance at March 31, 2020													$	681,087		$	32,828		$	186,452		$	111,375

	Employee Restructuring			Employee Restructuring
Balance at December 31, 2018	$	22,112
Balance at December 31, 2019				$	3,900
Charges to income		8,607			46
Payments		(28,422	)		(2,077	)
Balance at September 30, 2019	$	2,297
Balance at March 31, 2020				$	1,869

	September 30, 2019			December 31, 2018			March 31, 2020			December 31, 2019
Gross accounts receivable	$	1,347,401		$	1,349,588		$	1,437,336		$	1,470,706
Allowance for doubtful accounts		(1,893	)		(2,340	)		(739	)		(2,201	)
Contract charge-backs and sales volume allowances		(799,266	)		(829,596	)		(681,087	)		(829,807	)
Cash discount allowances		(28,133	)		(36,157	)		(32,828	)		(34,308	)
Subtotal		(829,292	)		(868,093	)		(714,654	)		(866,316	)
Trade accounts receivable, net	$	518,109		$	481,495		$	722,682		$	604,390

	Three Months Ended September 30, 2019		Nine Months Ended September 30, 2019
Operating lease cost ⁽¹⁾	$	5,960	$	16,850
Finance lease cost:
Amortization of right-of-use assets		652		1,956
Interest on lease liabilities		1,115		3,358
Total finance lease cost		1,767		5,314
Total lease cost	$	7,727	$	22,164

	March 31, 2020		December 31, 2019
Deposits and advances	$	373	$	1,123
Prepaid insurance		2,648		3,858
Prepaid regulatory fees		2,330		4,016
Income and other tax receivables ⁽¹⁾		124,527		13,740
Prepaid taxes		3,200		3,255
Other current receivables		16,364		15,996
Other prepaid assets		30,575		28,176
Chargebacks receivable ⁽²⁾		24,392		—
Total prepaid expenses and other current assets	$	204,409	$	70,164

Operating leases	September 30, 2019
Operating lease right-of-use assets	$	56,455
Operating lease right-of-use assets - related party		14,930
Total operating lease right-of-use assets	$	71,385

Operating lease liabilities	$	44,375
Operating lease liabilities - related party		14,271
Current portion of operating lease liabilities		13,467
Current portion of operating and financing lease liabilities - related party		2,299
Total operating lease liabilities	$	74,412

Financing leases
Financing lease right of use assets - related party	$	61,936

Financing lease liabilities - related party	$	61,719
Current portion of operating and financing lease liabilities - related party		1,054
Total financing lease liabilities	$	62,773

	Three Months Ended September 30, 2019		Nine Months Ended September 30, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from finance leases	$	1,117	$	2,987
Operating cash flows from operating leases		4,964		14,968
Financing cash flows from finance leases		252		1,118
Non-cash activity:
Right-of-use assets obtained in exchange for new operating lease liabilities	$	—	$	360

~~Weighted average remaining lease term - operating leases~~	~~6 years~~(2)
~~Weighted average remaining lease term - finance leases~~	~~23 years~~
~~Weighted average discount rate - operating leases~~	~~6.1%~~
~~Weighted average discount rate - finance leases~~	~~7.0%~~	When a sale occurs on a contract item, the difference between the cost paid to the manufacturer by the Company and the contract cost that the end customer has with the manufacturer is rebated back to the Company by the manufacturer. The Company establishes a chargeback (rebate) receivable and a reduction to cost of goods sold in the same period as the related sale.

	March 31, 2020		December 31, 2019
Deferred revolving credit facility costs	$	3,434	$	3,099
Security deposits		1,730		1,938
Long-term prepaid expenses		5,875		6,438
Interest rate swap		—		16,373
Financing lease right-of-use assets		10,703		11,442
Other long-term assets		4,714		4,980
Total other assets	$	26,456	$	44,270

	Operating Leases			Financing Leases
2019 (1)	$	4,999		$	1,368
2020		19,812			5,474
2021		16,173			5,474
2022		12,327			5,474
2023		10,038			5,474
Thereafter		26,930			106,740
Total lease payments		90,279			130,004
Less: Imputed interest		(15,867	)		(67,231	)
Total	$	74,412		$	62,773

	March 31, 2020			December 31, 2019
Term Loan due May 2025	$	2,652,126		$	2,658,876
Rondo Term Loan due January 2025		180,000			—
Other		624			624
Total long-term debt		2,832,750			2,659,500
Less: debt issuance costs		(30,985	)		(28,975	)
Total debt, net of debt issuance costs		2,801,765			2,630,525
Less: current portion of long-term debt		(29,736	)		(21,479	)
Total long-term debt, net	$	2,772,029		$	2,609,046

	Operating Leases		Financing Obligation
2019	$	25,885	$	5,474
2020		12,071		5,474
2021		11,105		5,474
2022		10,329		5,474
2023		10,043		5,474
Thereafter		28,128		107,196
Total lease payments		97,561		134,566
Less: Imputed interest		—		(95,217	)
Total	$	97,561	$	39,349

	Future Amortization		Future Amortization
Remainder of 2019	$	40,163
2020		147,242
Remainder of 2020			$	137,058
2021		150,941		174,569
2022		140,971		159,512
2023		131,778		148,090
2024		127,107		140,704
Thereafter		315,074		334,113
Total	$	1,053,276	$	1,094,046

	Foreign currency translation adjustment			Unrealized gain (loss) on cash flow hedge, net of tax			Accumulated other comprehensive loss
Balance December 31, 2018	$	(7,755	)	$	—		$	(7,755	)
Other comprehensive (loss) income before reclassification		(729	)		7,764			7,035
Amounts reclassified from accumulated other comprehensive loss		1,461			—			1,461
Reallocation of ownership interests		(809	)		—			(809	)
Balance December 31, 2019		(7,832	)		7,764			(68	)
Other comprehensive loss before reclassification		(2,525	)		(30,812	)		(33,337	)
Reallocation of ownership interests		(7	)		7			—
Balance March 31, 2020	$	(10,364	)	$	(23,041	)	$	(33,405	)

	Payments Due by Period (in thousands)
Contractual Obligations	Total		Less Than 1 Year		1-3 Years		3-5 Years		More Than 5 Years
Rondo Term Loan ⁽¹⁾	$	180,000	$	6,750	$	18,000	$	18,000	$	137,250
Revolving Credit Facility ⁽²⁾		300,000		300,000		—		—		—
Interest payments on Rondo Term Loan ⁽³⁾		36,507		6,338		15,651		13,966		552

Exhibit No.		Description of Document


10.1		Separation Agreement between ~~Robert Stewart,~~Todd Branning, Amneal Pharmaceuticals, Inc. and Amneal Pharmaceuticals LLC, dated as of ~~August 2, 2019 (incorporated by reference to Exhibit 10.4 to the Company's Quarterly Report on Form 10-Q, filed August 5, 2019)~~March 11, 2020 †

10.2		~~Amendment No. 1, dated as of August 2, 2019, to Second Amended and Restated Stockholders~~Employment Agreement by and among Amneal Pharmaceuticals ~~Holding Company,~~ LLC, a Delaware limited liability company, AP Class D Member, LLC, a Delaware limited liability company, AP Class E Member, LLC, a Delaware limited liability company, AH PPU Management, LLC, a Delaware limited liability company,Amneal Pharmaceuticals, Inc. and David Buchen, dated as of December 28, 2018. †

10.3		Separation Agreement between David Buchen, Amneal Pharmaceuticals, Inc. and Amneal Pharmaceuticals LLC, dated as of August 2, 2019.†

10.4		First Amendment to Separation Agreement between David Buchen, Amneal Pharmaceuticals, Inc. and Amneal Pharmaceuticals LLC, dated as of November 4, 2019. †

10.5		Employment Agreement dated March 11, 2020, by and among Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals, Inc. and Anastasios (Tasos) G. Konidaris (incorporated by reference to Exhibit ~~10.5~~10.1 to the Company’s Current Report on Form 8-K filed on March 12, 2020).†

10.6		Form of Amneal Pharmaceuticals, Inc. 2018 Incentive Plan Performance Restricted Stock Unit Grant Notice and Performance Restricted Stock Unit Agreement. †

10.7		Amended and Restated Operating Agreement of Rondo Partners, LLC(incorporated by reference to Exhibit 2.1 to the Company's ~~Quarterly~~Current Report on Form ~~10-Q,~~8-K, filed ~~August 5, 2019)~~on February 3, 2020).

10.8		Revolving Credit and Term Loan Agreement, dated as of January 31, 2020, by and among Rondo Intermediate Holdings and LLC and Rondo Holdings, LLC, the lenders from time to time party thereto, and Trust Bank, as Administrative Agent (incorporated by reference to Exhibit 2.2 to the Company's Current Report on Form 8-K, filed on February 3, 2020).

31.1		Certification of the Co - Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2		Certification of the Co - Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.3		Certification of the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1		Certification of the Co - Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**

32.2		Certification of the Co - Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**

32.3		Certification of the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**

101		The following materials from the Company’s Quarterly Report on Form 10-Q for the quarter ended ~~September 30, 2019~~March 31, 2020 formatted in inline XBRL (eXtensible Business Reporting Language): (i) Consolidated Statements of Operations for each of the three ~~and nine~~ months ended ~~September 30,~~March 31, 2020 and 2019, ~~and 2018,~~ (ii) Consolidated Statements of Comprehensive ~~Loss/~~Income (Loss) for each of the three ~~and nine~~ months ended ~~September 30,~~March 31, 2020 and 2019, ~~and 2018,~~ (iii) Consolidated Balance Sheets as of ~~September 30, 2019~~March 31, 2020 and December 31, ~~2018,~~2019, (iv) Consolidated Statements of Cash Flows for each of the ~~nine~~three months ended ~~September 30,~~March 31, 2020 and 2019, ~~and 2018,~~ (v) Consolidated Statements of Stockholders' ~~Equity/ Members' Deficit~~Equity for each of the three ~~and nine~~ months ended ~~September 30,~~March 31, 2020 and 2019 ~~and 2018~~ and (vi) Notes to Consolidated Financial Statements. *

104		Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

Date: ~~November 6, 2019~~May 11, 2020	Amneal Pharmaceuticals, Inc.
		(Registrant)

	By:	/s/ Chirag Patel
		Chirag Patel
		President and Co-Chief Executive Officer
		(Co-Principal Executive Officer)

	By:	/s/ Chintu Patel
		Chintu Patel
		Co-Chief Executive Officer
		(Co-Principal Executive Officer)

	By:	/s/ ~~Todd P. Branning~~Anastasios Konidaris
		~~Todd P. Branning~~Anastasios Konidaris
		Senior Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)